

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)


PCT

(10) International Publication Number
WO 2004/026888 A2

(51) International Patent Classification⁷: C07H
(21) International Application Number: PCT/US2003/029577
(22) International Filing Date: 19 September 2003 (19.09.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data: 60/412,479 19 September 2002 (19.09.2002) US
(71) Applicants (for all designated States except US): COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE). UNIVERSITY OF SASKATCHEWAN [CA/CA]; Kirk Hall, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). QIAGEN GMBH [DE/DE]; Max-Volmer-Strasse 4, 40724 Hilden (DE).
(72) Inventors; and
(75) Inventors/Applicants (for US only): LIPFORD, Grayson, B. [US/US]; 38 Bates Road, Watertown, MA 02472 (US). MOOKHERJEE, Neeloffer [IN/CA]; Apt 408, 2233 Allison Road, Vancouver, BC V6T 1T7 (CA). BABIU, Lorne [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA). BROWNLIE, Robert [CA/CA]; 123 O'Brien Crescent, Saskatoon, Saskatchewan S7K 5K3 (CA). GRIEBEL, Philip [CA/CA]; Box 36, RR5, Saskatoon, Saskatchewan S7K 3J8 (CA). MUTWIRI, George [CA/CA]; 569 Nordstrum Road, Saskatoon, Saskatchewan S7K 7X6 (CA). HECKER, Rolf [DE/DE]; Benrodestr. 60, 40597 Düsseldorf (DE).
(74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
(81) Designated States (national): AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

[Continued on next page]

(54) Title: TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES



(57) Abstract: Novel amino acid and nucleotide sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) Toll-like receptor 9 (TLR9) are provided. Also provided are amino acid and nucleotide sequences for dog (canine), cat (feline), mouse (murine), and human TLR9. Comparison of these sequences, especially in combination with functional assessment for species-specific CpG motif preferences, permits identification of specific regions and amino acid residues of interest in TLR9 ligand interaction. Novel chimeric TLR9 receptor molecules, cells expressing these molecules, and methods for their use in screening assays for TLR9 ligands are also provided.

WO 2004/026888 A2



MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES**Background of the Invention**

Synthetic oligodeoxynucleotides (ODN) and DNA containing immunostimulatory 5 CpG motifs (CpG DNA) function as potent adjuvants and activators of the innate immune system. Heeg K et al. (2000) *Int Arch Allergy Immunol* 121:87-97; Krieg AM (2001) *Vaccine* 19:618-22. A wide variety of CpG-containing sequences have been screened for biological activity and it is reported that optimal CpG DNA sequences can vary among species. Rankin R et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:333-40.

10 Toll-like receptor 9 (TLR9) has recently been identified as a receptor for CpG ODN. Hemmi H et al. (2000) *Nature* 408:740-5. The molecular mechanism by which TLR9 recognizes CpG DNA is not understood.

Summary of the Invention

15 Toll-like receptor 9 (TLR9) is known to be involved in innate immunity and to signal in response to CpG DNA. To date, the amino acid sequences only of human and murine TLR9 have been reported, and, interestingly, these two species are known to prefer different CpG motifs. The structural basis for this species-specific CpG motif preference has not yet been fully elucidated. The instant invention provides, in part, novel amino acid and 20 nucleotide sequences of rat, pig, cow, and horse TLR9. These novel TLR9 sequences are useful for elucidating certain key structural features of TLR9. Specifically, comparison of sequences of murine, human, and these novel TLR9 sequences permits identification of areas of highly conserved sequence, areas of group conservation, and areas of hypervariability. In addition, such comparisons permit an assessment of evolutionary relatedness among TLR9 25 molecules of the various species, as well as an assessment of inter-species homologies. Importantly, such comparisons permit a rational basis for identifying amino acids in TLR9 that may be involved in the CpG binding site, as well as amino acids involved in conferring species specificity for particular CpG motifs. Such information may be used to design and construct novel TLR9 molecules which incorporate specific point or regional mutations and 30 which possess desired ligand binding characteristics. Such information may also be useful in designing and identifying novel ligands for TLR9 of a given species.

- 2 -

In one aspect, the invention provides isolated polypeptides having amino acid sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) TLR9 polypeptides. These amino acid sequences correspond to SEQ ID NOS 1, 5, 9, 13, and 17, respectively. Each of these sequences is believed to include at least a majority of an 5 extracellular domain, as well as a transmembrane region and at least part of a TLR/IL-1 receptor (TIR) domain. To the extent any such sequence may lack an amino-terminal and/or carboxy-terminal sequence, such sequence is ascertainable, without undue experimentation, using conventional molecular biology techniques and the sequence information provided herein.

10 In another aspect the invention provides isolated polypeptides having amino acid sequences for essentially the whole extracellular domain, optionally including a signal peptide, of each of rat, porcine, bovine, equine, and ovine TLR9. These amino acid sequences correspond to SEQ ID NOS 2, 6, 10, 14, and 18, respectively. Such extracellular domains are believed to include sequence specifically involved in binding to TLR9 ligand, 15 such as CpG DNA. In addition, such extracellular domains are believed to include sequence that confers species specificity for particular CpG motifs.

Isolated nucleic acid molecules encoding the polypeptides just described above are also provided according to further aspects of the invention. Such nucleic acid molecules include, but are not limited to, nucleic acid molecules having sequences provided by SEQ ID 20 NOS 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively. Isolated nucleic acid molecules encoding the TLR9 polypeptides of SEQ ID NOS 1, 5, 9, 13, 17; and 2, 6, 10, 14, and 18 also include nucleic acid molecules that differ in sequence from SEQ ID NOS 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively, due to degeneracy of the genetic code. Such nucleic acid molecules will hybridize, under stringent conditions, with suitably selected nucleic acid 25 molecules having sequences selected from SEQ ID NOS 3, 4, 7, 8, 11, 12, 15, 16, 19, and 20.

30 In another aspect the invention provides a vector which includes an isolated nucleic acid molecule of the invention. In one embodiment the vector is an expression vector and the isolated nucleic acid molecule of the invention is operably linked to a regulatory sequence in the vector. When present within a cell, an expression vector according to this aspect of the invention causes the cell to express a polypeptide of the invention.

The invention according to another aspect provides a cell in which a vector of the invention is present. In one embodiment the cell containing the vector expresses a

polypeptide of the invention. In certain embodiments the cell also contains a reporter construct that transduces a TLR9-mediated signal in response to contact of the polypeptide of the invention or a TLR9 with a suitable TLR9 ligand. The cell containing the vector, and optionally containing the reporter construct, can be used in screening methods also provided by the invention.

In yet another aspect the invention provides an antibody or antibody fragment that binds specifically to an isolated polypeptide of the invention. In certain embodiments the antibody or antibody fragment binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide. More specifically, the antibody or antibody fragment binds uniquely to one of the isolated polypeptides of the invention. In one embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide also binds to either mouse or human TLR9. In another embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide does not also bind to either mouse or human TLR9. In some embodiments the antibody or antibody fragment binds selectively to a chimeric TLR9 polypeptide of the invention. In certain embodiments the antibody or antibody fragment of the invention is a monoclonal antibody or fragment of a monoclonal antibody.

In one aspect the invention provides a method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species. The method involves aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species; generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

- 4 -

In another aspect the invention provides a method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9. The method according to this aspect of the invention involves aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9; generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids. In one embodiment the method according to this aspect of the invention is performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

In another aspect the invention also provides an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (extracellular domain (ECD) of murine TLR9) except for substitution of at least one key amino acid identified according to the method above. The polypeptide according to this aspect of the invention is a chimeric TLR9 polypeptide. Preferably the polypeptide according to this aspect of the invention binds to CpG DNA optimized for human TLR9 better than does the isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (ECD of murine TLR9). In one embodiment the polypeptide includes only one substituted amino acid. The isolated polypeptide according to this aspect of the invention may further include sequence involved in TLR/IL-1R signal transduction, e.g., intracellular domain of TLR9 as provided in SEQ ID NOs 29 and 33. For example, in one embodiment a polypeptide according to this aspect of the invention is an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:29 (full length murine TLR9) except for substitution of at least one key amino acid identified according to the method above.

- 5 -

In another aspect the invention provides an isolated nucleic acid molecule including a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described. In one embodiment the isolated nucleic acid molecule has a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described.

5 In yet another aspect, the invention provides a screening method to identify a TLR9 ligand. The method involves contacting a polypeptide (including a chimeric TLR9 polypeptide) of the invention with a candidate TLR9 ligand; measuring a signal in response to the contacting; and identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling. In one embodiment 10 the candidate TLR9 ligand is an immunostimulatory nucleic acid. In one embodiment the candidate TLR9 ligand is a CpG DNA.

The invention also provides, in yet a further aspect, a screening method to identify species-specific CpG-motif preference of an isolated polypeptide of the invention. The method according to this aspect of the invention involves contacting an isolated polypeptide 15 of the invention with a CpG DNA including a hexamer sequence selected from the group consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACTTT, GACGCT, GACGAT, GACGGT, GACGTC, GACGTA, and GACGTG; measuring a signal in response to the contacting; and identifying a species-specific CpG-motif preference when the signal in 20 response to the contacting is consistent with TLR9 signaling. In one embodiment the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

25	TCCATGACGTTTTGATGTT	(SEQ ID NO:39),
	TCCATAACGTTTTGATGTT	(SEQ ID NO:40),
	TCCATCACGTTTTGATGTT	(SEQ ID NO:41),
	TCCATTACGTTTTGATGTT	(SEQ ID NO:42),
	TCCATGGCGTTTTGATGTT	(SEQ ID NO:43),
	TCCATGCCGTTTTGATGTT	(SEQ ID NO:44),
	TCCATGTCGTTTTGATGTT	(SEQ ID NO:45),
	TCCATGATGTTTTGATGTT	(SEQ ID NO:46),
30	TCCATGAAGTTTTGATGTT	(SEQ ID NO:47),
	TCCATGAGGTTTTGATGTT	(SEQ ID NO:48),
	TCCATGACATTTTGATGTT	(SEQ ID NO:49),
	TCCATGACCTTTGATGTT	(SEQ ID NO:50),
	TCCATGACTTTTGATGTT	(SEQ ID NO:51),
35	TCCATGACGTTTGATGTT	(SEQ ID NO:52),
	TCCATGACGATTTGATGTT	(SEQ ID NO:53),
	TCCATGACGGTTTGATGTT	(SEQ ID NO:54),

- 6 -

TCCATGACGTCTTGATGTT (SEQ ID NO:55),
TCCATGACGTATTGATGTT (SEQ ID NO:56), and
TCCATGACGTGTTGATGTT (SEQ ID NO:57).

In certain embodiments of the screening methods of the invention, the signal includes
5 expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway. In one
embodiment the reporter gene is operatively linked to a promoter sensitive to NF- κ B. In one
embodiment the signal in response to contacting is binding of the candidate TLR9 ligand or
CpG DNA to the polypeptide of the invention.

In one embodiment the screening method is performed on a plurality of test
10 compounds. In one embodiment the response mediated by the TLR9 signal transduction
pathway is measured quantitatively and the response mediated by the TLR9 signal
transduction pathway associated with each of the plurality of test compounds is compared
with a response arising as a result of an interaction between the functional TLR9 and a
reference immunostimulatory compound.

15

Brief Description of the Figures

Figure 1 depicts a Clustal W multiple sequence alignment of deduced amino acid
sequences for cat (feline), dog (canine), cow (bovine), mouse (murine), sheep (ovine), pig
(porcine), horse (equine), human, and rat TLR9 polypeptides. The deduced amino acid
20 sequences for feline, canine, bovine, murine, ovine, porcine, equine, human, and rat TLR9
polypeptides shown in the figure correspond to SEQ ID NOs 25, 21, 9, 29, 17, 5, 13, 33, and
1, respectively. Lines labeled "multiple" refer to the multiple sequence alignment of all six
sequences shown. Lines labeled "mo/hu" refer to a paired sequence alignment of mouse and
human TLR9 sequences alone.

25 Figure 2 is a cladogram depicting an evolutionary relatedness tree for rat, murine,
porcine, bovine, equine, and human TLR9 polypeptides in Figure 1.

Figure 3 is a graph depicting species specificity of TLR9 signaling with selected
oligonucleotides having strong specificity for human (2006), mouse (5890), or neither (1982).

30

Detailed Description of the Invention

The present invention provides novel amino acid and nucleotide sequences for TLR9
derived from rat, pig, cow, horse, and sheep. These sequences can be used to identify key
features of the primary sequences of these and related TLR molecules, including previously

known primary sequences of human and mouse (murine) TLR9. Such key features include binding site information and species specificity toward particular CpG motifs. Native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to identify and to design novel TLR9 ligands.

5 Additionally, the native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to compare various TLR9 ligands, including CpG DNA.

In one aspect the invention provides isolated TLR9 polypeptides, and isolated nucleic acid molecules encoding them, from rat, pig, cow, horse, and sheep. The term "isolated" as 10 used herein with reference to a nucleic acid molecule or polypeptide means substantially free of or separated from components with which it is normally associated in nature, e.g., other nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids or polypeptides are sufficiently pure and are sufficiently free from other biological constituents of host cells so as 15 to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid or polypeptide of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the nucleic acid or polypeptide may represent only a small percentage by weight of such a preparation. The nucleic acid or polypeptide is nonetheless substantially pure in that it has been substantially separated from 20 the substances with which it may be associated in living systems.

An amino acid sequence of rat TLR9 is provided as SEQ ID NO:1. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:1 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of rat TLR9 (See 25 Figure 1). Amino acids numbered 1-821 of SEQ ID NO:1 are presumptively extracellular domain and correspond to SEQ ID NO:2. SEQ ID NO:3 is a nucleotide sequence of rat TLR9 cDNA having an open reading frame corresponding to nucleotides 1-3096. SEQ ID NO:4 is a nucleotide sequence of rat cDNA encoding amino acids 1-821 of SEQ ID NO:1.

An amino acid sequence of porcine TLR9 is provided as SEQ ID NO:5. Based on 30 comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:5 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of porcine TLR9

- 8 -

(See Figure 1). Amino acids numbered 1-819 of SEQ ID NO:5 are presumptively extracellular domain and correspond to SEQ ID NO:6. SEQ ID NO:7 is a nucleotide sequence of porcine TLR9 cDNA having an open reading frame corresponding to nucleotides 77-3166. SEQ ID NO:8 is a nucleotide sequence of porcine cDNA encoding amino acids 1-819 of SEQ ID NO:5.

5 An amino acid sequence of bovine TLR9 is provided as SEQ ID NO:9. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:9 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of bovine TLR9
10 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:9 are presumptively extracellular domain and correspond to SEQ ID NO:10. SEQ ID NO:11 is a nucleotide sequence of bovine TLR9 cDNA having an open reading frame corresponding to nucleotides 84-3170. SEQ ID NO:12 is a nucleotide sequence of bovine cDNA encoding amino acids 1-818 of SEQ ID NO:9.

15 An amino acid sequence of equine TLR9 is provided as SEQ ID NO:13. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:13 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of equine TLR9
20 (See Figure 1). Amino acids numbered 1-820 of SEQ ID NO:13 are presumptively extracellular domain and correspond to SEQ ID NO:14. SEQ ID NO:15 is a nucleotide sequence of equine TLR9 cDNA having an open reading frame corresponding to nucleotides 115-3207. SEQ ID NO:16 is a nucleotide sequence of equine cDNA encoding amino acids 1-820 of SEQ ID NO:13.

25 An amino acid sequence of ovine TLR9 is provided as SEQ ID NO:17. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:17 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of ovine TLR9 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:17 are presumptively extracellular domain and correspond to SEQ ID NO:18. SEQ ID NO:19 is a nucleotide sequence of ovine
30 TLR9 cDNA having an open reading frame corresponding to nucleotides 92-3178. SEQ ID NO:20 is a nucleotide sequence of ovine cDNA encoding amino acids 1-818 of SEQ ID NO:17.

- 9 -

SEQ ID NO:1 (Rat TLR9)

5 MVLCRRTLHPLSLLVQAALAEALALGTLPAFLPCELKPHGLVDCNWLFKSVPHFSAAEPRSNITSLSLIANRI
HHHLNLDVFVHLPNVRQLNKWCNCPGGLSPHLFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSL
SHTNLLVLDASSLAGLHSRVLFDGNCYYKNPCNGAVNVTPTDAFLGLSNLTHLSLKYNNTTEVPRQLPPSLEYL
LLSYNLLIVKLGAEIDLNLTSRMLDVGGNCRRCDHAPDLCTECRQKSLLDPQTFFHLSHLEGVLKDSSLHSLN
SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLTSFNYCKKVSFARLHASSFKSLVSLQELNMNGIF
FRLLNKNTLRWLAGLPKHLTHLHQMFNINQAOQLSVFSTFRALRFVDLSNNRISGPPTLSRVAPEKADEAKGVPW
10 PASLTPALPSTPVSKNFMVRCKNLRFTMDLSRNNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK
VLDLSSYNKLDLYHSKSFSELPQLQALDLSYNSQPFMSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS
VEYLDMSGNGVGRMWDEEDLYLYFFQDQLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKLSFRDNHLSFFNWSSL
FLPNLRDLDLLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVPAFFAIAVELKEVNLSHNIKTVDRSWFGPIV
MNLTVLDVSSNPLHCACGAPFVDLLLEVQTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFGLSLL
AVAVGTVLPLLQHLCGWDWVYCFHLCIWAFLPLLTRGRRSAQALPYDAFVVFDAKAQSAVADWVYNELRVLEERRG
15 RRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQQRILLEDRKDVVVLVILRPDA
HRSRYVRLRORLRCQSVLFWPHQPNQGSFWAQQLSTALTRDNHHFYNRNFRCRGPTAE

SEQ ID NO:2 (Rat TLR9)

20 MVLCRRTLHPLSLLVQAAVLAELALGTLPAFLPCELKPHGLVDCNWFLKSVPHFSAAEPRSNITSLSLIANRI
HHLHNLDVFVHLPNVRQLNLKWCNCPGGLSPHLFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRPLPSSLTMLSL
SHTNIVLVDASSLAGLHSRVLFDGNCYYKNCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSSLEYL
LLSYNLIVKLGAEDLANLTSRMLDVGGNCRRCDHAPDLCTECRQKSLLHPQTFFHLSHLEGIVLKDSLSSHLNSL
SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHASSFKSLVSLQELNMNGIF
FRLNKNTLRLWLAGLPKLIHTLHLQMNFINQAOQLSVFSTFRAILRFVDLSNNRISGPPTLSRVAPEKADEAEKGVPW
25 PASLTPALPSTPVSKNFMVRCKNLRTMDLSRNQNVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK
VLDLSYNKLDLYHSKSFSELPLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS
VEYLDFTSGNGVGRMWDEEDLYLYFFQDLRSLIHLDSQNKLHILRPQNLNYLPKSLSLTKLSFRDNHLSFFNWSSL
FLPNLRDLDLAGNLLKALTNGTLPNGTLLQKDVSSNSIVFVVPAFFALAVELKEVNLSHNILKTVDRSRWFGPIV
MNI.TVLDVSSNPLHCACGAPFVLDLJLEVQTKVPGIANGVKCGS PROLOGRSIFAODRLCLDDVLSRDCFG

SEO ID NO:3 (Rat TLR9)

35 atggttctctgtcgaggaccctgcacccctgtctctcctggatcaggccgcagtgtggctgaggctctggcc
ctgggtaccctgcctgccttcaccctgtgaactgaagccatggccctggtagactgcacactggctttcctg
aagtctgtgcctacttctgtccgcagaaccctgttccaaacatcaccagcccttcattgtatgcaccaaccgcac
caccacactgcacaacactcgactttgtccacctgcccacgtgcacagctgaacctcaagtggactgtccggcc
cctggcctcagcccttgcacttctctgcgcattgaccattgagccaaaaccttctggctatgcgcattgt
gaagagctgaacctgagctataacgttatcaccactgtgccccgcctgcccagctccctgacgaatctgagcc
agccacaccaacatcctgtactcgatgccagcagccctcgctggcctgcacagccctgcagttcttcattggac
gggaactgtactacaagaacccctgcaacggggcggtgaacgtgacccggacgccttcctggcttagacaa
40 ctcacccactgtcccttaagtataacaacactcacagaggtgccccgcacactgccccccagctggagtagactc
ctgctgtcctataacactcatcgtaagctggggccgaagacactgacccacactgacttcccttgcattgt
gtgggtggattgcgtcgctgtatcacgcggccgcaccttgcacagaatgcggcagaagttcccttgcattgt
caccctcagactttccatcacctgagccaccttgcacggccctggctgtgaaggacaggatcttcactcgctgaac
tccaagtgggtccagggtctggcgaacctctcggtctggacctaagcgagaactttcttacgagagcatcaac
45 aaaaccagcgcccccacacttgcacggccatgtccatcgcaagctgcacactgccttcaattactgcacaaaggatcg
ttccggccgcctccacacttgcacggccatgtccatcgcaagctgcacactgccttcaattactgcacaaaggatcg
ttccgcattactcaacaagaacacgcctcagggtggctggctgtgcacccaaagctccacacgcgtgcacccatcaat
aatttcatcaaccaggcgcagctcagcgttttagtaccttgcacggcccttcgttgcacccatgtccaaataat
cgcatcagcgccgcctccaaacgcgttccagactgcgtccatcgccggccgaaaaggcagacgcggccgagaagggggttccatgg
50 cctgcaagtctcaccctcagacttcccgagactccctgcattaaagaacttcatggcgtcagggtgttaagaacactcaga
ttcaccatggacactgtctcggaacaaccagggtgactatcaagccagagatgtcgtcaacctctccatctcc
tgtctgagccctgagccacaactgcattgcgcagggctgtcaatggctctcagttccctggccgtgaccaacactgaa
gtgctggacactgtccctataacaagctggacactgttaccattcgaaatcggtcagactccacagttgcaggcc

- 10 -

ctggacctgagctacaacagccagccattcagcatgcagggataggccacaacttcagtttctggccaatctg
 tccagggtacagaaccccttagcctggcacacaatgcacattcacagccgcgtgcctcacgccttacacgcaccta
 gtggagtatctgacttcagccgcaacccgtgtggccatgtggacgaggaggaccccttaccttacatcttc
 caagacctgagaagccctgattcatctggacccgttcagaataagctgcacatccctccggcccccagaacccctcaac
 5 tacctccccaaagccctgacgaagctgagttccgtgacaatcacctcttttaactggagcagtctggcc
 ttccctgcccataatctgcgagacccctggacccctggcaggacaatctactaaaggccctgaccaacggcaccctgccta
 ggcacgctccctccagaaactggatgtcagtagcaacagttatgcgtctttgtgtcccgcccttgcgtctggcg
 gtagagctaaaagaggtcaacccctcagccataacatctcaagactgtggatgcctctgggtttggcccatgtg
 10 atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgcctgcggtgacccctttagactactg
 ctggaagtgcagaccaagggtccctggcttggtaacccgtgtgaagtgtggcagtccccccagctgcaggccgc
 agcatcttgcgcacccctgggtgtgcctggatgcgtcccttcgcggactgtgtttccatctg
 gctgtggccgtggcacgggtgtgccttactgcagcatctctgcggctggacgtctggactgtgtttccatctg
 tgcctggcatggctacccctgtgcacccctggccggcgcagcccccagctctccctttagatgccttcgtggtg
 ttgcataaggcgcagagccgggtgtgactgggttataacccgtgtcagtgccgttagaggagccgcgcgg
 15 cggccggccctacgttgcgttgcggaggacccggatggctgcgtggccagacactcttcgagaacactctggcc
 tccatctatggcagcccaagactctgtttgtgcgtggccacacggacaggtcagtgccctctgcgcaccagc
 ttccctgctggctcagcagccctgtgcgtggaggaccgaaggacgtgggtgtgcgtccctgtatgc
 caccgcctccgcatactgcactgcgcacccgcctgcgcagactgtgttccatcagcccaac
 20 gggcaggccagcttctggccagctgactgtgactacgcctgacttagggacaaccaccacttataaccggaaacttc
 tgccggggacctacagcagaatag

SEQ ID NO:4 (Rat TLR9)

atggttctctgtcgcaggacccctgcaccccttgcctctggtaacggccgcagtgcgtggctgaggctctggcc
 ctgggttaccctgcctgccttcttaccctgtgaactgaaggctcatggcctgttagactgcacactggctttctc
 25 aagtctgtgcctacttctctgcgcagaaccccttccacatcaccagccttccttgcatacgccaaaccgcattc
 caccacccctgcacccctgcactttgtccacccctgcacccgtgcacagctgaacccctcaagtggaaactgtccgc
 cccctgcctcagcccttgcacttctctgcgcacccattgagccaaaccccttgcgtatgcgcacatgc
 gaagagactgaacctgagctataacccgtatcaccactgtgcctgcctgcgcagactccctgcacaaactgagc
 30 agccacaccaacatctggtaactgcgttgcgcagccgcgtgcacccctgcgcaggatcttcatggac
 gggactgtactacaagaacccctgcacccggccgtgaacgtgcacccgcacgccttctggctgagcaac
 ctcacccacttgccttaagtataacaacccctcagaggtgcctccgcacactgccttgcgttgcgttgc
 35 ctgcgtgcctataacccctcatgcgtcaagctggggccgaagacccctgcaccccttgcataatgc
 gtgggtggaaatggcgtcgctgtgcatacgccttcgcctgcgttgcacagaatgcggcagaactcccttgc
 caccctcagacttccatccatgcgttgcacccctgcacccggctgttgcacccatgcgttgc
 tccaaagtggttccagggtctggcaaccccttcgggtgtggacccataaggcgagaacttcttc
 40 aaaaacccaggcccttccagaaacctgcacccgtctgcgcacccgtgcacccctgccttcaattactgc
 ttgcggccgcctccacctggcaagttccatgcgttgcacccgtgcacccctgcacccatgc
 ttccgcgttactcaacaagaacccgcgttgcacccgtgcacccatgcgttgcacccatgc
 aatttcatcaaccaggcgcagctcagcgttgcacccgtgcacccatgcgttgcacccatgc
 45 cgcatcaggcccctccaacgcgttgcacccgtgcacccatgcgttgcacccatgc
 cctgcacgcgttgcacccatgcgttgcacccatgcgttgcacccatgcgttgcacccatgc
 ttccacccatggacccgttgcacccatgcgttgcacccatgcgttgcacccatgc
 tgcgttgcacccatgcgttgcacccatgcgttgcacccatgcgttgcacccatgc
 50 ctggacctgagctacaacccgcattcagcatgcaggggataggccacaacttc
 tccaggttacagaaccccttagcctggcacacaatgcacattcacagccgcgtgc
 gtggaggtatctgacttcagccgcaacccgtgtggccatgtggacgaggaggac
 55 caagacctgagaagccctgattcatctggacccgttcagaataagctgcacatcc
 tacctccccaaagccctgacgaagctgagttccgtgacaatcacctcttttgc
 ttccctgcccataatctgcgagacccctggcaggccatctactaaaggcc
 ggcacgcgttgcacccatgcgttgcacccatgcgttgcacccatgc
 gtagagctaaaagaggtcaacccctcagccataacatcc
 atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgc
 ctggaaagtgcagaccaagggtccctggcgttgcacccgtgtga
 agcatcttgcgcacccctgcgtgcgttgcacccatgcgttgc
 agcatcttgcgcacccatgcgttgcgttgcacccatgc

- 11 -

SEQ ID NO:5 (Porcine TLR9)

MGPRCTLHPLSLLVQVTALAAAALAQGRIPAFPLPCELQPHGLVNCNWFLKSVPHFSAAAPRANVTSLSLLSNRIH
 HLHDSDFVHLSSIRTLNLKWNCPPAGLSPMHFPCHMHTIEPNTFLAVPTLEELNLSYNSITTVPALPDSLVSLSLS
 5 RTNIVLVDPTHTLGLHALRYLYMDGNCYYKNPCQGALEVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLL
 LSYNHIVTLPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPDKHPKLHSDTFSHLSRLEGLVLDNLSLYNLD
 RWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSFGHLRSLKELDMHGIFF
 RSLSETTLQPLVQLPMLQTLRLQMFNQAOQLSIFGAFPGLLYVDSLSDNRISGAARPVAITREVDRERVWLPSR
 NLAPRPLDTRLSEDFMPNCKAFSFTLDSRNNLVTIQSEMFARLSRLSHNSISQAVNGSQFVPLTSLRVL
 10 DLSHNKLDLYHGRSFTELPRLEALDLISYNSQPFTMQGVGHNLSFVAQLPALRVLSLAHNDIHSRVSQQLCSASLC
 ALDFSGNDLSRMRWAEGDLYLRFQGLRSVWLDLISQNHLLHTLLPRALDNLPKSLKHLHLRDNNLAFFNWSSLTLL
 PKLETLDLAGNQLKALSNGSLPSGTQLRRLDSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWFGSMVGN
 LKVLDVDSANPLHACGATFVGFLLEVQAAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFGISLLAM
 ALGLVVPMLHHLCGWDLWYCFHLCWLPHRGQRRGADALFYDAFVVFDAQOSAVADWVYNELRVQLEERRGRRA
 LRLCLEERDWLPGKTLFENLWASVYSSRKTFLVLAHTDRVSGLLRASFLLAQQLLEDRKDVVVLVILRPDAYRS
 15 RYVRLRQLRCQSLLWPHQPRGQGSFWAQLGTALTRDNHHFYNRNFCRGPTTAE

SEQ ID NO:6 (Porcine TLR9)

MGPRCTLHPLSLLVQVTALAAAALAQGRIPAFPLPCELQPHGLVNCNWFLKSVPHFSAAAPRANVTSLSLLSNRIH
 HLHDSDFVHLSSIRTLNLKWNCPPAGLSPMHFPCHMHTIEPNTFLAVPTLEELNLSYNSITTVPALPDSLVSLSLS
 20 RTNIVLVDPTHTLGLHALRYLYMDGNCYYKNPCQGALEVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLL
 LSYNHIVTLPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPDKHPKLHSDTFSHLSRLEGLVLDNLSLYNLD
 RWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSFGHLRSLKELDMHGIFF
 RSLSETTLQPLVQLPMLQTLRLQMFNQAOQLSIFGAFPGLLYVDSLSDNRISGAARPVAITREVDRERVWLPSR
 NLAPRPLDTRLSEDFMPNCKAFSFTLDSRNNLVTIQSEMFARLSRLSHNSISQAVNGSQFVPLTSLRVL
 25 DLSHNKLDLYHGRSFTELPRLEALDLISYNSQPFTMQGVGHNLSFVAQLPALRVLSLAHNDIHSRVSQQLCSASLC
 ALDFSGNDLSRMRWAEGDLYLRFQGLRSVWLDLISQNHLLHTLLPRALDNLPKSLKHLHLRDNNLAFFNWSSLTLL
 PKLETLDLAGNQLKALSNGSLPSGTQLRRLDSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWFGSMVGN
 LKVLDVDSANPLHACGATFVGFLLEVQAAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFG

30 SEQ ID NO:7 (Porcine TLR9)

gagcacgaacatccttcaactgttagctgtggccggctgtccagccagaccctttggagaagaccccactccctgt
 catggggcccccgtgcacccctgcaccccccctttcttcctgtggctggatggcgtggctggctggccca
 gggcaggctgcctgcctgcctgtggatggcgtggctggatggcgtggctggccca
 35 gtccgtgccccacttctcgccggcagccccccccggccaacgtcaccgcctctcctactctccaaaccgcacatcca
 ccacctgcacgactccgacttcgtccacactgtccgcctacgaactctcaacctcaagtggaaactgcccggc
 tggccctcagccccatgcacttccctgcacatgaccatcgagccccacacttcttcgtggccgtgccccccctgg
 ggagctgaacctggactacaacacagcatcagccgtgcctgcctgcctgcctgcctgcctgcctgcctgc
 40 ccgcaccaacatctggctgtagacccccacccactcaactggctacatgcctgcgtactgtacatggatgg
 caactgtactacaagaacccctgcccggggggcgctggagggtggtggccgggtgccttcctcggcctggcaaccc
 cacacatctctcaactcaagtacaacaatctcacgagggtggccggcagcctggccggccacttgc
 gttgtcctacaaccacattgtcaccctgacgcctgaggacactggccatctgactgcctgcgtgttatgt
 45 gggggggaaactggccgcgtgtgaccatggccacccctgcaggagggtggccaaaggaccacccaaagctgca
 ctctgacaccttcagccacctgagccgcctcgaaaggctgggtggaaagacagttctctacaacactggacac
 cagggtggttccgaggcctggacaggctocaagtgtggacactgtggatggacttcccttacgactgcatcacca
 50 gaccacggccctccaggccgtggccgcactgcgcagccactcaacctgtccctcaattaccacaagaagggtgc
 tgcccacctgcacccctggcaccccttggcacccctccgtccctgatggcatggcatcttctt
 cgcctcgctcgtgagaccacgcctcaacctctggccatctgcctatgcctcagaccctgcgcctgcagatgaa
 cttcatttaaccaggcccacgtcagcatcttggggcccttcctggcctgtgtacgtggacactatggacaacc
 catcagcggagctgcaaggccagtgccattacttagggagggtggatggtagggagagggtctggctgccttcc
 gaacctcgctccacgtccactggacactctccgcctcagaggactcatgcacccactgcacggccctcagctt
 cttggacactgtctcggaacaacactggatggcacaatccactgcggatgtttgtccctctcagccctcgact
 55 ggcctcgagccacaacagcatctccaggccgtcaatggctctcgtttgtccctgcctgaccaggctgcgggt
 ggacctgtcccacaacaagctggacactgtatcacggccgtcgatggcggactgcacggactgcggccctgg
 cctcagactacaatagccagcccttaccatgcagggtgtggccacaacactcagcttcgtggcccgactgc

- 12 -

cctgcgtacccatgcggcacaatgacatccatagccagtgcccagcagctctgttagcgccactgtg
 cgccctggacttttagcggcaacgatctgagccgatgtggctgagggagaccttatctccgcttcttccaagg
 cctaagaaggcttagtctggctggacctgtcccagaaccacctgcacaccctctgccacgtgcctggacaacct
 cccaaaaggctgaagcatctgcatctccgtgacaataacctggccttctcaactggagcagcctgaccctct
 5 gcccaagctggaaaccctggacttggctggaaaccagctgaaggccctaagacaatggcagcctgcccattggcac
 ccagctgcccggaggctggacccatcggtggcaacagcatcggtttgtgaaccctggcttcttgcctggcaagca
 gtttagaaggagctcaacccatcgccaaatgcccctcaagacagtggagccctctgcactgtccctgtggggctcgatggggca
 cctggaaaggcttagacgtgagccaaaccctctgcactgtccctgtggggccacccctgtggggcttctgtgg
 10 ggtacaggctgcgtgcctggctggccagccgctgcaagtgtggcagttccggggcagctccagggccatagcat
 ctttgcgaagacactgcgcctctgcctggatgagacccctctgtggactgtttggcatctcgctgtggccat
 ggccttggctgggttgcctggatctgcgtcaccacccctgcggctggaccctctgttactgtttccacccctgtgcct
 ggcctggctgccccaccggaggcagccggggggcgcagacccctgttctatgtatgccttcgtggcttgcacaa
 agctcagactgtgtggccgactgggttacaacacgagctgcgggtcagctggagggagccgtggccgc
 15 actgcgcctgtgcctggaggagcggagactggtaacctggcaagacgccttcgtgagaacccctgtggccctcagtc
 cagcagccgaagacccctgttgcgtggccacacggaccgtgcagccgttctgcgtggccctcagtttcgt
 ggccttggc
 20 cggc
 tggcccaacccatgttcgtcagccacaccactgtctgtccctgtttcccaacccacccacccaccc
 aacatgtgccaataatgtaccggaggccaaaaaaaaaaaaaaaaaaaaaaaa

SEQ ID NO:8 (Porcine TLR9)

atggggcccccgtgcaccctgcaccccttctccctggtgccaggtagcagcgctggctggctggcccaag
 25 ggcagggtgcctgccttcctgcctgtgagctccagccccacggccctgttgcactggcttccatccaaaccgcac
 tccgtgccccacttctcgccggcagccggccggccaaacgttgcaccagcccttcctactctccaaaccgcac
 cacctgcacgactccgacttcgtccacccgtccagccatcgaaactctcaactcaagtggactgtccggccggct
 ggcctcagcccatgcactttccctgcacccatgaccatcgagccaaacaccccttcgtggccgtggccaccctggag
 gagctgaacctgagctacaacacgatcaccggccgtgcctggccctgcactccctgtgtccctgtgcgt
 30 cgcaccaacatctggcttagacccacccacccactcaactggccctacatgcctctgcgttacactggatgg
 aactgtactacaagaacccctgcacggggggcgtggaggtgtggcccttcctggccctggccac
 acacatctctactcaactcaacccatctcaccggagggtgcggccggcggcgtggccctggagaccctgt
 ttgtccctacaacccatgttgcaccctgcacccgtggccatctgactgccttcgtgcgttgc
 ggggggaaactgcggccgtgtgaccatggcccaacccctgcacggggatgtcccaaggaccacccaaagctgcac
 35 tctgacacccatcgccacccatcgccgttgcacggccctgcacggccgtgtgaaaagacacttctctacaacccatgg
 aggtgggtcccgaggccctggacaggcttcaactgtgtggccactgtggatgtggccatccatccaccaag
 accacggcccttcaggccctggccggactgcgcacccctcaacccatgtccctcaattaccacaagaagggtgt
 gccacccatgcacccatggccacccatccctggccacccatccctgttgcacggatgtgcacatggcat
 40 ttcattaaaccaggccagctcagcatcttggggcccttcctggctgttgcacggccatccatgg
 atcagcggagctgcacggccactggccattacttagggagggtggatgtggatggggctggctgccttcagg
 aacccatcgccacccatggccacttcggacacttcggccatccatggccatccatggccatcc
 ttggacccatgtctcggaacaacccatggccacaatccatggccatccatggccatccatggccat
 45 cgcctgagccacaacacgatctcccaaggccgtcaatggccatccatggccatccatggccatccatggcc
 gacccatggccatccatggccatccatggccatccatggccatccatggccatccatggccatccatggcc
 ctccatggccatccatggccatccatggccatccatggccatccatggccatccatggccatccatggcc
 50 ctcagtcacccatggccatccatggccatccatggccatccatggccatccatggccatccatggccat
 ctggccatccatggccatccatggccatccatggccatccatggccatccatggccatccatggccat
 ctaagaaggcttagtctggctggacccatgttcccaagaaccacccatgcacccctctgc
 55 cccaaaggctgaagcatctgcacccatccatggccatccatggccatccatggccatccatggccat
 cccaaaggctggaaaccctggacttggctggaaaccagctgaaggccctaaacatggc
 cagctgcggaggctggacccatcggtggcaacagcatcggtttgtgaaccctggctt
 ttagaaggactcaacccatcgccaaatggccatccatggccatccatggccat
 ctgaaaggcttagacgtgagccaaaccctctgcactgtgcctgtggggcc
 gtacaggctgcgtgcctggctggccacccgcgtcaagtgtggc
 tggcactgtccggccatccatggccatccatggccatccatggccat
 tttgcgcaagacccatgcgccttcgtggatgagacccatctcg
 tggaaactgtttggc

SEQ ID NO:9 (Bovine TLR9)

5 MGPYCAPHPLSLLVQAAAALAAEGLPAFLPCELOPHQVDCNWLFLKSVPHSAGAPRANVTSLSLISNRIH
 HLHDSDFVHLSNLRVLNWKWCNPPAGLSPMHPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLISL
 10 HTSILVLGPTHFTGLHALRFLYMDGNCYYMNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPTRLPPSLDTLL
 LSYNHIVTLPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLDSSLYKLEK
 DWFRGLGRLQVLDLSENFLYDITKTTIFNDLTQLRLNLSFNYHKKVSAHLHLASSFGSLVSLEKLDMHGIFF
 RSLTNITLQSLTRLPKLQSLHLQLNFINQAOQLSIFGAPPSSLLFVDSLSDNRISGAATPAAALGEVDSRVEVWRLLPR
 15 GLAPGPLDAVSSKDFMPSCNLNFTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLSLRVLD
 LSHNKLDLYHGRSFTELPQLEALDLISYNSQFSMQMVGVGNLNSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
 LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLDNNLAFFNWSSLTVLP
 RLEALDLAGNQLKALSGNSLPPGIRLQKLDVSSNSIGFVIPGFVURATRLIELNLSANALKTVDPFWFGSLAGTLL
 KILDVSANPLHACGAAAFVDFLLERQEAAPGLSRRVTCGSPQQLQGRSIFTQDLRLCLDETLSDLCFGSLLMVA
 IGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEERRGRRAL
 20 RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLAQQLLEDRKDVVVLVILRPAAYRSR
 YVRLRQRLCRQSLLWPHQPSQGSFWANLGIALTRDNRHFYNRNFCRGTTAE

SEQ ID NO:10 (Bovine TLR9)

20 MGPYCAPHPLSLLVQAAAALAAEGLPAFLPCELOPHQVDCNWLFLKSVPHSAGAPRANVTSLSLISNRIH
 HLHDSDFVHLSNLRVLNWKWCNPPAGLSPMHPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLISL
 25 HTSILVLGPTHFTGLHALRFLYMDGNCYYMNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPTRLPPSLDTLL
 LSYNHIVTLPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLDSSLYKLEK
 DWFRGLGRLQVLDLSENFLYDITKTTIFNDLTQLRLNLSFNYHKKVSAHLHLASSFGSLVSLEKLDMHGIFF
 RSLTNITLQSLTRLPKLQSLHLQLNFINQAOQLSIFGAPPSSLLFVDSLSDNRISGAATPAAALGEVDSRVEVWRLLPR
 30 GLAPGPLDAVSSKDFMPSCNLNFTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLSLRVLD
 LSHNKLDLYHGRSFTELPQLEALDLISYNSQFSMQMVGVGNLNSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
 LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLDNNLAFFNWSSLTVLP
 RLEALDLAGNQLKALSGNSLPPGIRLQKLDVSSNSIGFVIPGFVURATRLIELNLSANALKTVDPFWFGSLAGTLL
 KILDVSANPLHACGAAAFVDFLLERQEAAPGLSRRVTCGSPQQLQGRSIFTQDLRLCLDETLSDLCFG

SEQ ID NO:11 (Bovine TLR9)

35 gggaaagtgggcgccaagcataccttcctgcagctgcctccaaacctggccgcagaccctctggagaagccgcat
 tccctgtcatggggccctactgtgcggccgcacccctttctcttcgtggcaggccggactggcagccggcc
 tggcccgagggcaccctgcctgccttcgtggcggccatggctcagggtggactgcaactggctgt
 40 tcttgaagtctgtgcgcacccatggctggagccccccggccaatgtcaccaggccttccttaatctccaacc
 gcatccaccacttgcactgtgcacttcgtccacccgtccaaacctgcgggtccatcaacctcaagtggaaactggc
 cgccggccggccatgcacttcctgcgtatgaccatgcggccaaacaccttcctggctgtggcc
 ccctggaggagctgaacctgagctacaacggcatcagaccgtgcctgcctggccaggccctctgtgtccctgt
 cgctgagccacaccagcatctggcttaggccccaccacttcaccggccgtcagccctgcgttctgtaca
 45 tggacggcaactgtactacatgaacccctgcccggccctggagggtggcccccaggccctccggccctgg
 gcaacccctacgcacccgtcgctcaagtacaacaacctcagggagggtgcggccctgcggccctggaca
 ccctgtctgtgcctacaaccatgtgcacccctggcaccggaggacctggccaaacctgtactgcctgcgtgc
 ttgacgtgggtggaaactgcgcgcgtgcgaccatgcggcaacccctgcaggagggtggccaaagaacttcccc
 agctgcacccctgacacccatgtcactgcggccctgcgacccctggagggtggccaaagacttctctaca
 50 tagagaaagattggccggccctggggcaggctcaagtgcgtcaccgtggactgtgagaacttcccttatgactaca
 tcaccaagaccaccatcttcaacgcacccgtgcgcacactcaacctgtccttcattaccacaagaagg
 tgccttcgcctccacccatgcacccatgcgtccctttggggaggctggctgtccctggagaagctggacatgcacggca
 tcttcttcgcctccctccatccaacatcagccgtccatgcgtccctggagggtggccaaacctgtccagactgt
 agctgaacttcatcaaccaggcccagctcagcatcttggggccttcggcagggtggacagcagggtggaaagtctggc
 gatgcacccgcattcggcggccgcacgcggccaggccctggggagggtggacagcagggtggaaagtctggc
 55 acaaccgcattcggcggccgcacgcggccaggccctggggagggtggacagcagggtggaaagtctggc
 tgcccaggggccctcgctccaggccccgtggacccgtcagctcaaaggacttcatgcacccgcacttcc
 tcacccctggacccgttcacggaaacaacctgggtgacaatccaggcaagagatgttacccgccttc
 ccgcctccactgcgcctgagccacaacagcatctcgcaggccgttaatggctccaggccgtgaccaggc
 ctgcg

- 14 -

5 tgctegacctgtcccacaacaagaacctggacgttaccatggcgctcattcacggagctgccgcagctggaggcac
 tggacctcagctacaacagccagcccttcagcatgcagggcggtggccacaacactcagcttcgtggcccagctgc
 ctcctgcgtacaccttcagcggcaactccctgaggccatgtggacatccatggcatccacaggccgcgtcacagaagctcagcgcctcg
 tgcgcgcctggacttcagcggcaactccctgaggccatgtggacatccatggcatccacaggccgcgtcacagaagctcagcgcctcg
 10 aaggcttgaggaaaccttggctcagctggacatccatggcatccacaggccgcgtcacagaacccatctgcacacccttcgtcgtcacctggaca
 acctggccaaagagcctgcggcagctgcgttcggagaaacccatgtggacatccatggcatccatggcatccacaggccgcgtcac
 tcctgccccggcttggaaaggccctggatcttggcaggaaacccatgtggacatccatggcatccatggcatccatggcatcc
 15 gcatccggctccagaagactggacgtgagcagcaacagcatccgcgtatccatggcatccatggcatccatggcatccatggcatcc
 ctccggctatagagcttacccatggcggcaatggcatccatggcatccatggcatccatggcatccatggcatccatggcatcc
 20 ggacccctgaaaatcctagacgtgcggcaaccccttcactgcgcctgcggggggggccttggacttcctgc
 tggagagacaggaggccgtggccgggttcggcggcgtcacatgtggcagtcggggccagctccaggccgc
 gcatcttcacacaggacacttcgccttcgtggatggaccccttccttggactgtttggccttcactgtcaa
 tggggcgtggccctggcgtggcgtggcaccatgtgcaccacccatgtggactgtggactgttccacccatgt
 gtctggcccatttgcggccggccggcggcggcggcggcggcggcggcggcggcggcggcggcggc
 15 acaagggtgcagagtgcgtgctgattgggttacaacagagctccgcgtcagtgaggacaccctgtctatgtatgcgcgtggatcc
 gggcgctccgccttcgcctggaggagcggagactggccctggtaagacgcgttcgcggccatccatggcc
 tctacagcagcccaagaccatgttcgtgctggaccacacggccgggtcgcggccatccatggcc
 tgctggcccagcagccgttggaggaccgcggcggcggcggcggcggcggcggcggc
 ggtccgcgtacgtgcggctgcggccagccgttgcggccatccatggcc
 20 agggtagttctggccaacctggcatagccctgaccaggacaaccgtcaacttctataaccggaaacttctgc
 gggggccccacgcacagccgaatagcacaaggactgtactgc

SEQ ID NO:12 (Bovine TLR9)

25 atggggccctactgtggcccccacccctttcttcctggcaggcgccggcactggcagccgcctggccgag
 ggcacctgcctgccttcgtggccctgtgagctccagccatgtcaggtggactgcactggctttctgaag
 tctgtgcgcacttttcggctggagccccccggccaatgtcaccgccttccttaatctccaaaccgcac
 cacttgcgtactctgacttcgtccacccatgtccacccatgtggccctcaacccatgcggcc
 ggcctcagcccatgtcacttccctggccgtatgaccatgcggccacacccatgcggcc
 gagctgaacctgagctacaacggcatcaccgcggcgtccctggcc
 30 cacaccacatcctggcttgcggcccccacttcaccggcctgcacgccttcgttatggaccc
 aactgtactacatgaacccctgcggccggccctggaggtggcccccaggccgccttcggcctggcaaccc
 acgcacctgtcgtcaagtacaacaacccatgcggaggtggccggccctggcc
 ctgtccatacaaccacattgtcaccctggccacccggaccctgactgc
 ggtgggaactgcggccgtgcggccatgcggccaaacccctgcagg
 35 ggttatggccatgcggccatgcggccatgcggccaaaggaaacttcccaagctgcac
 cctgcacacccatgtcgtccatggccatgcggccatgcggccatgc
 ggttatggccatgcggccatgcggccatgcggccatgcggccatgc
 ggttatggccatgcggccatgcggccatgcggccatgcggccatgc
 40 ttcatcaaccaggcccacgcacatcttggggcctcccgagcc
 atcagggagccgcacgcacccgcggccctgggggggggggg
 ggcctcgctccaggccgcgtggacccgcgtcaaaaggact
 gacccgtcaccgcgttatggccatgcggccatgcggccatgc
 ctgagccacaacacgcacatctgc
 45 ctgtcccacaacaagaacctgttaccatggcgctcatt
 agctacaacacgcaccccttcacgcacccgcgttatgg
 cgctacccatgcgttcgcacaatggcatccacaggccgc
 ctggacttcagccgttatccatggc
 50 aagagccgcggcagctgcgttcggagaaaccatctgc
 cggcttgcggatctggcaggaaaccatgtgg
 ctccagaagctggacgtgagcagcaacacgcac
 atagagcttaacctcagcccaatggcc
 55 aaaatcttagacgtgagcgc
 caggaggccgtggccggctgtccaggcc
 acacaggacctgcgccttcgc

SEQ ID NO:13 (Equine TLR9)

5 MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWFLKSVPHFSAAAPRDNVTSLSLLSNRI
 HHLHSDFAQLSNLQKLNWKNCPPAGLSPMHPCCHMTIEPNTFLAVPTLEELNSYNGITTVPALPSSLVSLIL
 SRTNILQLDPTSLTGLHALRFLYMDGNYYKNPCGRALEVAPGALLGLGNLTHLSLKYNLTTVPRSLPPSLEYL
 LLSYNHIVTLPEDLANLTALRVLVDGGNCRRCDHARNPCVECPHFPQLHSDFSHLSRLEGLVLDSSLYQLN
 PRWFRGLGNLTVIDLSENFLYDCITKTAKFQGLAQIQLRLNLSFNYHKKVSFAHLLAPSFGSLLSLQELDMHGIF
 FRSLSQKTLQPLARLPMLQRLYQLQMFNQAOQLGIFKDFPGLRYIDLSDNRISGAVEPVATTGEVDGGKKVWLTS
 RDLTPGPLDTPSSEDFMPSCNLSFTLDSRNNLTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV
 10 LDLSHINKLDLYHGRSFTELPRLEALDLSYNSQPFMSMRGVGHNLSFVAQLPTLRLYLSLAHNGIHSRVSQQLCSTSL
 WALDFSGNSLSQMAEGDLYLRRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLLRLRNYYLAFFNWSSLTL
 LPNLETLDLAGNQALKALSNGSLPSGTQLQRLDVSRSNIIFFVPGFFALATRLRELNLSANALRTEEPSWFGFLAG
 SLEVLVDVSANPLHCACGAAFDVDFLLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFGSLLV
 15 VALGLAMPMLHHLCGWDLWYCFHLGLAWLPRRGWQRGADALSYDAFVVFDAQSAADVWVYNELRVLEERRGR
 ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQRLLLEDRKDVVVLVILSPDARR
 SRYVRLRQRLCROSVLFWPHQPSGQRSFWAQLGMALTRDNRHFYQNQNFCRGPTMAE

SEQ ID NO:14 (Equine TLR9)

20 MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWFLKSVPHFSAAAPRDNVTSLSLLSNRI
 HHLHSDFAQLSNLQKLNWKNCPPAGLSPMHPCCHMTIEPNTFLAVPTLEELNSYNGITTVPALPSSLVSLIL
 SRTNILQLDPTSLTGLHALRFLYMDGNYYKNPCGRALEVAPGALLGLGNLTHLSLKYNLTTVPRSLPPSLEYL
 LLSYNHIVTLPEDLANLTALRVLVDGGNCRRCDHARNPCVECPHFPQLHSDFSHLSRLEGLVLDSSLYQLN
 PRWFRGLGNLTVIDLSENFLYDCITKTAKFQGLAQIQLRLNLSFNYHKKVSFAHLLAPSFGSLLSLQELDMHGIF
 FRSLSQKTLQPLARLPMLQRLYQLQMFNQAOQLGIFKDFPGLRYIDLSDNRISGAVEPVATTGEVDGGKKVWLTS
 25 RDLTPGPLDTPSSEDFMPSCNLSFTLDSRNNLTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV
 LDLSHINKLDLYHGRSFTELPRLEALDLSYNSQPFMSMRGVGHNLSFVAQLPTLRLYLSLAHNGIHSRVSQQLCSTSL
 WALDFSGNSLSQMAEGDLYLRRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLLRLRNYYLAFFNWSSLTL
 LPNLETLDLAGNQALKALSNGSLPSGTQLQRLDVSRSNIIFFVPGFFALATRLRELNLSANALRTEEPSWFGFLAG
 SLEVLVDVSANPLHCACGAAFDVDFLLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFG
 30

SEQ ID NO:15 (Equine TLR9)

35 ctctgttctctgagctgttgcgcgtgaaggactgcgagcacaaagcatctccctctgcagctgtgtccccagtg
 tgccagctggaccctctggatcatctccactccctgtcatggcccttgcacggccctgtctccctgtccctgtct
 ctccctggtcaggccatgtggccgtggcttgcacggccatgtggcccttgcacggccatgtggcccttgcacggcc
 cagccccacggccatgtgaaactgcacactggctgttccctgaagttccgtgtcccttgcacggccatgtggcc
 gacaatgtcaccagccttccttgctctccacccgcacccgcactccacactccgcacttgcacccactgtcc
 aacctgcagaaaactcaacccaaatggaaactggccgcgcctcagcccatgcacttccctgcacatgc
 accatcgagccaaacactttccctggctgtaccacccctggaggagctgaacttgacactacaacggcatc
 gtgcctgcctgcctgcgttccctgtatccctgatccctgagccgcacccatgtgcacccatgtgcaccc
 40 ctcacggccctgcacgcctgcgttccctatccatggatggcaactgtactacaagaacccctgcggccggcc
 ctggagggtggcccccaggcccttcctggccctggcaacccatccacccgcacttcactcaactacaaccc
 acgggtgcggccgcgcctgcgttccctgtatccctggccgcctcagcccatgcacttccctgcacatgc
 gaggacctggccaaatctgactgcctgcgtgtgtatccctggccgcctgcacccatgcaccc
 aacccctgcgtggaggccacataaaatcccccagctgcactccgcacacccatgcaccc
 45 ggcctcgtgttgcacccatgcacccatgcacccatgcacccatgcacccatgcacccatgcaccc
 ctgcacccatgcacccatgcacccatgcacccatgcacccatgcacccatgcacccatgcaccc
 agactcaacttgccttcattaccataagaagggtgccttcgcacccatgcacccatgcaccc
 ctgcctccctgcacccatgcacccatgcacccatgcacccatgcacccatgcaccc
 50 gacttccctggctgcgtacatagacccatgcacccatgcacccatgcacccatgcacccatgcaccc
 gggagggtggatggggaaaagggtctggctgcacccatgcacccatgcacccatgcaccc
 tctgaggacttgcacccatgcacccatgcacccatgcacccatgcacccatgcaccc
 cagccagagatgttgcctgcacccatgcacccatgcacccatgcacccatgcaccc

- 16 -

5 aatggctcacagttcgccactgaccagcctgcagggtgtggacactgtccataacaaactggacctgtacca
ggcgtcggttacggagctggccgcactggaggccctggacactacaacagccagcccttcagcatgcgg
ggtgtggccacaacctcagttgtggccagctgcccacccctgcgtacactcagctggcacacaatggcata
cacagccgtgtgtcccagcagctctgcagcacctcgctgtggccctggacattcagcggcaattccctgagccag
atgtggctgagggagactctatctcgcttctccaaggcctgagaagctaatcccgctagactctgtccca
aatcgctcgatcacccctctgcccattgcacccctggcaacctcccaaggacttgcagctgtgcgtctcgtaac
aattacctggccttctcaattggagcagcctgaccctctgcccacccctggaaacccctggacactggctggaaac
cagctgaaggctcgagcaatggcagcctgccttctggcaccctgacactccagctccagaggctggacgtcagcaggaaac
atcatcttcgtggccctggctttgtctggccacggctgcagagactcaacccctagtgccaaacgcgcctc
10 aggacagaggagccctctgggttgggttccctagcaggctccctgaaagtcttagatgtgagcgcacccctctg
caactgcgcctgtggggcagcccttggacttctgtcaggttcaggctgcccgtctggctgcccacccgc
gtcaagtgtggcagttccggccagctccagggcccagcatcttcgcacaagacactgcgcctctggacaag
tccctctccctggactgtttggctctcattgtctgggttgcgcctggccatgcctatgttgacccac
ctctgcggctggacactctggactgtttgtctcattgtctgggttgcgcctggccatgcctatgttgacccac
15 gccgatgccttagatgtgccttgcggcttcgacaaggcacagagcgcagtgcccactgggtgtcaaat
gaactgcgggtgcggctagaggagcggcgtggccggcgcctccgtgtctggaggagcgtgactggcta
cctggcaagacgcgttgcggaaaacctgtggcctcagtcacagcggcgaagatgtctgggtgtcaaat
acggaccaggcgtggcccttgcgtgcagctccctgtgcgcctggaggaccccaaggac
gttgggtgtggtaatctgagccctgacgcccgttccctgtgtggctgcgcctggccagcgcctctggcc
20 cagagtgtcccttctggcccccacccgcctactgtggccagcgcagcttcgtggccctggccatggcatggcc
aggacacccgcacactataaccagaactctgcggggccgcacgtggctgagtagcacagactgacagcc
tggcatgtacaaccccccagccctgacccctgcctctgcctatgtatgcctcactctgtgaccc
tgcctgcctccgcacccctcaccctggcatacagcaggcactcaataatgccactggcaggccaaacagcca
aaaaaaaaaaaaaaaaaaaa

SEQ ID NO:16 (Equine TLR9)

atggggcccttgccatgggcctgcagccccctgtctctctggtcaggccatgtggccgtggctctggcc
30 caaggcaccctgcctcccttcctgcctgtgactccagccccacggcctgtgaactgcacactggctttctggcc
aagtccgtgcccacttcctcagcagcagccccggacaatgtcaccaggccttcctgtctccaaaccgcac
caccacccatccacgactccgactttgcctcaactgtccaaactgcagaaactcaacccatcaatggaaactggcc
35 gccggcctcagccccatgcacttccctgcacatgaccatcggccaaactttctggctgtacccaccctg
gaggagctgaacctgagctacaacggcatcagactgtgcctccctggccagctccctcggtgcctgtatccctg
agccgcaccaacatccctgcagctagacccaccagcctcagggcctgcacggccctgcgtccctatatacatggat
ggcaactgtctactacaagaacccctgcggggggccctggaggtggcccaggccgccttcctggctggccaaac
35 ctcacccacccctgtcactcaagtacaacccatcacaacggtgccctgcagctggcccttagctggagttacccctg
ctgttgcctacaaccacattgtcaccctggcactggagactggccatctgactgcctgcgtgtctcgat
gtgggtggaaactgcgcgcgtgtgaccatgcacgcacccctgcgtggagtgcccacataattccccccagctg
cactccgacacccatcagccacctaagccgcctagaaggcctgtgtgaaggatagttctctacccagctgaaac
40 cccagatggttccgtggctggcaacccatcagtgctgactggagtgagaacttcctctacgactgcac
aaaaccaaggcattccagggcctggccagctgcgaagactcaacttgtcctcaattaccataagaagggtgtcc
ttcgcccacccgtacgcgtggccatccctgggagccctgtctccctgcaggaactggacatgcatggcatcttc
ttccgtctactcagccagaagacgcgtccagccactggccgcctgcctatgcctccagcgtctgtatctgcagatg
aacttcatcaaccaggcccagctccgcacatcttcaaggacttcctggctgtgcctacatagacccatgcagacaac
45 cgcacatcgtggagctgtggagccgtggccaccacagggggaggtggatggggaaagaaggctgtggctgacatcc
aggacccactccaggcccactggacaccccccagctctgaggacttcatgcacactgcagaactccatcgttc
acccctggacccctgtcagggacaacccatgttaacagtgccagccagagatgttgcctccagctctcgccctccagtg
ctgcgcctgagccacaacagcatctcgcaggccgtcaatggctcacagttcgtgcctactgaccagccgtcagggt
50 ctggacccatgtccataacaaactggacccatgtaccatgggcgtcgatccggagactgcggccactggaggccctg
gaccatcagctacaacagccagcccttcagcatgcgggggtgtggccacaacccatgcgttttgcctccagctgccc
acccttgcgtacccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
55 tggggccctggacttcagccaaatccctgagccagatgtgggtcgagggggagacccatctatctccgttcttccaa
ggccctgagaagccataatccctgtagccatgtcccaatccatccatccatccatccatccatccatccatccatcc
ctcccaagagatgtcagctgtcgctccgtaaacattacccatccatccatccatccatccatccatccatccatcc
ctgccccacccatggaaacccctggacccatggtaacccatccatccatccatccatccatccatccatccatcc
accagactccagggatgtggacgtcagcaggaaacccatccatccatccatccatccatccatccatccatcc
aggctgcgagactcaacccatcgtgcacccatccatccatccatccatccatccatccatccatccatccatcc
tcccttgaactgttagtgcggccaaacccatctgcactgcggctgtggggcagcccttgcgtggacttccatcagggc

- 17 -

caggttcaggctccgtgcctggctgcccagccgcgtcaagtgtggcagtcggccagtcagggccgcagc
atcttcgcacaagacacctgcgcctctgcctggacaagtcctctcggactgttttgtt

SEQ ID NO:17 (Ovine TLR9)

5 MGPYCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGVNCNWLFLKSVPRFSAGAPRANVTSLSLISNRIH
HLHDSDFVHLSNLRVLNWKWCNPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTPALPSSLVSLSLIS
RTSILVLPPTHFTGLHALRFLYMDGNCYYKNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPKNFPKLHPTDFSHLSRLEGLVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRNLNSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF
10 RSLTNNTLRPLTQLPKLQSLQSLQLNFINQAEELSIFGAFPSLLFVDSLSDNRISGAARPVAALGEVDSGVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPSMVGVGNLSSFAQLPSLRLYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGLYLCFFKGLRNVLQVLDLSKNHLHLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
QLEALDLAGNQLKALSNGSLPPGTRLQKLDVSSNSIGFVTPGFVLANRLKELNLSANALKTVDPFWFGRLTETL
15 NILDVSANPLHCAAGAAFDLLEMQAAVPGLSRRVTGSPGQLQGRSIFAQDLRLCLDETLSDLCFGFSLLMVA
LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAFVVFDKAQSAAVADWVYNELRVQLEERRGRRAL
RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLAQQLLEDRKDVVVLVILRPAAYRSR
YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGMALTRDNRFYNRNFCRGPTTAE

20 SEQ ID NO:18 (Ovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGVNCNWLFLKSVPRFSAGAPRANVTSLSLISNRIH
HLHDSDFVHLSNLRVLNWKWCNPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTPALPSSLVSLSLIS
RTSILVLPPTHFTGLHALRFLYMDGNCYYKNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPKNFPKLHPTDFSHLSRLEGLVLKDSSLYKLEK
25 DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRNLNSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF
RSLTNNTLRPLTQLPKLQSLQSLQLNFINQAEELSIFGAFPSLLFVDSLSDNRISGAARPVAALGEVDSGVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPSMVGVGNLSSFAQLPSLRLYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGLYLCFFKGLRNVLQVLDLSKNHLHLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
30 QLEALDLAGNQLKALSNGSLPPGTRLQKLDVSSNSIGFVTPGFVLANRLKELNLSANALKTVDPFWFGRLTETL
NILDVSANPLHCAAGAAFDLLEMQAAVPGLSRRVTGSPGQLQGRSIFAQDLRLCLDETLSDLCFG

SEQ ID NO:19 (Ovine TLR9)

35 gtcggcacgggaagtgagcgccaagcatccctccctgcagctgccgcacacttgcggccagaccctctggaga
agccgcattccctgcacatggcccccactgtgcggccgcacccctttctctctggcggccgcgtggc
agcagccctggcccaggccacccctgcctgccttcctgcctgtgagctccagccccgggtaaggtaactgcaa
ctggctgttccctgaagtctgtgcggcggtttcggccggagccccccggccaatgtcaccagccttccttaat
ctccaaccgcattccaccactgcacgactgtacttcgtccacctgtccaaactgcgggtcctcaacactcaagtg
gaactgcccgcggccggctcagccccatgcacttccctgcgcacatgcggccaaacacttcctggc
40 tggcccaccctggaggagctgaacctgagctacaatggcatcacgaccgtgcctgcctgcggccaggttctctgt
atccctgtcgctgagccgcaccagcatctggctgtaggccccaccacttcaccggcgcacgcctgcgcct
tctgtacatggacggcaactgtctactataagaaccctgcacggcggtggagggtggcccccaggccctct
tggctggcaacctcagcacctgtcgtcaagtacaacaacctcagggagggtggccgcctgccccccag
cctggacaccctgtctgtcgttacaaccatcatcaccctgcacccgaggacctggccaaatctgactgcct
45 gcgtgtgcttgatgtggcgaaactgcggccgtgcaccacccgcacccctgcaggaggatggccaaagaa
cttcccaagctgcaccctgacaccctcagccacctgagccgcctgcacggcctgggttgaaggacagttct
ctacaaactagagaaaagactgggtccggccctggcaggctcaagtgcgtcaccactgatgagaacttcctcta
tgactacatcaccatcaccacatcttcaaggaacctgcaccacccgcgtgcgcagactcaaccctgccttcaattacca
caagaagggtgccttcgcaccctgcacactggcaccctccctttggggcctgggtgtccctggagaagctggacat
50 gcacggcatcttcctccgcctccctcaccacaccacgcgtccggccgtgacccagctgcccagctccagact
gagtctgcagctgaacttcatcaaccagccgcagctcagcatcttggggcctccgcaggcctgccttcgtgg
cctgtcgaccaaccgcacagcggagctgcggagggccgggtggcccccctcgccggaggtggacagcgggtggaaagt
ctggcggtggcccaaggggccctgcgtccaggccgcgtggccgcgtcagcgcacaggacttcatgcacactgca

- 18 -

25 SEQ ID NO:20 (Ovine TLR9)

- 19 -

caggccggccgtgcctggctgtccaggcgcgtaacgtgtggcagtcggccagctccaggccgcacatttc
gcacaggacctgcgcctgtgcctggatgagacccttccttgactgcttggc

Complete nucleotide and amino acid sequences for canine and feline TLR9 are
5 publicly available. For example, an amino acid sequence for canine TLR9 is available as
GenBank accession number BAC65192 and its corresponding nucleotide sequence is
available as GenBank accession number AB104899. An amino acid sequence for feline
TLR9 is available as GenBank accession number AAN15751 and its corresponding
nucleotide sequence is available as GenBank accession number AY137581.

10 Complete nucleotide and amino acid sequences for canine and feline TLR9 were also
determined independently from those available from public databases.

An amino acid sequence of canine TLR9 is provided as SEQ ID NO:21. Based on
comparison with known amino acid sequences of human and murine TLR9, it appears that
SEQ ID NO:21 includes sequence for at least a majority of the extracellular domain, all of the
15 transmembrane domain, and at least a portion of the intracellular domain of canine TLR9
(See Figure 1). Amino acids numbered 1-822 of SEQ ID NO:21 are presumptively
extracellular domain and correspond to SEQ ID NO:22. SEQ ID NO:23 is a nucleotide
sequence of canine TLR9 cDNA having an open reading frame corresponding to nucleotides
91-3186. SEQ ID NO:24 is a nucleotide sequence of canine cDNA encoding amino acids 1-
20 822 of SEQ ID NO:21.

An amino acid sequence of feline TLR9 is provided as SEQ ID NO:25. Based on
comparison with known amino acid sequences of human and murine TLR9, it appears that
SEQ ID NO:25 includes sequence for at least a majority of the extracellular domain, all of the
transmembrane domain, and at least a portion of the intracellular domain of feline TLR9 (See
25 Figure 1). Amino acids numbered 1-820 of SEQ ID NO:25 are presumptively extracellular
domain and correspond to SEQ ID NO:26. SEQ ID NO:27 is a nucleotide sequence of feline
TLR9 cDNA having an open reading frame corresponding to nucleotides 87-3179. SEQ ID
NO:28 is a nucleotide sequence of feline cDNA encoding amino acids 1-820 of SEQ ID
NO:25.

30

SEQ ID NO:21 (Canine TLR9)

MGPCRGALHPLSLLVQAAALALALAQQTLPNFLPCELQPHGLVNCNWLFLKSVPRFSAAAPRGNVTSLSLYSNRI
HHLHDYDFVHFVHLRRLNWKWCPPASLSPMHFPCHMTIEPNTFLAVPTLEDLNLSYNSITTVPALPSSLVSLSL
SRTNILVLDPATLAGLYALRFLLDGNCYYKNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYL

- 20 -

5 LLSYNHIITLAPEDLANLTALRVLVGGNCRRCDHARNPCRECPKGFPQLHPTFGHLSHLEGLVLRDSSLYSLD
PRWFHGLGNLMLVLDSENFLYDCITKTKAFYGLARLRLNLNSFNYHKVSPAHHLASSFGSLLS1QELDINGIF
FRSLSKTTLQSLAHLPMQLRLHLQLNF1SQAOLS1FGAFPGLRYVLDSDNR1SGAAEPAAATGEVADGERVWP
QSRDLALGPLGTPGSEAMPSCRTLNFTLDLSRNLLVTQPEMFVRLARLQCLGLSHNS1SQAVNGSQVPLS1L
RVLDLSHNKLDLYHGRSFTELPRLEALDL1SYNSQPFMSMRGVGHNL1S1FVAQ1PALR1YLSLAHNG1HSRVSQQLRSA
SLRALDFSGNTLSQMWAEGLYLRFFQGLRSLVQLDLSQNRLH1LLPRNL1DLPKSL1RL1RLRDNLYAFFNWSSL
10 ALLPKLEALDLAGNQLKALSNGSLPNGTQ1QLRDL1SGNS1GFFV1PSFF1ALAVRL1NLS1ANALKTVEPSWF1GSL
AGALKV1LDVTANPLHCACGATFVDF1LEVQAAVPG1PSRVKCGSPGQ1LQGRS1FAQD1RL1CL1DEAL1SWVCF1S1L
LAV1SLAVPMLHQLCGWDLWYCF1L1CAWL1P1RR1GRR1GVD1ALAYDAF1V1FD1KAQSS1VADWVYNE1LRVQ1EERRG
RRALRL1CLEERD1WVPGKT1F1EN1L1WASVYSSRKT1F1L1ARTD1RV1G1L1RAS1F1LAQ1R1L1ED1R1KD1VV1L1V1CP1DA
HRSRYV1RL1Q1R1C1Q1S1L1W1P1H1Q1P1G1R1F1Y1N1O1C1R1G1P1T1A

SEQ ID NO:22 (Canine TLR9)

15 MGPGRGALHPLSLLVQAAALALALAQGTLPAFLPCELQPHGLVNCNWFLKSVPFRSAAAPRGNVTSLSLYSNRI
HHLHDYDFVHFVHLRRLNLKWNCPPASLSPMFPCMHMTIEPNTFLAVPTILEDNLNSYNSITTVPALPSSLVSLSL
SRTNIVLVLDPATLAGLYALRFLFLDGNCYYKNPQOOALQVAPGALLGLGNLTHLSLKVNNLTVVPRGLPPSLEYL
LLSYNHIITLAPEDLANLTALRVLVDVGGNCRRCDHARNPCCRECPKGFPQJLHPNTFGHLSHLEGVLVRDSSLYSLD
PRWFHGLGNLMLVLDLSENFLYDCITTKAFYGLARLRLNLFSFNYHKKVSFAHLHLSASSFGSLLS1QELDIHGF
FRSLSKTTLQSLAHLPLMQLRLHLQLNFISQAOQLS1FGAFPGPLRYVLDLSDNRISGAAEPAATGEVEADCGERVWP
20 QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLRSRNLLTVQPEMFVRLARLQCLGLSHNS1SQAVNGSQFVPLSNL
RVLDDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFMSRGVGHNLSFVAQLPALRYLSLAHNGIHRSVSQLRSA
SLRALDFSGNTLSQMWAEGDLYLRFQGLRSLVQQLDSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSSL
ALLPKLEALDLAGNQLKALNSNGSLPNTQLQRLDLSGNS1GFVVPSSFALAVRLRELNLSANALKTVEPSWFGSL
AGALKVLDVTANPLHACCGATFVDFLLEVQAAVPGPLPSRVKGSPGQLQGRS1FAQDIRLCLDEALSWVCF5

SEQ ID NO:23 (Canine TLR9)

30 aggaaggggctgtgagotccaagcataccttcctgcagctgtgcggccagccatggagaa
cccccgctccctgtcatggccctgcgtggccctgcacccctgtctctccctgtcaggtgcgcgcta
gcctggccctggcccaggcaccctgcctgcctgcctgtgagctccagccatggcttggtaactgc
aactggctttcctcaagtccgtggcccggttcctggcagctgcaccccgccgtaaacgtcaccagecttccttg
tactccaaaccgcattccaccacccatgcactatgactatgcatttgccttcacatgcggcgtctcaatctcaag
tggaaactgcccggccgcagcctcagccccatgcactttccctgtcatacatgaccattgagccaaacaccccttcctg
gtgtggccaccctagaggacctgaatctgagctataaacagcatcacgactgtgcggccctgcggcagttcgctt
gtgtccctgtccctgaggcgacccatcctgtgtggaccctgcaccccttgcaggcccttatggccctgccc
35 ttctgttccggatggcaactgctactacaagaacccctgcacccctgcaggccctgcagggtggcccccagggtgcctc
ctggggcctgggcaacctcacacaccctgtcactcaagtacaacaacccatcaccgtggccgcggggcctgcctggccccc
acccctggagtagacctgtcttgcctacaaccacatcatcaccctggcacctggagacactgtggccaaatctgactgc
ctgcgtgtccctcgatgtgggtggaaactgtgcggctgtgaccatgcctgtgtggccctgcaggaggtggcccaag
ggcttccccccagctgcaccccaacacccatcggccacccctgagccacccctgagaaggcctgtgttgaggagacagctct
40 ctctacagccctggacccagggtggttccatggcctggcaacctcatgggtgtggacactgagtgagaacttcctg
tatgactgcatcacaaaaccaaaagcccttacccgcctggccggctgcccggctgcccggactcaacccatccttcattat
cataagaagggtgtcccttgcacccatgcacatctggcatctcccttcctggagactgtccctgcaggagactggac
atacatggcatcttctccgcgtcgtcagcaagaccacgcctccagtcgtggccaccctgcccattgcctcagcc
45 ctgcacatctgcagttgaactttatcagccaggccacagtcagcatottcgcccttccctggactgcggtagctg
gacttgtcagacaaccgcacatcagtgagctgcagagcccgccgtccacaggggaggttagaggcagactgtgg
gagagagtctggccacagtcggggacccctgtctggccactgggcaccccccggctcagaggccattgc
actgcaggaccctcaacttcacccctggacccctgtctcggaacaacccatgtgactgttcagccggagatgttgc
50 cggctggcgcgcctccagtcgtggccgtgagccacaacagcatctcgccaggcgtcaatggctcgagttcg
cctctggacacccctgggggtgtggacccctgtccatataacaagctggacccctgtaccacccggcgtcgttac
ctggccggctggaggccctggacccctcagtcataacagccaccccttcagcatgcggggcgtggccacaatctc
acttttgccacagtcgtggccacccctgcgtacccctcagccctggccgtccatggccatccacagccgcgtgtcc
55 cagtcgtccgcacccctgcgtccggccctggacttcgtggcaataccctgagccagatgtggccggagggagac
ctctatctccgttccatcaaggccctgagaaggccctgggtcagtcgtggacccctgtaccacccggcgtcata
ctggccacccatggacacccctcccaaggagccctgcggcccttcgtgacaaattacccctggcttcttc
aactggagcagccctggcccttcataccaaagctggaaagccctggacccctggccggaaaccagctgaaggccctgac

- 21 -

aatggcagcttgcaccaacggcaccaggctccagaggctggacctcagcggcaacacgcacatcggttcgtggcccc
 agctttttgccttggccgtgaggctcagagactcaacccatcgccaaacgcctcaagacggtgagccctcc
 tggttgttccctggccgtggccctgaaagtccatagacgtgaccgccaacccctgtcaattgcgttcgtggccgca
 accttcgtggacttcttgcggaggtcaggctgcgggtgcccggctgcctagccgtgtcaagtgcggcagcccg
 5 ggccagctccagggccgcagcatcttcgcacaggacctgegcctctgcctggacgaagcgtctccctgggtctgt
 ttcaagcctctcgctgtggctgtggccctgagcctggctgtgcctatgcaccagactctgtggctggaccc
 tggtaactgttccacctgtgcctggctggctgcctggccgggggggggggggggggggtgtggatgcctggccat
 gacgccttcgtggcttcgacaaggcgcagagactcggtggccgactgggttacaatgagctgcgggtacagcta
 gaggagcgcgtggggccggccggccgtacgcctgtgtggaggaaacgtgactgggtacccggcaaaaccctttc
 10 gagaacctctggccctcagttacagcagccgcagacgcgtttgtgtgcggccgcacggacagagtcagccgc
 ctccctgcgtgccttcgtggcccaacagcgcctgtggaggaccgcaggacgtcggtgtgtgatc
 ctgtggcccccacgcgcctccgcgttgcgcctgcgcgcctgcgcgcacaggtgtctccctctgg
 cccaccagcccaactgtggccagcgcagcttcgtggccacgcgcctgcaccaggacaaccgcacttc
 tacaaccagaacttctgcggggcccccacgcacagcctgtataggcagacagccagcaccctcgccctacacc
 15 ctgcctgtctgtctggatggccgcctgt
 taaagcgaccgctcaataatgctgtgttagac

SEQ ID NO:24 (Canine TLR9)

atggggccctgcggcgcctgcaccccccgtctctctggcgcggctgcggcgctagccctggccctggcc
 20 caggccacccctgcctgccttcctgcctgtgagctccagcccatggcctggtaactgcacactggctttcc
 aagtccgtggcccgcttcgtggcagctgcaccccgccgtaaacgtcaccaggccttcctgtactccaaaccgcac
 caccacccatgcactatgactatgtttgcacatcgccatgcggcgtctcaatctcaactggaaactggcc
 gccagccctcagcccatgcactttccctgtcacatgaccattgagccaaacacccatccctggctgtgcccacc
 gggacactgaatctgagctataacagcatcgcactgtgcgcgcctgcggccagttcggtgtgtccctgtcc
 25 agccgcaccaacatcctggcgtggccacccctggcaggcctttagccctcgccgtttccctgttccctggat
 ggcaactgtactacaagaacccctgcacgcaggccctgcagggtggcccccagggtgccttcctggctggcaac
 ctcacacacccctgtcactcaagtacaacaacccctcaccgtggcgcggggcctgccccccagcctgagttac
 ctcttgctctacaaccacatcatcaccotggcaccctggcaggacctggccaaatctgactgcctgcgttc
 gtgggtggaaactgtgcgcgtgtgaccatgcccgtaaaccctgcaggagtgcccaagggttccctccagctg
 30 caccacccacacccctggccacccatggcggccatggcggccacatcgaaaggcctgggttggggacagact
 cccaggtggccatggcctggcaacccatggcggccatggcggccatggcggccatggcggccatggcggcc
 aaaaccaaggccttctacggcctggccggctgcgcagactcaacctgtccatcaattatcataagaagggt
 ttgcacccacccatgtggcatctccctcctggggacccactgttccctgcaggagctggacatacatggcat
 ttccgcgtcgctcagcaagaccacgcgtccagtcgtggccacccatgtccacgcgtctgcacatgc
 35 aactttatcagccaggccagctcagcatcttcggccctccctggactgcggtaactggacttgtcagacaac
 cgcacatcggtggactgtcagagccgcggctggccacaggggaggtagaggcagactgtggggagagact
 cagtcggccggacccctgtctggggccactggggccacccggctcagaggccctcatgccgcgcgtcagg
 aacttcacccatggacccatgtctcggaacaacccatgtactgtttcagccggagatgttgc
 40 cagtcgtggccctggacttcagtgcaataccctgagccagatgtggggccaggagacccatctatcc
 cgggtgtggacccatgtccatggcggccatggcggccatggcggccatggcggccatggcggccatgg
 gccttggacccatgtcactacaacccgcgcgcctcagcatgcggggcgtggccacaatctc
 45 tggccagccctgcgttccatgcggccatggcggccatggcggccatggcggccatggcggccatgg
 tggccgtggccggccctggacttcagtgcaataccctgagccagatgtggggccaggagacccat
 ttccaaggccctgagaaggcctggtcagtgccatggcggccatggcggccatggcggccatgg
 50 gacaaccccccacccatggcggccatggcggccatggcggccatggcggccatggcggccatgg
 ccccttccatggcggccatggcggccatggcggccatggcggccatggcggccatggcggccatgg
 aacggccacccatggcggccatggcggccatggcggccatggcggccatggcggccatggcggccatgg
 gccgtggccctggacttcagtgcaacccatggcggccatggcggccatggcggccatggcggccatgg
 gccgtggccctggacttcagtgcaacccatggcggccatggcggccatggcggccatggcggccatgg
 ttgtgg
 cgcagcatcttcgcacaggacccctgcgcctctgcctggacgcacgcgtctccctgggtctgtttc
 cagc

SEQ ID NO:25 (Feline TLR9)

MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAPRGNVTSLSLYSNRI
 55 HHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTPALPSSLVSLSL

- 22 -

5 SRTNIVLDPANLAGLHSRLFLFDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEY
LLSYNHIITLAPEDLANLTALRVLVDVGNCRRCDHARNPCMCECPKGFPHLPTDFSHLNHLEGIVLKDKSSLYNLN
PRWFHALGNLMLVLDLSENFLYDCITKTTFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSFGSLLSLQQLDMHGIF
FRSLSETTLRSLVHLPMIQLSLLQMFINQAOQLSIFGAFFPGLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS
6 GDLALGPPGTPSSEGFMPCGCKTLNFTLDLSRNNLVTIQPEMFARLSRLQCLLSSRNSISQAVNGSQFMPMLTSIQLV
LDLSHNKLDLYHGRSFTELPRLEALDLSSYNSQFMSMQGVGHNLFSVAQLPALRYLSLAHNDIHSRVSQQLCSASL
RALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHLLPRTLNDLPKSRLRLRLRDNYLAFFNWSSLVL
LPRLEALDLAGNQLKALSNGLSPNGTQLQRLDLSSNSISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG
7 TLKVLDVTGNPLHCACGAAVFDFLLEVQAAVPGLPGVKCGSPGQLQGRSIFAQDRLCLDEALSWDCFGSLLLT
VALGLAVPMHLHLCGWDLWYCFHLCIWLPRRGRRRGADALPYDAFVVFDAKAQSAVADWVYNELRVLEERRGRR
8 ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQRLEDRKDVVVLVILRPDAHR
SRYVRLRQLRCQSVLLWPHQPSGQRSFWAOLGTALTRDNOHFYUNQFCRGPTTAE

SEQ ID NO:26 (Feline TLR9)

15 MGPCHGALHPPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRI
HHLHDSDFVHLSSLRRLNLKWNCPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTVPALPSSLVSLSL
SRTNIVLVDLDPANLAGLHSLRFLFLDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSIEYL
LLSYNHIITLAPEDLANLTALRVLVDGGNCRRCDHARNPCMCECPKGFPHLPTFSHLNHLLEGIVLKDSSLVNLN
PRWFHALGNLMLVLDLSENFYDCITKTTAFQGLAQLRRNLNSFNYHKVSAFHLLAPSGSLLSQQLDMHGIF
20 FRSLSSETTLRSLVHLPLMQLS1HLQMNFINAQQLS1FGAFCGLRYVDLSDNR1SGAMELAAATGEVDGGERVRLPS
GDLALGPPGTPSSEGFPMPGCKTLNFTLDSLRSRNLVTTIQPEMFARLSRLQCLLSSRNS1SQAVNGSQFMPPLTSLQV
LDLSSHNLKLDLYHGRSFTELPRLEALDLSSYNSQPSFSMQGVGHNLFSV4QLPALRYSLAHNDIHSRSVSQLCSASL
RALDFSGNALSRSRMAEGDLYLHFFRGLRSVLVRDLSLQNRLHLLPRTLDNLPKSLRLLRLRDNYLAFFNWSSLVL
25 LPRLEALDLAGNQLKALSNGLSPNGTQLQRLDLSSNS1SFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG
TLKVLDVTGNPLHCACGAAVFDFLLEVOAAVPGPLPGHVKGCGSPGOLOGRS1FAQD1RLCLDEALSWDCFG

SEO ID NO:27 (Feline TLR9)

30 agggctcgagctccaggcattctctgcctatcgctgcccagtcgtccatccagaccctctggagaagcccc
cactccctgtcatgggcccctgcctatggccctgcacccctgtctctctggctgcaggctgcgcgtggccg
tggccctggcccaggcaccctgccttctgcctgttagctccagcgcacggctggtaatttgcact
ggctgttcctaagtccgtgccccacttctcgccggcagggccctgtggtaacgtcaccagccttcctgtact
ccaaccgcattcaccacccacgcactccgacttgccttgcacccatgtccagcgcgtctcaacccteaatgg
actgcccaccggccaggcctcagccccatgcacttccctgtcatacatgaccattgagccccacacccatggccg
tgccccaccctggaggagctgaacctgagctacaacacgcatacgcacagttaccgcctgcggcaggccctgtgt
35 ccctgtccttggccgtaccaacatccctgggtctggaccctgcacccctgcaggcgtcactccctgcgttcc
tgttcctggatggcaactgtactacaagaaccctgcggccaggccctgcagggtggcccccggggcccttc
gcctgggcaacccattacgcacccgtcactcaagttacaacaaccctactgcgggtgccccggcctggccctgg
tggagtacctgtattgtcctacaaccatcatcaccctggcacctgaggacctggccaaacctgaccggccctgc
gtgtgtcgatgtgggtggaaactggcgtcgctgaccacccgcacccctgtatggagtggcccaagggt
40 tcccgcacctgcaccctgacacccttcagccacccgtaaaccacccctgcacccctgcgggttgaaggacagctct
acaacccatgcaccccaaggatggttccatgcctggcaacccatgggtgtccgtggacactgagttgagaactt
actgcattacccaaaaccacccacgcctccaggccctggcccaaggctgcgcagactcaacttgcatttcaatt
agaagggtgtccttgcacccctgcacccctgcattggcccttcctggagccctgtctccctgcacccatgc
atggcatcttctccgtcgctcagccggacaccacgcctccggcgctggccatctggccatgcctccagactgc
45 acctgcagatgaacttcatcaatcaggcccaaggctcagcatcttcggggcccttcctggccatgcgatacgtggacc
tgtcagacaaccgcataagtggagccatggagctggccgcacggggagggtggatgggtggagagactcc
ggctgcacccatgtgggacccatgccttcctggccacccctgcacccctgcacccctgcacccctgc
ccctcaacttcacccctggacccctgcacccgcacccatgcacccctgcacccctgcacccctgc
50 gctccaggctgcgtggaccctgtccctgcacccgcacccatgcacccctgcacccctgcacccctgc
gctccaggctgcgtggaccctgtccctgcacccgcacccatgcacccctgcacccctgcacccctgc
gctccagggtgtggaccctgtccctgcacccgcacccatgcacccctgcacccctgcacccctgc
tggaggccctggacccatgcacccatgcacccgcacccatgcacccctgcacccctgcacccctgc
cacagctgcggccctgcgtatctcagccctggccgcacccatgcacccctgcacccctgcacccctgc
55 ggcctgcgtgcggccctggacttcagccgcacccatgcacccctgcacccctgcacccctgcacccctgc
acttcttcggaggccctgcacccatgcacccgcacccatgcacccctgcacccctgcacccctgc
ccctggacccatgcacccctgcacccatgcacccctgcacccctgcacccctgcacccctgc

- 23 -

5 gcttggccctcccccaggctggaaaggccctggacactggggaaaccaggctgaaggccctgagcaacggcact
tgcttaatggaaaccaggctccagaggctggacactcagcagcaacaggatcagcttcgtggccctccaggcttttg
ctctggccaccaggctggagagactcaacctcagtgccaaacggccctcaagacggtgagccctctgggttcgggt
ctctagcgggaccctgaaaggcttagatgtgactggcaacccctgcaactgcgcctgtggggggccctcggttgg
acttcttgcggagggtgcaggctgcagtgcggccctggccaggccacgtcaagtgtggcagtccaggctcagtc
aggccgcagcatcttgcgcaggatctgcgcctctgcctggatgagggccctctcggactgtttggccct
cgctgcgtgaccgtggccctgggcgtgcgcctgcgcaccatgcgcaccacccgtggctggacctctggactctgt
tccacctgtgcgcctggcgtgcgcctggcgtgcgcgggggggggggggggggggggggggggggggggggggg
tggtcttcgacaaggcacagagcgcggtgccgactgggtgacaacagactgcggtaacggctagaggagcc
10 gtggacgcgcagcgtccgcctgtgcgcctggaggaaacgtgactggctacccgtaaaacgcctttgagaacccgt
gggcctcagttacagcagccgcagatgtgttgcgcctggccacacagacagggtcagccgccttcgcgc
ccagcttcgtgcgcctggccacgcgcctgcgcggggaccgcaggacgttgcgtgtgcgccttcgcgc
acgcccaccgcgtcccgctatgtgcggctgcgcgcctgcgcggccagacggcgtcctctggcccccacc
ccagtgccgcagcgcagctctggccgcagactggcgcacggccctgaccaggacaaccaggacttctataacc
15 acttgcgcggggcccccacgcacggcagactgaccgcgcagaccctcaagccttcacacctgcgtctgcctg
ggatgcgggg

SEQ ID NO:28 (Feline TLR9)

Complete nucleotide and amino acid sequences for murine and human TLR9 are publicly available. For example, an amino acid sequence of murine TLR9 is available as

- 24 -

GenBank accession no. AAK29625, provided as SEQ ID NO:29. Amino acids numbered 1-821 of SEQ ID NO:29 presumptively include the entire extracellular domain and correspond to SEQ ID NO:30. SEQ ID NO:31 corresponds to GenBank accession number AF348140, which is a nucleotide sequence of murine TLR9 cDNA. SEQ ID NO:32 is a nucleotide sequence of murine cDNA encoding amino acids 1-821 of SEQ ID NO:29.

5 An amino acid sequence of human TLR9 is available as GenBank accession no. AAF78037, provided as SEQ ID NO:33. Amino acids numbered 1-820 of SEQ ID NO:33 presumptively include the entire extracellular domain and correspond to SEQ ID NO:34. SEQ ID NO:35 corresponds to GenBank accession number AF245704, which is a nucleotide 10 sequence of human TLR9 cDNA. SEQ ID NO:36 is a nucleotide sequence of human cDNA encoding amino acids 1-820 of SEQ ID NO:33.

SEQ ID NO:29 (Murine TLR9)

15 MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPRFSAAACSNITRLSLISNRI
HHLHNSDFVHLSNLRQLNLKWNCPPTGLSPHLFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL
SHTNLLVLDANSLAGLYSLRVLFMDGNCYYKNPCTGAVKVTGALLGLSNLTHLSLKYNMLTKVPRQLPPSLEYL
LVSYNLIVKLGPEDLANLTSRVLVDGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGVLKDSSLHTLN
SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRLRLNLSFNYRKVKSFARLHLASSFKNLVSLQELNMNGIF
FRSLNKYTLRWLADLPKLHTLHQMFNFINQAOQLSIFGTFRALRFVDSLSDNRISGPSTLSEATPEEADDAEQQEELL
10 SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ
VLDLSHNKLDLYHWKSFSLEPQQLQALDLISYNSQPFMSKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLSNS
VRFLDFSGNGMGRWDEGGGLYHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSL
FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV
20 MNLTVDVRSNPLHACGAAFV DLLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFGLSLL
25 AVAVGMVVPILHLCGWDVYCFHLCALWPLLLARSRRSAQALPYDAFVVFDKAQSAADVYNELRVLEERRG
RRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDRVSGLLRTSFLIAQQRLLLEDRKDVVVLVILRPDA
HRSRYVRLQRQLCQSVLFWPQQPNGQGGFWAQLSTALTRDNRHFYQNQFCRGPTAE

SEQ ID NO:30 (Murine TLR9)

30 MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPRFSAAACSNITRLSLISNRI
HHLHNSDFVHLSNLRQLNLKWNCPPTGLSPHLFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL
SHTNLLVLDANSLAGLYSLRVLFMDGNCYYKNPCTGAVKVTGALLGLSNLTHLSLKYNMLTKVPRQLPPSLEYL
LVSYNLIVKLGPEDLANLTSRVLVDGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGVLKDSSLHTLN
SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRLRLNLSFNYRKVKSFARLHLASSFKNLVSLQELNMNGIF
FRSLNKYTLRWLADLPKLHTLHQMFNFINQAOQLSIFGTFRALRFVDSLSDNRISGPSTLSEATPEEADDAEQQEELL
35 SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ
VLDLSHNKLDLYHWKSFSLEPQQLQALDLISYNSQPFMSKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLSNS
VRFLDFSGNGMGRWDEGGGLYHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSL
FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV
40 MNLTVDVRSNPLHACGAAFV DLLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFG

SEQ ID NO:31 (Murine TLR9)

tgtcagagggagcctcgggagaatcctccatctccaaacatggttcccgctcgaggactctgcaccccttgtcc
ctcctggtagggctgcagtgcggctgagactctggccctgggtaccctgcctgcctaccctgtgagctg

- 25 -

SEQ ID NO:31 (Murine TLR9)

45 atgggtctccgtcgaggactctgcacccctgtccctcctggtagcaggctgcagtgtggctgagactctggcc
ctgggtaccctgcctgccttcaccctgtgagctgaagcctcatggcctggactgcattggctgttctg
aagtctgtaccccgttctctgcggcagcatctgtccaaacatcaccgccttccttgatctcaaccgtat
caccacctgcacaactccgacttcgtccacctgtccaaacctggggcagtgAACCTCAAGTGGAACTGTCCACCC
actggccttagccccctgcacttcttgccacatgaccattgagccccagaaccttctggctatgcgtacatgc
gaggagctgaacctgagctataatggtatcaccactgtgccccgactgcccagctccctggtaatctgagcctg
50 agccacaccaacatctgttagatgtcaacagcctgcgcggcctatacagcctgcgcgttcttcatggac
gggaaactgtactacaagaacccctgcacaggagcggtaaggtgaccccaaggcgccttcctggcctgagaaat
ctcacccatctgtctctgaagtataacaacctcacaagggtccccgccaactgccccccagctggagtagacctc
ctgggtgtctataacctcattgtcaagctggggctgaagacctggccatctgaccccttcgttagacttgat
gtgggtgggaaattggcgtcgctgcgaccatgcccccaatccctgtatagaatgtggccaaagtccctccacctg
55 caccctgagacccatccatcacctgagccatctggaaggcctggtagcaggacagctctccatcacactgaac
tcttcctggttccaaggctggtaacccctcgggtctggacctaagcgagaactttctctatgaaagcatcaac
cacaccaatgccttcagaacctaaccgcctggcgaagctcaacctgtccttcaattaccqcaaaagctatcc

- 26 -

5 tttgcggccctccacctggcaagttccccaagaacctgggtcactgcaggagctgaacatgaacggcatttc
 ttccgcgtcaacaaggtaacacgcctcagatggctggccgatctgcccactccacactctgcacatctcaaatg
 aacttcataaccaggcacagctcagatcttggtacccctccgagccctcgcttgcggacttgcagacaat
 cgcatcagtgccgttcaacgcgtcagaaggccacccctgaagaggcagatgtgcagagcaggaggactgttg
 10 tctgcggatcctcaccctggacttgcggacacccctgttcaagaacttgcggacagggtgttaagaacttcaag
 ttcaccatggacactgtctcgaaacaacctggactatcaaggcagagatgtttgtcaatcttcacgcctccag
 tgcgttgcggacttgcggacttgcggacacccctgttcaagaacttgcggacagggtataggccacaatttcagtttgcggccatctg
 15 tccatgcgtacacacgccttagcggcacacaatgcacatccctgtgtcctcacatctcaacagcaactca
 gtggaggtttcttgcgttgcggcaacggatgggtatggggccatgtgggatgagggggccctttatctccatcttc
 caaggcctgagttggccctgtgaagactgtggacactgtctcaaaataacctgcatactccggccccagaaccccttgac
 aaccccccagagcctgaagactgtggacactgcggacacccatcttactggaccaggctgtcc
 20 ttcctgccccacccctggaaactcctagacactggcagggcaccaggatgggtatgggtgtggcagccccggccagctgcaggccgt
 ggcaccctcctccagaaactggatgtcagcggcaacaggatgggtatggggccatgtgggatgagggggccctttatctccatcttc
 gtcgagctgaaagaggtcaacccctggccacaacattctcaagacgggtatgggtatgggtatggggccatttg
 atgaacactgacagttcttagacgtgagaagcaacccctgtggactgtggcctgtggcagcccttcgttagacttactg
 ttggagggtgcagaccaggcctggcggctggctatgggtgtgaagtgtggcagccccggccagctgcaggccgt
 agcatcttcgcacaggacctggcggctgtggcctctttggactgttttggc

SEQ ID NO:33 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWFLKSVPHFMSMAAPRGNVTSLSLSSNRI
 HHLHDSDFAHPLPSLRHLNLKWNCPVGLSPMHPCMHMTIEPSTFLAVPTLEELNSYNNTMTPALPKSLISL
 25 SHTNILMDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNTLVVPRNLPSSLEYL
 LLSYNRIVKLAPEDLANLTALRVLVDGGNCRRCDHAPNPMCECPRFHPQLHPDTFSHLSRLEGLVLKDSSLWLN
 ASWFRGLGNLRLVLDLSENFLYKCIKTKAFQGLTQLRKLNLNSFNYQKRVSAFHLSLAPSFGSLVALKEELDMHGIF
 FRSLDETTLRPLARLPMQLTQLRQMFNINQAOQLGIFRAFPGLRYVDSLSDNRIISGASELTATMGEADGGEKVWLQP
 GDLAPAPVDTPSSEDFRPNCSTLNFTLDSRNNLVTVQPEMFQALSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
 30 LDLSRNKLDLYHEHSFTELPRLEALDLISYNSQPFGMQGVGHNFSVAHRLTRHLSLAHNNIHSQVSQQLCSTSL
 RALDFSGNALGHMWAEGDLYLHFQGLSGLIWLDLQLSNRLHLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHF
 LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLISANALKTVDHSGWGPLAS
 ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLA
 35 VALGLGVPMILHLCGWDLWYCFHLCIWLWPAWVYGSRKTFLVLAHTDRVSGLLRASFLIAQQLLEDRKDVVVLVILSPDG
 RWAIRLCLEERDWLPGKTLFENLWASVYGSRKTFLVLAHTDRVSGLLRASFLIAQQLLEDRKDVVVLVILSPDG
 RRSRYVRLQRQLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHFYNRNFCQGPTAE

SEQ ID NO:34 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWFLKSVPHFMSMAAPRGNVTSLSLSSNRI
 HHLHDSDFAHPLPSLRHLNLKWNCPVGLSPMHPCMHMTIEPSTFLAVPTLEELNSYNNTMTPALPKSLISL
 40 SHTNILMDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNTLVVPRNLPSSLEYL
 LLSYNRIVKLAPEDLANLTALRVLVDGGNCRRCDHAPNPMCECPRFHPQLHPDTFSHLSRLEGLVLKDSSLWLN
 ASWFRGLGNLRLVLDLSENFLYKCIKTKAFQGLTQLRKLNLNSFNYQKRVSAFHLSLAPSFGSLVALKEELDMHGIF
 FRSLDETTLRPLARLPMQLTQLRQMFNINQAOQLGIFRAFPGLRYVDSLSDNRIISGASELTATMGEADGGEKVWLQP
 GDLAPAPVDTPSSEDFRPNCSTLNFTLDSRNNLVTVQPEMFQALSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
 45 LDLSRNKLDLYHEHSFTELPRLEALDLISYNSQPFGMQGVGHNFSVAHRLTRHLSLAHNNIHSQVSQQLCSTSL
 RALDFSGNALGHMWAEGDLYLHFQGLSGLIWLDLQLSNRLHLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHF
 LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLISANALKTVDHSGWGPLAS
 ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFA

50 SEQ ID NO:35 (Human TLR9)

aggctggataaaaaatcttacttcctctattctctgagccgctgtgcggccatggggacctcgagtgta
 agcatcttcctctgttagctgtgtccagctgtccggccagaccctctggagaagccctgccccccagcatgggt
 ttctggccgcagccctgcacccgctgtcttcctgggtcaggccatcatgtggccatgaccctggccctgggt

- 27 -

SEQ ID NO:36 (Human TLR9)

45 atgggtttctgcgcagccctgcaccgcgtgtctctccctggtcagggccatcatgtctggccatgaccctggcc
 ctgggtaccttgcctgccttccatccctgtgagctccagccccacggcgtgtgaactgcactggctttcttgc
 aagtctgtgccttgcacttccatggcagcaccctgtggcaatgtcaccagccttcctgtcctccaaccgcac
 caccacccatgattctgactttggccacctggccagcctggcatactcaaccctcaagtggaaactggcc
 gttggcctcagcccatgcacttccctgccacatgaccatcgagccagcaccttctggctgtgcccaccc
 50 gaagagctaaacctgagctacaacaacatcatgactgtgcctgcgtgccttgcacatccctcatatcc
 agccataccacatcctgtatgctagactctgcacgcctcgccggcctgcacgcctgcgttccattcatgg
 ggcactgttattacaagaaccctgcaggcaggcactggagggtggcccccgggtgccttgccttggc
 55 ctacccacccatgtcactcaagtacaacaacactactgtgggtgcacccgcacccgccttgccttgc
 ctgttgcctacaaccgcacgcgtcaactggcgcctgaggacactggcaatctgaccgcctgcgtgt
 gtggggcggaaattggccggcgtgcgaccacgcgtccaaaccctgcacgtggccctgcgtacttcc
 catcccgatacccttgcggccacccatggcgtttgaaggcctgggtgtgaaggacaggatct
 60 gccaggatgggttccgtggctggaaacctccgagtgctggacactgacttgccttgcata
 gacat

- 28 -

5 aaaaccaaggccttccagggcctaacacagctgcgcaagcttaacctgtccttcaattacaaaagagggtgtcc
 tttcccacctgtctctggcccttcctcgagacctggctggccatgtccagactctgcgtctgcagat
 ttccgctactcgatgagaccacgctccggccactggccctgcctatgtccagactctgcgtctgcagat
 aactcatcaaccaggccagctcgcatcttcaggcccttcctggctgcgtacgtggacctgtcgacaaac
 10 cgcatcagcggacttcggagctgacagccaccatggggaggccagatggagggagaaggctggctgcagcc
 gggaccttgcggcccccagtggacactccagcttgcagacttgcagacttgcacccactgcagcaccctcaacttc
 acctggatctgtcgggaaacactgtgtggccacttgcacccacttgcacccacttgcacccactgcagtg
 ctgcgcctgagccacaactcgatctcgccaggcacttgcacccacttgcacccacttgcacccactgcagtg
 cttagacactgtccgcataaagctggactctaccacgagcacttgcacccacttgcacccacttgcacccacttgc
 15 gacctcagactacaacacgcccggccatgcggggcgtggccacaacttcagcttgcacccacttgcacccacttgc
 accctgcggccacccatgcggccacaacaacatccacagccaaactgtcccagcagctctgcagtg
 cggggccctggatctcgccggccatgcactggccatgtggggccggggagacccatctgcacttgcacccacttgc
 ggcctgagccgggttgcacccacttgcacccacttgcacccacttgcacccacttgcacccacttgcacccacttgc
 ctccccaagagccatcaggtgtcgatctccgtgacaattacctggcccttcattaaatgtggggagccctccacttgc
 20 ctggcccaaaactggaaagtctcgacactggcaggaaaaggctgaaaggccctgaccaatggcagccctgcctgtgg
 accccggctccggaggctggatgtcagctgcacccacttgcacccacttgcacccacttgcacccacttgcacccacttgc
 gagctgcgagagctcaacccatgcacccacttgcacccacttgcacccacttgcacccacttgcacccacttgcacccacttgc
 gccctgcaataactagatgtaaagccaaacccctctgcacttgcacccacttgcacccacttgcacccacttgcacccacttgc
 gaggtgcaggctccgtgcccggctggccagccgggtgaagtgtggcagttccggggccagctccaggccctcagc
 atcttgcacaggacactgcgcctctgcctggatgaggcccttcctggactgtttcgcc

In addition to the foregoing native rat, porcine, bovine, equine, and ovine TLR9
 polypeptides and nucleic acid molecules encoding them, chimeric TLR9 polypeptides and
 nucleic acid molecules encoding them are provided by the invention. The chimeric
 25 polypeptides include at least one amino acid substitution based on a comparison of
 conserved and non-conserved amino acids among at least two of rat, murine, porcine, bovine,
 equine, ovine, canine, feline, and human TLR9. The information contained in a multiple
 sequence alignment of these various TLR9 polypeptide sequences, provided for example in
 Figure 1, can be used to identify and select individual amino acid positions and even
 30 individual amino acids to substitute in designing a chimeric TLR9. The substitution or
 substitutions can be effected using methods known to those of ordinary skill in molecular
 biology. Nucleic acids encoding the native or chimeric polypeptides of the invention can be
 inserted into an expression vector and used to express TLR9 polypeptide.

A conservative amino acid substitution shall refer to a substitution of a first amino
 35 acid for a second amino acid, wherein side chains of the first amino acid and the second
 amino acid share similar features in terms of hydrophobicity, size, aromaticity, or tendency to
 alter conformation. For example, conservative amino acid substitutions generally may be
 made between members within each of the following groups: hydrophobic (A, I, L, M, V),
 neutral (C, S, T), acidic (D, E), basic (H, K, N, Q, R), and aromatic (F, W, Y). A non-
 40 conservative amino acid substitution refers to any other amino acid substitution.

An expression vector for TLR9 will include at least a nucleotide sequence coding for a TLR9, or a fragment thereof coding for a functional TLR9 polypeptide, operably linked to a gene expression sequence which can direct the expression of the TLR9 nucleic acid within a eukaryotic or prokaryotic cell. A "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked. With respect to TLR9 nucleic acid, the "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the TLR9 nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPRT), adenosine deaminase, pyruvate kinase, β -actin promoter, and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus (e.g., SV40), papillomavirus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), cytomegalovirus (CMV), the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase (TK) promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein (MT) promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined nucleic acid coding sequence for a TLR9 polypeptide. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

- 30 -

Generally a nucleic acid coding sequence and a gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or control of the gene expression sequence. Thus the TLR9 nucleic acid coding sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the TLR9 nucleic acid coding sequence under the influence or control of the gene expression sequence. If it is desired that the TLR9 sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the TLR9 sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the TLR9 sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a TLR9 nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that TLR9 nucleic acid sequence such that the resulting transcript might be translated into the desired TLR9 protein or polypeptide.

A "TLR9 ligand" as used herein refers to a molecule that specifically binds a TLR9 polypeptide. In one embodiment the TLR9 ligand specifically binds a TLR9 polypeptide corresponding to at least a ligand-binding portion of the extracellular domain of TLR9. In most instances a TLR9 ligand will also induce TLR9 signaling when contacted with TLR9 under suitable conditions. TLR9 signaling refers to TLR/IL-1R signal transduction mediated through the TLR9, as described in further detail elsewhere herein. As mentioned above, CpG nucleic acids have been reported to be TLR9 ligands, but TLR9 ligands may include other entities as well, including, for example, small molecules. As also previously mentioned, there appears to be a species-specific preference for at least certain TLR9s and certain CpG motifs. As used herein, a species-preferred CpG DNA refers to a particular CpG DNA that is optimized for signal induction by a TLR9 of a particular species. A CpG DNA that is optimized for signal induction by a TLR9 of a particular species refers to a CpG DNA having a sequence that preferentially binds to and/or induces signaling by TLR9 of that species. For example, a human-preferred CpG DNA shall refer to a CpG DNA that optimally stimulates human TLR9 to signal through its TIR domain. Likewise, a murine-preferred CpG DNA

shall refer to a CpG DNA that optimally stimulates murine TLR9 to signal through its TIR domain. Examples of human-preferred and murine-preferred CpG DNA are ODN 2006 (SEQ ID NO:58) and 1668 (SEQ ID NO:60), respectively.

5 The binding and species specificity of TLR9s are believed to be influenced by key amino acids present in the extracellular domain of TLR9. Key amino acids in a TLR9 as used herein refer to those amino acids which contribute significantly to ligand binding and ligand specificity of a particular TLR9 polypeptide.

10 A "CpG nucleic acid" or a "CpG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e., "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanine and linked by a phosphate bond) which activates a component of the immune system. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

15 In one embodiment a CpG nucleic acid is represented by at least the formula:



wherein X_1 and X_2 are nucleotides, N is any nucleotide, and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

20 Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Pat. Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a 25 non-sequence specific manner.

An immunostimulatory nucleic acid molecule, including for example a CpG DNA, may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e., molecules comprising 30 a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base. As

used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base-containing polymer. The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides 5 with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the 10 nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

The substituted purines and pyrimidines of the immunostimulatory nucleic acids 15 include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted 20 aromatic moieties.

The immunostimulatory nucleic acid is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are 25 well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' to 3' (or equivalent) order from left to right and that "A" denotes 30 adenine, "C" denotes cytosine, "G" denotes guanine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

- 33 -

Immunostimulatory nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g., genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g., produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

The immunostimulatory nucleic acids can be produced on a large scale in plasmids, (see *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, 10 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

15 For use in the instant invention, the immunostimulatory nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the β -cyanoethyl phosphoramidite method (Beaucage SL and Caruthers MH, *Tetrahedron Lett* 22:1859 (1981)); nucleoside H-phosphonate method (Garegg et al., *Tetrahedron Lett* 27:4051-4054 (1986); Froehler et al., *Nucl Acid Res* 14:5399-5407 (1986); 20 Garegg et al., *Tetrahedron Lett* 27:4055-4058 (1986); Gaffney et al., *Tetrahedron Lett* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

25 The immunostimulatory nucleic acid may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Immunostimulatory nucleic acids can be produced on a large scale in plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

30 A "stabilized immunostimulatory nucleic acid" shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an

oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized immunostimulatory nucleic acids have a modified backbone. It has

5 been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the immunostimulatory nucleic acids when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3' end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

10 Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail in U.S. Pat. Nos. 6,194,388 and 6,207,646, the entire contents of which are incorporated herein by

15 reference. It is believed that these modified oligonucleotides may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization. Both phosphorothioate and phosphodiester nucleic acids are active in immune cells.

Other stabilized immunostimulatory nucleic acids include: nonionic DNA analogs,

20 such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

25 Phosphorothioate nucleic acid molecules may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid

30 phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described. Uhlmann E and Peyman A (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165.

- 35 -

Other sources of immunostimulatory nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty 5 vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene 10 be expressed in the cell.

Nucleic acid-binding fragments of TLRs are believed to include the extracytoplasmic (extracellular) domain or subportions thereof, such as those which include at least an MBD motif, a CXXC motif, or both an MBD motif and a CXXC motif.

Both mouse and human TLR9 have an N-terminal extension of approximately 180 15 amino acids compared to other TLRs. An insertion also occurs at amino acids 253-268, which is not found in TLRs 1-6 but is present in human TLR7 and human TLR8. This insert has two CXXC motifs which participate in forming a CXXC domain. The CXXC domain resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g., methyl-CpG binding protein-1 (MBD-1). Fujita N et al. (2000) 20 *Mol Cell Biol* 20:5107-18. Both human and mouse TLR9 CXXC domains occur at aa 253-268:

CXXC motif:	GNCXXCXXXXXXCXXC	SEQ ID NO:62
Human TLR9:	GNCRRCDHAPNPCMEC	SEQ ID NO:63
25 Murine TLR9:	GNCRRCDHAPNPCMIC	SEQ ID NO:64

An additional motif believed to be involved in CpG binding is the MBD motif, also found in MBD-1, listed below as SEQ ID NO:53. Fujita, N et al.(2000) *Mol Cell Biol* 20:5107-18; Ohki I et al. (1999) *EMBO J* 18:6653-61. Amino acids 524-554 of hTLR9 and 30 aa 525-555 of mTLR9 correspond to the MBD motif of MBD-1 as shown:

MBD motif:

- 36 -

MBD-1	R-XXXXXXX-R-X-D-X-Y-XXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:65
hTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:66
mTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:67
5	hTLR9 Q-VLDLSRN-K-L-D-L-Y-HEHSFTELP-R-L-EALDLS-Y	SEQ ID NO:68
	mTLR9 Q-VLDLSHN-K-L-D-L-Y-HWKSFSELP-Q-L-QALDLS-Y	SEQ ID NO:69

Although the signaling functions of MBD-1 and TLR9 are quite different, the core D-X-Y is conserved and is believed to be involved in CpG binding.

10 According to another aspect of the invention, a screening method is provided for identifying an immunostimulatory compound. The method according to this aspect of the invention involves contacting a functional TLR9 with a test compound; detecting presence or absence of a response mediated by a TLR9 signal transduction pathway in the presence of the test compound arising as a result of an interaction between the functional TLR9 and the test compound; and determining the test compound is an immunostimulatory compound when the presence of a response mediated by the TLR9 signal transduction pathway is detected.

15 An immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell. A TLR9 ligand that is an immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell that expresses TLR9. A TLR9 ligand that is an immunostimulatory compound is also a natural or synthetic compound that is capable of inducing a TLR/IL-1R signal transduction pathway when contacted with a TLR9. Immunostimulatory compounds include but are not limited to immunostimulatory nucleic acids. The immunostimulatory compound can be, for example, a nucleic acid 20 molecule, polynucleotide or oligonucleotide, a polypeptide or oligopeptide, a lipid or lipopolysaccharide, a small molecule.

25 A basis for certain of the screening assays is the presence of a functional TLR9 in a cell. The functional TLR9 in some instances is naturally expressed by a cell. In other instances, expression of the functional TLR9 can involve introduction or reconstitution of a species-specific TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an

immunostimulatory nucleic acid. In yet other instances, expression of the functional TLR9 can involve introduction of a chimeric or modified TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact
5 with an immunostimulatory nucleic acid. Examples of cell lines lacking TLR9 or immunostimulatory nucleic acid responsiveness include, but are not limited to, 293 fibroblasts (ATCC CRL-1573), MonoMac-6, THP-1, U937, CHO, and any TLR9 knock-out. The introduction of the species-specific, chimeric or modified TLR9 into the cell or cell line is preferably accomplished by transient or stable transfection of the cell or cell line with a
10 TLR9-encoding nucleic acid sequence operatively linked to a gene expression sequence (as described above). Methods for transient and for stable transfection of a cell are well known in the art.

The screening assays can have any of a number of possible readout systems based upon either TLR/IL-1R signaling pathway or other assays useful for assessing response to
15 immunostimulatory nucleic acids. It has been reported that immune cell activation by CpG immunostimulatory sequences is dependent in some way on endosomal processing.

In certain embodiments, the readout for the screening assay is based on the use of native genes or, alternatively, cotransfected or otherwise co-introduced reporter gene constructs which are responsive to the TLR/IL-1R signal transduction pathway involving
20 MyD88, TRAF, p38, and/or ERK. Häcker H et al. (1999) *EMBO J* 18:6973-6982. These pathways activate kinases including κB kinase complex and c-Jun N-terminal kinases. Thus reporter genes and reporter gene constructs particularly useful for the assays can include a reporter gene operatively linked to a promoter sensitive to NF-κB. Examples of such promoters include, without limitation, those for NF-κB, IL-1 β , IL-6, IL-8, IL-12 p40, CD80,
25 CD86, and TNF- α . The reporter gene operatively linked to the TLR-sensitive promoter can include, without limitation, an enzyme (e.g., luciferase, alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase (CAT), etc.), a bioluminescence marker (e.g., green-fluorescent protein (GFP, U.S. Pat. No. 5,491,084), blue fluorescent protein, etc.), a surface-expressed molecule (e.g., CD25), and a secreted molecule (e.g., IL-8, IL-12 p40, TNF- α). In
30 certain embodiments the reporter is selected from IL-8, TNF- α , NF-κB-luciferase (NF-κB-luc; Häcker H et al. (1999) *EMBO J* 18:6973-6982), IL-12 p40-luc (Murphy TL et al. (1995)

Mol Cell Biol 15:5258-5267), and TNF-luc (Häcker H et al. (1999) *EMBO J* 18:6973-6982).

At least one of these reporter constructs (NF- κ B-luc) is commercially available (Stratagene, La Jolla, CA). In assays relying on enzyme activity readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, 5 color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using FACS analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many such readout systems are well known in the art and are commercially available.

10 According to one embodiment of this method, comparison can be made to a reference immunostimulatory nucleic acid. The reference immunostimulatory nucleic acid may be any suitably selected immunostimulatory nucleic acid, including a CpG nucleic acid. In certain embodiments the screening method is performed using a plurality of test nucleic acids. In certain embodiments comparison of test and reference responses is based on comparison of 15 quantitative measurements of responses in each instance.

In another aspect the invention provides a screening method for identifying species specificity of an immunostimulatory nucleic acid. The method involves contacting a TLR9 of a first species with a test immunostimulatory nucleic acid; contacting a TLR9 of a second species with the test immunostimulatory nucleic acid; measuring a response mediated by a 20 TLR signal transduction pathway associated with the contacting the TLR9 of the first species with the test immunostimulatory nucleic acid; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the TLR9 of the second species with the test immunostimulatory nucleic acid; and comparing the two responses. The TLR9 may be expressed by a cell or it may be part of a cell-free system. The TLR9 may be part of 25 a complex, with either another TLR or with another protein, e.g., MyD88, IRAK, TRAF, I κ B, NF- κ B, or functional homologues and derivatives thereof. Thus for example a given ODN can be tested against a panel of human fibroblast 293 fibroblast cells transfected with TLR9 from various species and optionally cotransfected with a reporter construct sensitive to TLR/IL-1R activation pathways. Thus in another aspect, the invention provides a method for 30 screening species selectivity with respect to a given nucleic acid sequence.

Test compounds can include but are not limited to peptide nucleic acids (PNAs), antibodies, polypeptides, carbohydrates, lipids, hormones, and small molecules. Test

- 39 -

compounds can further include variants of a reference immunostimulatory nucleic acid incorporating any one or combination of the substitutions described above. Test compounds can be generated as members of a combinatorial library of compounds.

In preferred embodiments, the screening methods can be performed on a large scale and with high throughput by incorporating, e.g., an array-based assay system and at least one automated or semi-automated step. For example, the assays can be set up using multiple-well plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are well known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are well known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

The following examples are provided for illustrative purposes and are not meant to be limiting in any way.

Examples

Example 1. Cloning and Sequencing of Rat, Porcine, Bovine, Equine, Ovine, Canine, and Feline TLR9

Cells and Tissues. Lymphoid tissues, primarily spleen or blood mononuclear cells (PBMC) from five mammalian species were collected: mouse, pig, bovine, rat and horse. Spleen samples were collected in *RNAlater*TM (Ambion[®], Austin, TX, USA), stabilized at 30 4°C overnight and stored at -70°C. Blood samples were centrifuged at 500 x g for 25 min at room temperature and the buffy coat, containing enriched PBMC, was then removed and stored at -70°C. The mouse specimen was used as a comparative positive control.

- 40 -

First-strand cDNA synthesis. Total RNA from the spleen and PBMC samples was isolated using a monophasic solution of phenol and guanidine isothiocyanate: TRIzolTM reagent (GIBCO BRL[®], Burlington, ON, Canada) according to the manufacturer's instructions. First-strand cDNA was synthesized from the total RNA using 5 SUPERSCRIPTTM II reverse transcriptase (GIBCO BRL[®], Burlington, ON, Canada). Approximately 3 µg of total RNA was added to 50 pmoles of oligo(dT) primer [poly T₍₁₈₎]; the mixture was heated to 70°C for 10 min and subsequently chilled on ice. The following was added to the cooled reaction mixture: 1 µl of mixed dNTP stock containing 10 mM each dATP, dCTP, dGTP and dTTP (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) at 10 neutral pH, 1X first strand buffer (50 mM Tris-HCl pH 8.3/ 75 mM KCl/ 3 mM MgCl₂) and 2 µl of 0.1 M DTT. The mixture was subsequently heated to 42°C for 2 min, followed by addition of 200 units of SUPERSCRIPTTM II reverse transcriptase. The reaction was carried out at 42°C for 50 min, followed by 70°C for 15 min. The first-strand cDNA was used as the template for subsequent polymerase chain reaction (PCR) amplifications.

15 *PCR amplification.* TLR9 gene was PCR amplified from each of the above-mentioned species using primers designed from known mouse and human TLR9 sequence in Genbank: Accession AF314224 and AF259262, respectively. The primers were designed using the primer design software, Clone Manager 5 (Scientific and Educational Software, Durham, NC, USA). TLR9 gene-specific primers used were:
20 forward primer 5'-ACCTTGCCTGCCTTCCTACCCCTGTGA-3' (SEQ ID NO:37) and reverse primer 5'-GTCCGTGTGGGCCAGCACAAA-3' (SEQ ID NO:38). The 2.7 Kbp fragment was PCR amplified using Advantage[®] 2 DNA polymerase mix (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. PCR reaction volumes of 25 µl contained 15 pmoles of each primer, 0.2 mM of dNTP mix 25 and 1 µl of reverse transcription reaction. PCR amplification was conducted by initial denaturation at 94°C for 1 min followed by 30 cycles of 94°C denaturation (15 sec), 65°C annealing (45 sec) and 72°C extensions (2 min), with a final extension at 72°C for 5 min.

30 *Cloning and sequencing.* The PCR amplified fragment was treated with 500 units of T4 DNA polymerase (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) for 15 min at room temperature prior to cleaning the reaction with QIAquick PCR purification kit (QIAGEN Inc., Mississauga, ON, Canada). The fragment was then ligated to pZErOTM - 2

- 41 -

vector (Invitrogen™ Life Technologies, Burlington, ON, Canada), treated with *Eco RV* restriction enzyme, using T4 DNA Ligase (GIBCO BRL®, Burlington, ON, Canada). *E. coli* TOP 10 chemically competent cells (Invitrogen™ Life Technologies, Burlington, ON, Canada) were used to transform ligated products. Plasmids containing the 2.7 Kbp fragment 5 were sequenced using an automated DNA sequencer, CEQ™ 2000XL DNA analysis system (Beckman Coulter Inc., Fullerton, CA, USA).

Sequences of the 2.7 Kbp fragment were derived from three clones of each species selected from independent PCR reactions to account for errors that may have been incurred during the PCR amplifications and to confirm the sequence data.

10 Nucleotide sequences of the rat, porcine, bovine, equine, ovine, canine, and feline TLR9 were extended and completed using standard 5' and 3' RACE PCR and primers designed using the sequences obtained from the 2.7 Kbp fragments.

15 *Results.* Nucleotide sequences of rat, porcine, bovine, equine, canine, and feline TLR9 cDNA obtained by the methods above are provided as SEQ ID NOs 3, 7, 11, 15, 19, 23, and 27, respectively. Deduced amino acid sequences are provided as SEQ ID NOs 1, 5, 9, 13, 17, 21, and 25, respectively. Deduced amino acid sequences of full-length murine and human TLR9 are provided as SEQ ID NOs 29 and 33, respectively.

Example 2. Comparison of Aligned Sequences for TLR9 from Various Mammalian Species.

20 Multiple sequence alignment of deduced amino acid sequences for feline, canine, bovine, mouse, ovine, porcine, horse, human, and rat TLR9 polypeptides was performed using Clustal W 1.82 (see, for example, www.cmbi.kun.nl/bioinf/tools/clustalw.shtml). In addition, paired sequence alignment of deduced amino acid sequences for murine and human TLR9 polypeptides was performed using Clustal W 1.82. The results of the multiple 25 sequence alignment are presented in Figure 1. As will be appreciated from Figure 1, certain amino acids are highly conserved across all species examined. Similarly, certain amino acids differ only by conservative amino acid substitutions among the various species. In addition, it is evident that certain amino acids which are conserved between murine and human TLR9 are not conserved in other species. Furthermore, Figure 1 also indicates that certain amino 30 acids are highly divergent across various species. The information provided by the comparison of multiple species adds significantly to the information available by comparison between only murine and human TLR9 sequences.

The putative transmembrane regions of the TLR9 polypeptides are indicated in boxes in Figure 1. Sequence upstream of each transmembrane region is extracellular domain and is believed to include sequence primarily responsible for binding to TLR9 ligands, including CpG DNA. The extracellular domains of feline, canine, bovine, mouse, ovine, porcine, 5 horse, human, and rat TLR9 correspond to amino acids numbered 1-820, 1-822, 1-818, 1-821, 1-818, 1-819, 1-820, 1-820, and 1-821, respectively, as shown in Figure 1.

Figure 2 presents an evolutionary relatedness tree for six TLR9 polypeptides examined. The cladogram in Figure 2 was prepared using Clustal W (see above). As can be appreciated from this figure, murine and human TLR9 are nearly the most divergent TLR9s 10 in this group. Surprisingly, human and horse TLR9 appear relatively closely related.

Example 3. Reconstitution of TLR9 Signaling in 293 Fibroblasts.

Mouse TLR9 cDNA (SEQ ID NO:31) and human TLR9 cDNA (SEQ ID NO:35) in pT-Adv vector (from Clonetech) were individually cloned into the expression vector 15 pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

20 Since NF- κ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-258; Muzio M et al. (1998) *J Exp Med* 187:2097-101), cells were transfected with hTLR9 or co-transfected with hTLR9 and an NF- κ B-driven luciferase reporter construct. Human fibroblast 293 cells were transiently transfected with hTLR9 and a six-times NF- κ B-luciferase reporter plasmid (NF- κ B-luc) or with hTLR9 alone. 25 After stimulus with CpG-ODN (2006, 2 μ M, TCGTCGTTTGTCTGTTTGTCTT, SEQ ID NO:58), GpC-ODN (2006-GC, 2 μ M, TGCTGCTTTGTGCTTTGTGCTT, SEQ ID NO:59), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results representative of three independent experiments showed that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

30 Independently, human fibroblast 293 cells were transiently transfected with mTLR9 and the NF- κ B-luc construct or with mTLR9 alone. After stimulation with CpG-ODN (1668, 2 μ M; TCCATGACGTTCCCTGATGCT, SEQ ID NO:60), GpC-ODN (1668-GC, 2 μ M;

- 43 -

TCCATGAGCTTCCTGATGCT, SEQ ID NO:61), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results showed that expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG-DNA stimulation.

5 To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- κ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2×10^6 cells/plate) with 16 μ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe, Germany). Clones were tested for TLR9 expression by RT-PCR. The clones were also screened for IL-8 production or NF- κ B-luciferase activity after stimulation with
10 ODN. Four different types of clones were generated.

15 293-hTLR9-luc: expressing human TLR9 and 6-fold NF- κ B-luciferase reporter
293-mTLR9-luc: expressing murine TLR9 and 6-fold NF- κ B-luciferase reporter
293-hTLR9: expressing human TLR9
293-mTLR9: expressing murine TLR9

Results indicated that stable clones also responded to CpG-ODN.

Example 4. Similar ODN Sequence Specificity of TLR9 of Human and Equine TLR9.

20 3×10^6 293T cells were electroporated with 5 μ g NF- κ B-luc plasmid and 5 μ g of either horse TLR9-pcDNA3.1 plasmid or human TLR9-pcDNA3.1 plasmid at 200V, 975 μ F. After the electroporation the cells were plated in 96-well cell culture plates at 2.5×10^4 cells per well and grown overnight at 37°C. The cells were stimulated with the indicated concentration of ODN for 16h, after which the supernatant was removed and the cells lysed in lysis buffer and
25 frozen for at least 2 hours at -80°C. Luciferase activity was measured by adding Luciferase Assay substrate from Promega. Values are given as fold specific induction over non-stimulated control. Results are shown in Figure 3.

As shown in Figure 3, ODN 2006 (TCGTCGTTTGTCTGTTTGTCTGTT; SEQ ID NO:58) has a strong specificity for human TLR9. ODN 1982 (TCCAGGACTTCTCTCAGGTT; SEQ ID NO:70) was the negative control ODN. ODN 5890 (TCCATGACGTTTGTATGTT; SEQ ID NO:39) has a strong specificity for mouse

- 44 -

TLR9. This experiment demonstrates the similarity of horse TLR9 to human TLR9 in binding specificity, a result predicted by the evolutionary relatedness of horse TLR9 to human TLR9. Mouse TLR9 is more distant from horse TLR9 and human TLR9 in sequence homology, and ODN 5890 was not detected by either human or horse TLR9.

5

Example 5. Non-human, Non-murine Native Mammalian TLR9 Useful in Screening for Human-Preferred CpG DNA.

Native rat, porcine, bovine, equine, and ovine TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 10 2006). Rat, porcine, bovine, equine, or ovine TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The 15 cells expressing the selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

20 Example 6. Chimeric TLR9 Useful in Screening for Human-Preferred CpG DNA.

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector 25 containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

30

Example 7. Chimeric TLR9 Responsive to Both Human-Preferred and Murine-Preferred CpG DNA.

- 45 -

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006) and also screened for binding or TLR9 signaling activity when contacted with murine-preferred CpG DNA (ODN 1668). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling 5 activity in each of these assays are then used as the basis for screening for additional human-preferred CpG DNA and for screening for additional murine-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with 10 candidate human-preferred CpG DNA or candidate murine-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA. Candidate murine-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as murine-preferred CpG DNA.

15

Equivalents

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of 20 the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages of the invention are not necessarily encompassed by each embodiment of the invention.

25

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

- 46 -

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

5

2. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.

10 3. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

15 4. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.

5. A vector comprising the nucleic acid of any of claims 3-4.

6. A cell comprising the vector of claim 5.

20

7. An antibody or fragment thereof that binds specifically to the polypeptide of any of claims 1-2.

25 8. A method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species, comprising: aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species;

30 generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the

- 47 -

TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution;

generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

10 9. A method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9, comprising:

aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9;

generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution;

20 generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids.

25

10. The method according to claim 9, performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight, said weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

- 48 -

11. An isolated polypeptide comprising an amino acid sequence identical to SEQ ID NO:30 except for substitution of at least one key amino acid identified according to the method of any of claims 9 or 10.

5 12. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide according to claim 11.

13. A vector comprising the nucleic acid of claim 12.

10 14. A cell comprising the vector of claim 13.

15. An antibody that binds specifically to the polypeptide of claim 14.

16. A screening method to identify a TLR9 ligand, comprising:
15 contacting a polypeptide according to any of claims 1, 2, or 11 with a candidate TLR9 ligand;
measuring a signal in response to the contacting; and
identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling.

20 17. The method of claim 16, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.

25 18. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF- κ B.

19. The method of claim 17, wherein the candidate TLR9 ligand is an immunostimulatory nucleic acid.

30 20. The method of claim 19, wherein the immunostimulatory nucleic acid is CpG DNA.

- 49 -

21. A screening method to identify species-specific CpG-motif preference of an isolated polypeptide of claim 2 or claim 11, comprising:

contacting an isolated polypeptide of claim 2 or claim 11 with a CpG DNA comprising a hexamer sequence selected from the group consisting of GACGTT, AACGTT, 5 CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACTTT, GACGCT, GACGAT, GACGGT, GACGTC, GACGTA, and GACGTG;

measuring a signal in response to the contacting; and

10 identifying a species-specific CpG-motif preference when the signal in response to the contacting is consistent with TLR9 signaling.

22. The method of claim 21, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.

15 23. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF- κ B.

24. The method of claim 21, wherein the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

20 TCCATGACGTTTGATGTT (SEQ ID NO:39),
TCCATAACGTTTGATGTT (SEQ ID NO:40),
TCCATCACGTTTGATGTT (SEQ ID NO:41),
TCCATTACGTTTGATGTT (SEQ ID NO:42),
TCCATGGCGTTTGATGTT (SEQ ID NO:43),
25 TCCATGCCGTTTGATGTT (SEQ ID NO:44),
TCCATGTCGTTTGATGTT (SEQ ID NO:45),
TCCATGATGTTTGATGTT (SEQ ID NO:46),
TCCATGAAGTTTGATGTT (SEQ ID NO:47),
TCCATGAGGTTTGATGTT (SEQ ID NO:48),
30 TCCATGACATTTGATGTT (SEQ ID NO:49),
TCCATGACCTTTGATGTT (SEQ ID NO:50),
TCCATGACTTTTGATGTT (SEQ ID NO:51),
TCCATGACGCTTTGATGTT (SEQ ID NO:52),
TCCATGACGATTTGATGTT (SEQ ID NO:53),
35 TCCATGACGGTTTGATGTT (SEQ ID NO:54),
TCCATGACGTCTTGATGTT (SEQ ID NO:55),
TCCATGACGTATTGATGTT (SEQ ID NO:56), and
TCCATGACGTGTTGATGTT (SEQ ID NO:57).



Figure 1
(1/3)

feline	MGPCHGALHPLSLLVQAAAALAVALAQGTLPAFLPCELQRHGLVNCWDWLFLKSVPHFSAAA	60
canine	MGPCRGALHPLSLLVQAAAALALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAA	60
bovine	MGP-YCAPHPLSLLVQAAAALAAAALAEGLTPAFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
mouse	MGP-YCAPHPLSLLVQAAAALAAAALAEGLTPAFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
ovine	MGP-YCAPHPLSLLVQAAAALAAAALAEGLTPAFLPCELQPRGVNCNWLFLKSVPHFSAGA	59
porcine	MGP-RCTLHPLSLLVQVTALAAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAA	59
horse	MGPCHGALQPLSLLVQAAAALAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAA	60
human	MGFCRSALHPLSLLVQAAAALAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA	60
rat	MVLCRRTLHPLSLLVQAAAALAEALGTLPAFLPCELQPHGLVDCNWLFLKSVPHFSAAE	60
	*	:*****. ** :* * .*****: :* :;*****:*** .
feline	PRGNVTSLSLYSNRRIHHLHSDFVHLSSLRRLNWKNCPPASLSPMHFPCHMTIEPHTFL	120
canine	PRGNVTSLSLYSNRRIHHLHDYDFVHFVHLRRLNWKNCPPASLSPMHFPCHMTIEPNTFL	120
bovine	PRANVTSLSLISNRRIHHLHSDFVHLNSLRVLNWKNCPPAGLSPMHFPCHMTIEPNTFL	119
mouse	PRANVTSLSLISNRRIHHLHSDFVHLNSLRVLNWKNCPPAGLSPMHFPCHMTIEPNTFL	119
ovine	PRANVTSLSLISNRRIHHLHSDFVHLNSLRVLNWKNCPPAGLSPMHFPCHMTIEPNTFL	119
porcine	PRDNVTSLSLISNRRIHHLHSDFAQLSNLQKLNWKNCPPAGLSPMHFPCHMTIEPNTFL	119
horse	PRGNVTSLSLSSNRRIHHLHSDFAHPLSLRHLNWKNCPPVGLSPMHFPCHMTIEPNTFL	120
human	PRSNITSLSLISNRRIHHLHSDFAHPLSLRHLNWKNCPPVGLSPMHFPCHMTIEPNTFL	120
rat	*** :***** :*****: ** .: :***** .****:.*:***** ***	
feline	AVPTLEELNLSYSNISITTPALPSSLVSLSLSRNTILVLDPANLAGLHSIRFLFLDGNCY	180
canine	AVPTLEELNLSYSNISITTPALPSSLVSLSLSRNTILVLDPATLAGLYALRFLFLDGNCY	180
bovine	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRNTILVLDPATLAGLYALRFLFLDGNCY	179
mouse	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRNTILVLDPATLAGLYALRFLFLDGNCY	179
ovine	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRNTILVLDPATLAGLYALRFLFLDGNCY	179
porcine	AVPTLEELNLSYNGISITTPALPDSLVSLSLSRNTILVLDPTILTGLHALRYLYMDGNCY	179
horse	AVPTLEELNLSYNGISITTPALPDSLVSLSLSRNTILVLDPTILTGLHALRYLYMDGNCY	179
human	AVPTLEELNLSYNGISITTPALPDSLVSLSLSRNTILVLDPTILTGLHALRYLYMDGNCY	180
rat	AMRMLEELNLSYNGISITTPVRLPSSLTNLSLSRNTILVLDASSLAGLHSIRVLFLMDGNCY	180
	*: ***:*****.* *** .* ***:*** .:***:*** *:*****	
feline	KNPCPQALQVAPGALLGLGNLTHLSLKYNNTAVPRGLPSSLEYLLSYNHIITLAPEDL	240
canine	KNPCQALQVAPGALLGLGNLTHLSLKYNNTTVPRGLPSSLEYLLSYNHIITLAPEDL	240
bovine	MNPCPRALEVAPGALLGLGNLTHLSLKYNNTTEVPRRLPPLSITLSSLYNHIITLAPEDL	239
mouse	MNPCPRALEVAPGALLGLGNLTHLSLKYNNTTEVPRRLPPLSITLSSLYNHIITLAPEDL	239
ovine	KNPCQQADEVAPGALLGLGNLTHLSLKYNNTTEVPRRLPPLSITLSSLYNHIITLAPEDL	239
porcine	KNPCQGALEVAPGALLGLGNLTHLSLKYNNTTEVPRRLPPLSLEYLSSLYNHIITLAPEDL	239
horse	KNPCGRALEVAPGALLGLGNLTHLSLKYNNTTVPRSLPPLSLEYLSSLYNHIITLAPEDL	240
human	KNPCRQALEVAPGALLGLGNLTHLSLKYNNTTVPRNLPPSLEYLSSLYNRIVKLAPEDL	240
rat	KNPCNGAVNVTPDAFLGLSNLTHLSLKYNNTTEVPRQLPPLSLEYLSSLYNLIVKLGAEDL	240
	*** *:***** .* :***** .*****:***** *** .***:***** *:.* .***	
feline	ANLTALRVLVDGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLLEGVLVLDSSLYNLN	300
canine	ANLTALRVLVDGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLHLEGVLVLDSSLYSLD	300
bovine	ANLTALRVLVDGGNCRRCDHARNPCRECPKFNFKPLHPDTFSHLSRLEGVLVLDSSLYKLE	299
mouse	ANLTALRVLVDGGNCRRCDHARNPCRECPKFNFKPLHPDTFSHLSRLEGVLVLDSSLYKLE	299
ovine	ANLTALRVLVDGGNCRRCDHARNPCRECPKDNFKPLHPDTFSHLSDTFSHLSRLEGVLVLDSSLYNL	299
porcine	ANLTALRVLVDGGNCRRCDHARNPCRECPKDNFKPLHPDTFSHLSDTFSHLSRLEGVLVLDSSLYQLN	300
horse	ANLTALRVLVDGGNCRRCDHARNPCRECPKDNFKPLHPDTFSHLSDTFSHLSRLEGVLVLDSSLSWLN	300
human	ANLTSLRMLDVGNCRRCDHAPDLCTECRQKSLDLHPQTFHLSHLEGVLVLDSSLHSLN	300
rat	****:***:***** : * * : .***:*** .*****:*** *:	
feline	PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSEAHLLAPSF	360
canine	PRWFHGLGNLMVLDLSENFLYDCITKTKAFYGLARLRRRLNLSFNYHKKVSEAHLLASSF	360
bovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSEAHLLASSF	359
mouse	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSEAHLLASSF	359
ovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTOLRRLNLSFNYHKKVSEAHQLAPSF	359
porcine	TRWFGLDRLQVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSEAHLLAPSF	359
horse	PRWFRLGLGNLTVDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSEAHLLAPSF	360
human	ASWFRLGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSEAHLLAPSF	360
rat	SKWFQGLANLVSVDLSENFLYESINKTSAFQNLTRLRKLDLFSNYCKKVSFARLHASSF	360
	:.* .* ** .* .***:*** :***** *:*****:*** ***	

Figure 1
(2/3)

Figure 1
(3/3)

feline	SFFALATRLRELNLSANALKTVEPSWFGSLACTLKVLVDVTGNPLHCACGAAFVDFLLEVQ	778
canine	SFFALAVRLRELNLSANALKTVEPSWFGSLAGALKVLVDVTANPLHCACGATFVDFLLEVQ	780
bovine	GFFVRATRLIELNLSANALKTVDPSWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERQ	776
mouse	GFFVRATRLIELNLSANALKTVDPSWFGSLACTLKILDVSANPLHCACGAAFVDFLLERQ	776
ovine	GFFVLANRLKELNLSANALKTVDFWFGRLTELNLILDVSANPLHCACGAAFVDFLLEMQ	776
porcine	GFFALAKQLEELNLSANALKTVEPSWFGSMVGNLKVLDSANPLHCACGATFVGLLEVQ	777
horse	GFFALATRLRELNLSANALRTEEPSWFGFLAGSLEVLDVSANPLHCACGAAFVDFLLOVQ	778
human	GFFSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQ	778
rat	AFFALAVELKEVNLNLSHNLKTVDRSWFGPIVMNLTVLDVSSNPLHCACGAPFVDFLLEVQ	779
	**** * . * :**** * * : . * :**** :***** * . :**** :	
feline	AAVPGLPGHVKGSPGQQLQGRSIFAQDRLCLDEALSWDCFGSLSLLTVALGLAVPMLHHI	838
canine	AAVPGLPSRVKGSPGQQLQGRSIFAQDRLCLDEALSWVCFSLSLLAVALSLAVPMLHQL	840
bovine	EAVPGLSRRVTCGSPGQQLQGRSIFTQDRLCLDETLSDLCFGSLSLMVALGLAVPMLHHI	836
mouse	EAVPGLSRRVTCGSPGQQLQGRSIFTQDRLCLDETLSDLCFGSLSLMVALGLAVPMLHHI	836
ovine	AAVPGLSRRVTCGSPGQQLQGRSIFAQDRLCLDETLSDLCFGFSLLMVALGLAVPMLHHI	836
porcine	AAVPGLSRRVKGSPGQQLQGRHSIFAQDRLCLDETLSWNCFGISLLAMALGLVVPMMLHHI	837
horse	AAVPGLPSRVKGSPGQQLQGRSIFAQDRLCLDKSLSWDCFGLSLLVVALGLAMPMLHHI	838
human	AAVPGLPSRVKGSPGQLOGLSIFAQDRLCLDEALSWDCFALSLLAVALGLGVPMMLHHI	838
rat	AAVPGLANGVKCGSPRQLQGRSIFAQDRLCLDDVLSRDCFGLSLLAVAVGTVLPILLQH	839
	***** . * .***** ***** ***:***** . ** **.**** :*. :*:**** :	
feline	CGWDLWYCFHLCALWLPRRGRR--RGADALPYDAVVFDKAQSAADVWVYNELRVLEER	896
canine	CGWDLWYCFHLCALWLPRRGRR--RGVDALAYDAVVFDKAQSSADVWVYNELRVQLEER	898
bovine	CGWDLWYCFHLCALHLPRRRQ--RGEDTLLYDAVVFDKQSAADVWVYNELRVQLEER	894
mouse	CGWDLWYCFHLCALHLPRRRQ--RGEDTLLYDAVVFDKQSAADVWVYNELRVQLEER	894
ovine	CGWDLWYCFHLCALHLPRRRQ--RGEDTLLYDAVVFDKQSAADVWVYNELRVQLEER	894
porcine	CGWDLWYCFHLCALHLPRRRQ--RGADALFYDAVVFDKAQSAADVWVYNELRVQLEER	895
horse	CGWDLWYCFHLCALWLPRRGQW--RGADALSYDAVVFDKAQSAADVWVYNELRVLEER	896
human	CGWDLWYCFHLCALWLPWRGRQSGRDEDALPYDAVVFDKTQSAADVWVYNELRGQLEEC	898
rat	CGWDWYCFHLCALWLPILLTRGR-RSAQALPYDAVVFDKAQSAADVWVYNELRVLEER	898
	***** :***** * * . :*. :**** .***** ***:***** :***** :	
feline	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQLR	956
canine	RGRRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLLAQQLR	958
bovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDDHTDRVSGLLRASFLLAQQLR	954
mouse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDDHTDRVSGLLRASFLLAQQLR	954
ovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDDHTDRVSGLLRASFLLAQQLR	954
porcine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLLAQQLR	955
horse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQLR	956
human	RGRWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQLR	958
rat	RGRRALRLCLEERDWLPGKTLFENIWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQQLR	958
	***** :***** :***** :***** :***** :***** :***** :***** :***** :	
feline	LEDRKDVVVLVILRPDAHRSRYVRLRQLCRQSLLWPHQPSQRSFWAQLGTALTRDNQ	1016
canine	LEDRKDVVVLVILCPDAHRSRYVRLRQLCRQSLLWPHQPSQRSFWAQLGTALTRDNR	1018
bovine	LEDRKDVVVLVILRPAAYRSRYVRLRQLCRQSLLWPHQPSQGSFWANLGIALTRDNR	1014
mouse	LEDRKDVVVLVILRPAAYRSRYVRLRQLCRQSLLWPHQPSQGSFWANLGIALTRDNR	1014
ovine	LEDRKDVVVLVILRPAAYRSRYVRLRQLCRQSLLWPHQPSQGSFWANLGIALTRDNR	1014
porcine	LEDRKDVVVLVILRPAAYRSRYVRLRQLCRQSLLWPHQPRGQGSFWAQLGTALTRDNH	1015
horse	LEDRKDVVVLVILRPAAYRSRYVRLRQLCRQSLLWPHQPRGQGSFWAQLGTALTRDNH	1016
human	LEDRKDVVVLVILSPDARRSRYVRLRQLCRQSLLWPHQPSQGSFWAQLGMALTRDNH	1018
rat	LEDRKDVVVLVILRPDAHRSRYVRLRQLCRQSLLWPHQPSQGSFWAQLGMALTRDNH	1018
	***** :***** * . ***** :***** :***** :***** :***** :***** :***** :	
feline	HFYNQNFCRGPTTAE-----	1031
canine	HFYNQNFCRGPTTA-----	1032
bovine	HFYNRNFCRGPTTAE-----	1029
mouse	HFYNRNFCRGPTTAE-----	1032
ovine	HFYNRNFCRGPTTAE-----	1029
porcine	HFYNRNFCRGPTTAE-----	1030
horse	HFYNQNFCRGPTMAE-----	1031
human	HFYNRNFCQGPTTAE-----	1032
rat	HFYNRNFCRGPTTAE-----	1032
	***** :***** :*****	

Figure 2**Figure 3**

SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH
University of Saskatchewan
Qiagen GmbH

<120> TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES

<130> C1041.70040W000

<150> US 60/412,479
<151> 2002-09-19

<160> 70

<170> PatentIn version 3.1

<210> 1
<211> 1032
<212> PRT
<213> Rattus norvegicus

<400> 1

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn
50 55 60

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn
65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro
180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser
260 265 270

Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe
290 295 300

Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu
370 375 380

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr
420 425 430

Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val
435 440 445

Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser
450 455 460

Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp
515 520 525

Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser
565 570 575

Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val
580 585 590

Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly
595 600 605

Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe

610 615 620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu
645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser
660 665 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn
675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Pro Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser
805 810 815

Arg Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Thr Val
820 825 830

Leu Pro Leu Leu Gln His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
835 840 845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Thr Arg Gly Arg Arg Ser
850 855 860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
900 905 910

Trp Ile Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Lys Val Ser
930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
980 985 990

Leu Phe Trp Pro His Gln Pro Asn Gly Gln Gly Ser Phe Trp Ala Gln
995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
1025 1030

<210> 2
<211> 821
<212> PRT
<213> Rattus norvegicus

<400> 2

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn
50 55 60

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn
65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro
180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser
260 265 270

Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe
290 295 300

Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu
370 375 380

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr
420 425 430

Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val
435 440 445

Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser
450 455 460

Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp
515 520 525

Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser
565 570 575

Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val
580 585 590

Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly
595 600 605

Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe
610 615 620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu
645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser
660 665 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn
675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn

725

730

735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
 740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly
 755 760 765

Ala Pro Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly
 770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg
 785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser
 805 810 815

Arg Asp Cys Phe Gly
 820

<210> 3
 <211> 3099
 <212> DNA
 <213> Rattus norvegicus

<400> 3		
atggttctct gtcgcaggac cctgcacccc ttgtctctcc tggcacaggc cgcagtgc	60	
gctgaggctc tggccctggg taccctgcct gccttcctac cctgtgaact gaagcctcat	120	
ggcctggtag actgcaactg gctcttcctg aagtctgtgc ctcacttctc tgccgcagaa	180	
ccccgttcca acatcaccag ctttccttg atcgccaacc gcatccacca cctgcacaac	240	
ctcgactttg tccacactgcc caacgtgcga cagctgaacc tcaagtggaa ctgtccgccc	300	
cctggcctca gccccttgca ctttcctgc cgcatgacca ttgagccaa aaccttcctg	360	
gctatgcgcga tgctggaaga gctgaacctg agctataacg gtatcaccac tgtgccccgc	420	
ctgcccagct ccctgacgaa tctgagccta agccacacca acatcctggt actcgatgcc	480	
agcagcctcg ctggcctgca cagcctgcga gttctttca tggacgggaa ctgtactac	540	
aagaacccct gcaacggggc ggtgaacgtg accccggacg ctttcctggg cttgagcaac	600	
ctcaccact tggcccttaa gtataacaac ctcacagagg tgccccgcca actgcccccc	660	
agcctggagt acctcctgct gtcctataac ctcatgtca agctgggggc cgaagaccta	720	
gccaacctga cttcccttcg aatgcttcat gtgggtggga attgccgtcg ctgtgatcac	780	

gcccccgacc tctgtacaga atgccggcag aagtcccttg atctgcaccc tcagactttc	840
catcacctga gccaccttga aggccctggtg ctgaaggaca gttctctcca ctcgctgaac	900
tccaaagtggt tccagggtct ggcgaacetc tcgggtctgg acctaagcga gaactttctc	960
tacgagagca tcaacaaaac cagcgcctt cagaacctga cccgtctgctg caagctcgac	1020
ctgtccttca attactgcaa gaaggtatcg ttgcggcc tccacctggc aagttccctc	1080
aagagcctgg tgcgttgca ggagctgaac atgaacggca tcttcttccg cttactcaac	1140
aagaaacacgc tcaggtggct ggctggcttg cccaaagctcc acacgctgca cttcaaaatg	1200
aatttcatca accaggcgca gtcagcgctc ttttagtacct tccgagccct tcgccttgg	1260
gacctgtcca ataatcgcat cagcgggcct ccaacgctgt ccagagtcgc cccgaaaag	1320
gcagacgagg cggagaaggg ggttccatgg cctgcaagtc tcaccccaagc tctccgagc	1380
actcccgtct caaagaactt catggtcagg tgtaagaacc tcagattcac catggacctg	1440
tctcggaaaca accaggtgac tatcaagcca gagatgttcg tcaacctctc ccatctccag	1500
tgtctgagcc tgagccacaa ctgcacgcg caggctgtca atggctctca gttcctgccc	1560
ctgaccaacc tgaaggtgct ggacctgtcc tataacaagc tggacctgta ccattcgaaa	1620
tcttcagtg agctcccaca gttgcaggcc ctggacctga gctacaacag ccagccattc	1680
agcatgcagg ggataggcca caacttcagt tttctggcca atctgtccag gttacagaac	1740
cttagcctgg cacacaatga cattcacagc cgcgtgtcct cacgcctcta cagcacctca	1800
gtggagttatc tggacttcag cggcaacggc gtggccgca tgtggacga ggaggacctt	1860
tacctctatt tcttccaaga cctgagaagc ctgattcatc tggacctgtc tcagaataag	1920
ctgcacatcc tccggcccca gaacctcaac tacctccca agagcctgac gaagctgagt	1980
ttccgtgaca atcacctctc tttctttaac tggagcagtc tggccttcct gcccaatctg	2040
cgagacctgg acctggcagg caatctacta aaggccctga ccaacggcac cctgcctaatt	2100
ggcacgctcc tccagaaaact ggatgtcagt agcaacagta tcgtcttgc ggtccagcc	2160
ttctttgctc tggcggtaga gctaaaagag gtcaacctca gccataacat cctcaagact	2220
gtggatcgct cctgggtttgg gcccattgtg atgaacctga cggttctaga cgtgagcagc	2280
aaccctctgc attgtgcctg cggtgacccc ttttagtact tactgttgc agtgcagacc	2340
aaggtgcctg gcctggctaa cgggtgtgaag tgtggcagtc cccgcccagct gcagggccgc	2400
agcattttg cgcaagacct ggggtgtgc ctggatgacg tcccttcctg ggactgtttt	2460
ggccttcac tcctggctgt ggccgtgggc acgggtttgc ctttactgca gcatctctgc	2520
ggctggacg tctggtactg tttccatctg tgccctggcat ggctacccctt gctgaccctgt	2580

ggccggcgca	gcccccaagc	tctcccttat	gatgccttcg	tggtgttcga	taaggcgcag	2640
agcgcgggttgc	ctgactgggt	gtataacgag	cttcgagtgc	ggctagagga	gcggcgccgt	2700
cgccgagccc	tacgcttgtg	tctggaggac	cgagattggc	tgcctggcca	gacactcttc	2760
gagaacctct	gggcctccat	ctatggcagc	cgcaagactc	tgtttgtgt	ggcccacacg	2820
gacaaggta	gtggcctcct	gcccaccaggc	ttccctgtgg	ctcagcagcg	cctgctggag	2880
gaccgcaagg	acgtgggtgg	gttggtgatc	ctgcgcctg	atgcccacccg	ctcccgctac	2940
gtgcactgc	gccagcgcct	ctgcccagg	agtgtgtct	tctggcccca	tcagcccaac	3000
ggcaggggca	gcttctgggc	ccagctgagt	acagccctga	ctagggacaa	ccaccacttc	3060
tataaccgga	acttctgccc	gggacctaca	gcagaatag			3099

<210> 4
 <211> 2463
 <212> DNA
 <213> Rattus norvegicus

<400> 4	atggttctct	gtcgaggac	cctgcacccc	ttgtctctcc	tggcacaggc	cgcagtgtcg	60
	gctgaggctc	tggccctggg	taccctgcct	gccttcctac	cctgtgaact	gaagcctcat	120
	ggcctggtag	actgcaactg	gctcttcctg	aagtctgtgc	ctcaattctc	tgcgcagaa	180
	ccccgttcca	acatcaccag	ccttccttg	atgcacaacc	gcatccacca	cctgcacaac	240
	ctcgactttg	tccacctgcc	caacgtgcga	cagctgaacc	tcaagtggaa	ctgtccgccc	300
	cctggcctca	gccccttgca	cttctctgc	cgcacatgacca	ttgagccaa	aaccttcctg	360
	gctatgcga	tgctgaaaga	gctgaacctg	agctataacg	gtatcaccac	tgtccccgc	420
	ctgcccagct	ccctgacgaa	tctgagccta	agccacacca	acatcctggt	actcgatgcc	480
	agcagcctcg	ctggcctgca	cagcctgcga	gttctttca	tggacggaa	ctgctactac	540
	aagaacccct	gcaacggggc	ggtgaacgtg	accccgacg	cttcctggg	cttgagcaac	600
	ctcacccact	tgtcccttaa	gtataacaac	ctcacagagg	tgcggccca	actgcccccc	660
	agcctggagt	acccctgtct	gtcctataac	ctcatcgta	agctgggggc	cgaagaccta	720
	gccaacctga	cctcccttcg	aatgcttgat	gtgggtggga	attgccgtcg	ctgtgatcac	780
	gccccggacc	tctgtacaga	atgcggcag	aagtcccttg	atctgcaccc	tcaagacttc	840
	catcacctga	gccaccttga	aggcctggtg	ctgaaggaca	gttctctcca	ctcgctgaac	900
	tccaagtgg	tccagggtct	ggcgaacctc	tcggtgctgg	acctaagcga	gaactttctc	960
	tacgagagca	tcaacaaaac	cagcgcctt	cagaacctga	cccgctcg	caagctcgac	1020

ctgtccctca	attactgcaa	gaaggtatcg	ttcgcccgcc	tccacctggc	aagttccttc	1080
aagagcctgg	tgtcgctgca	ggagctgaac	atgaacggca	tcttcttccg	cttactcaac	1140
aagaacacgc	tcaggtggct	ggctggctcg	cccaagctcc	acacgctgca	ccttcaaatg	1200
aatttcatca	accaggcgca	gctcagcgtc	tttagtacct	tccgagccct	tcgctttgtg	1260
gacctgtcca	ataatcgcat	cagcgggct	ccaaacgctgt	ccagagtgc	ccccgaaaag	1320
gcagacgagg	cggagaaggg	ggttccatgg	cctgcaagtc	tcaccccage	tctcccgagc	1380
actcccgtct	caaagaactt	catggtcagg	tgtaagaacc	tcagattcac	catggacctg	1440
tctcggaaaca	accaggtgac	tatcaagcca	gagatgttcg	tcaacctotc	ccatctccag	1500
tgtctgagcc	tgagccacaa	ctgcacatcg	caggctgtca	atggctctca	gttcctgccc	1560
ctgaccaacc	tgaaggtgct	ggacctgtcc	tataacaagc	tggacctgta	ccattcgaaa	1620
tcgttcagtg	agctcccaca	gttgcaggcc	ctggacctga	gctacaacag	ccagccattc	1680
agcatgcagg	ggataggcca	caacttcagt	tttctggcca	atctgtccag	gttacagaac	1740
cttagcctgg	cacacaatga	cattcacagc	cgcgtgtcct	cacgcctcta	cagcacctca	1800
gtggagtatc	tggacttcag	cggcaacgg	gtggccgca	tgtggacga	ggaggacctt	1860
tacctctatt	tcttccaaga	cctgagaagc	ctgattcatc	tggacctgtc	tcagaataag	1920
ctgcacatcc	tccggcccca	gaaccta	tacccccc	agagcctgac	gaagctgagt	1980
ttccgtgaca	atcacctctc	tttcttaac	tggagcagtc	tggccttct	gcccaatctg	2040
cgagacctgg	acctggcagg	caatctacta	aaggccctga	ccaaacggcac	cctgccta	2100
ggcacgctcc	tccagaaact	ggatgtcagt	agcaacagta	tcgtctttgt	ggtcccagcc	2160
ttctttgtc	tggcggtaga	gctaaaagag	gtcaacctca	gccataacat	cctcaagact	2220
gtggatcgct	cctggtttgg	gcccattgt	atgaacctga	cggttctaga	cgtgagcagc	2280
aaccctctgc	attgtgcctg	cggtgcaccc	ttttagact	tactgctgga	agtgcagacc	2340
aagggtgcctg	gcctggctaa	cggtgtgaag	tgtggcagtc	cccgccagct	gcagggccgc	2400
agcatcttg	cgcaagacct	cgggctgtgc	ctggatgacg	tccttctcg	ggactgctt	2460
ggc						2463

:

<210> 5
 <211> 1030
 <212> PRT
 <213> Sus scrofa

 <400> 5

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val
1 5 10 15

Thr Ala Leu Ala Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu
20 25 30

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe
35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp Ser
65 70 75 80

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr
145 150 155 160

His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro
260 265 270

Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg
290 295 300

Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Cys Ile Thr Lys Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg
325 330 335

Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln
370 375 380

Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn
385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu
405 410 415

Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro
435 440 445

Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp
450 455 460

Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg
465 470 475 480

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg
 485 490 495

Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn
 500 505 510

Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser
 515 520 525

His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro
 530 535 540

Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met
 545 550 555 560

Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu
 565 570 575

Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln
 580 585 590

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp
 595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln
 610 615 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His
 625 630 635 640

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His
 645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu
 660 665 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu
 675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg
 690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe

705

710

715

720

Ala Leu Ala Lys Gln Leu Glu Glu Leu Asn Leu Ser Ala Asn Ala Leu
725 730 735

Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys
740 745 750

Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr
755 760 765

Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro
770 775 780

Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile
785 790 795 800

Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn
805 810 815

Cys Phe Gly Ile Ser Leu Leu Ala Met Ala Leu Gly Leu Val Val Pro
820 825 830

Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu
835 840 845

Cys Leu Ala Trp Leu Pro His Arg Gly Gln Arg Arg Gly Ala Asp Ala
850 855 860

Leu Phe Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val
865 870 875 880

Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg
885 890 895

Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro
900 905 910

Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg
915 920 925

Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu Leu
930 935 940

Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys
 945 950 955 960

Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala Tyr Arg Ser Arg
 965 970 975

Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp
 980 985 990

Pro His Gln Pro Arg Gly Gln Gly Ser Phe Trp Ala Gln Leu Gly Thr
 995 1000 1005

Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg Asn Phe Cys
 1010 1015 1020

Arg Gly Pro Thr Thr Ala Glu
 1025 1030

<210> 6
 <211> 819
 <212> PRT
 <213> Sus scrofa

<400> 6

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val
 1 5 10 15

Thr Ala Leu Ala Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu
 20 25 30

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe
 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Ala Asn Val
 50 55 60

Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp Ser
 65 70 75 80

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn
 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr
 100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr
145 150 155 160

His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro
260 265 270

Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg
290 295 300

Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Cys Ile Thr Lys Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg
325 330 335

Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln
370 375 380

Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn
385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu
405 410 415

Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro
435 440 445

Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp
450 455 460

Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg
465 470 475 480

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg
485 490 495

Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn
500 505 510

Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser
515 520 525

His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro
530 535 540

Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met
545 550 555 560

Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu
565 570 575

Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln
580 585 590

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp
595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln
610 615 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His
625 630 635 640

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His
645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu
660 665 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu
675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg
690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe
705 710 715 720

Ala Leu Ala Lys Gln Leu Glu Leu Asn Leu Ser Ala Asn Ala Leu
725 730 735

Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys
740 745 750

Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr
755 760 765

Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro
770 775 780

Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile
785 790 795 800

Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn
805 810 815

Cys Phe Gly

<210> 7
 <211> 3352
 <212> DNA
 <213> Sus scrofa

<400> 7
 gagcacgaac atccttcaact gtagctgctg cccggctctgc cagccagacc ctggagaa 60
 gaccccaactc cctgtcatgg gcccccgctg caccctgcac cccctttctc tcctggtgca 120
 ggtgacagcg ctggctgcgg ctctggccca gggcaggctg cctgccttcc tgccctgtga 180
 gctccagccc cacggcctgg tgaactgcaa ctggcttcc ctgaagtccg tgcccccactt 240
 ctggcggca gcgcgggggg ccaacgtcac cagcctctcc ttactctcca accgcatcca 300
 ccacctgcac gactccgact tcgtccacct gtccagccta cgaactctca acctcaagtg 360
 gaactgcccgg cccggctggcc tcagccccat gcacttcccc tgccacatga ccatcgagcc 420
 caacaccttc ctggccgtgc ccacccctgga ggagctgaac ctgagctaca acagcatcac 480
 gaccgtgcct gccctgcccgg actccctcggt ctcctgtcg ctgagccgca ccaacatcct 540
 ggtgctagac cccacccacc tcactggcct acatgcccgt cgctacctgt acatggatgg 600
 caactgctac tacaagaacc cctgccagg ggcgctggag gtggtgccgg tgccctcct 660
 cggcctgggc aacctcacac atctctcaact caagtacaac aatctcacgg aggtgccccgg 720
 cagcctgccc cccagcctgg agaccctgct gttgtcctac aaccacatttgc tcaccctgac 780
 gcctgaggac ctggccaaatc tgactgcct gcgcgtgttt gatgtgggggg ggaactgcccgg 840
 cccgtgtgac catgccccca acccctgcag ggagtgccca aaggaccacc ccaagctgca 900
 ctctgacacc ttccagccacc tgagccct cgaaggcctg gtgttggaaag acagttctct 960
 ctacaacctg gacaccagggt gtggccagg cctggacagg ctccaagtgc tggacctgag 1020
 tgagaacttc ctctacgact gcatcaccaaa gaccacggcc ttccaggggcc tggcccgact 1080
 ggcacccctcc tttgggcaco tccggccctt gaaggagctg gacatgeatg gcatttctt 1140
 cccgctcgctc agtggagacca cgctccaaacc tctggccaa ctgcctatgc tccagaccct 1200
 ggcgcgtgcagg atgaacttca ttaaccaggc ccagctcagc atctttgggg cttccctgg 1260
 cctgtgtac gtggacctat cggacaaccg catcagcggc gctgcaaggc cagtgccat 1320
 tactagggag gtggatggta gggagagggt ctggctgcct tccaggaacc tcgctccacg 1380
 tccactggac actctcccgct cagaggactt catgccaaac tgcaaggcct tcagcttcac 1440
 1500

cttggacctg	tctcggaaca	acctggtgac	aatccagtcg	gagatgttg	ctcgcccttc	1560
acgcctcgag	tgcctgcgcc	tgagccacaa	cagcatctcc	caggcggtca	atggctctca	1620
gtttgtccg	ctgaccagcc	tgcggtgtct	ggacctgtcc	cacaacaagc	tggacctgt	1680
tcacggcgc	tcgttcacgg	agctgcccgc	cctggaagca	ctggacctca	gctacaatag	1740
ccagccctt	accatgcagg	gtgtggcca	caacctcagc	ttcgtggccc	agctgcccgc	1800
cctgcgcctac	ctcagcctgg	cgcacaatga	catccatagc	cgagtgtccc	agcagctctg	1860
tagcgcctca	ctgtgcgcgc	tggactttag	cggcaacgat	ctgagccgga	tgtggctga	1920
gggagacetc	tatctccgct	tcttccaagg	cctaagaagc	ctagtctggc	tggacctgtc	1980
ccagaaccac	ctgcacaccc	tcctgcccacg	tgccctggac	aacctcccc	aaagcctgaa	2040
gcatctgcat	ctccgtgaca	ataacctggc	cttcttcaac	tggagcagcc	tgaccctcct	2100
gcccaagctg	gaaaccctgg	acttggctgg	aaaccagctg	aaggccctaa	gcaatggcag	2160
cctgcacatct	ggcacccago	tgcgaggagct	ggacctcagt	ggcaacagca	tcggctttgt	2220
gaaccctggc	ttctttgccc	tggccaagca	gttagaagag	ctcaacctca	gcccacatgc	2280
cctcaagaca	gtggagccct	cctgggttgg	ctcgatggt	ggcaacctga	aagtccctaga	2340
cgtgagcgc	aaccctctgc	actgtgcctg	tggggcgacc	ttcgtggct	tcctgctgg	2400
ggtagcaggct	gccgtgcctg	ggctgcccag	ccgcgtcaag	tgtggcagtc	cggggcagct	2460
ccagggccat	agcatctttg	cgcaagacct	gcgcctctgc	ctggatgaga	ccctctcg	2520
gaactgttt	ggcatctcgc	tgctggccat	ggccctggc	ctggttgtc	ccatgctgca	2580
ccacctctgc	ggctgggacc	tctggtactg	cttccacctg	tgcctggc	ggctgcccc	2640
ccgagggcag	cggcggggcg	cagacccc	gttctatgat	gccttcgtgg	tctttgacaa	2700
agctcagagt	gctgtggccg	actgggtgt	caacgagctg	cgggtgcagc	tggaggagcg	2760
ccgtggcgc	cgcgcactgc	gcctgtgcct	ggaggagcga	gactggttac	ctggcaagac	2820
gctcttcgag	aacctgtggg	cctcagtcta	cagcagccgc	aagaccctgt	ttgtgctgg	2880
ccacacggac	cgtgtcagcg	gcctcttcgc	tgccagtttc	ctgctggccc	agcagcgcct	2940
gctggaggac	cgcaaggacg	ttgttagtgc	ggtgatcctg	cgcggcgtat	cctaccgctc	3000
ccgctacgtg	cggctgcgc	agegcctctg	ccgcccagagt	gtccctctct	ggccccacca	3060
gccccgtgg	cagggcagct	tctggccca	gctggcaca	gcctgacca	gggacaacca	3120
ccacttctat	aaccggaaact	tctgccccgg	ccccacgaca	gccgaatagc	actgagtgac	3180
agcccagttg	ccccagcccc	cctggatttg	cctctctgc	tgggtgccc	caacctgctt	3240
tgctcagcca	caccactgct	ctgctccctg	ttccccaccc	caccccccag	cctggcatgt	3300

aacatgtgcc	caataaatgc	taccggaggg	ccaagaaaaa	aaaaaaaaaa	aa	3352
<210>	8					
<211>	2457					
<212>	DNA					
<213>	Sus scrofa					
<400>	8					
atggggccccc	gtgcacccct	gcacccctt	tctctctgg	tgcaggtgac	agcgctggct	60
gcggctctgg	cccagggcag	gtgcctgcc	ttcctgcct	gtgagctcca	gccccacggc	120
ctggtaact	gcaactggct	cttcctgaag	tccgtgcccc	acttctcggc	ggcagcgc	180
cgggccaacg	tcaccaggct	ctccttactc	tccaaccgca	tccaccacct	gcacgactcc	240
gacttcgtcc	acctgtccag	cctacgaact	ctcaacctca	agtggaaactg	cccgccggct	300
ggcctcagcc	ccatgcactt	cccctgccac	atgaccatcg	agcccaacac	tttcctggcc	360
gtgcccaccc	tggaggagct	gaacctgagc	tacaacagca	tcacgaccgt	gcctgcctg	420
cccgactccc	tcgtgtccct	gtcgctgagc	cgcaccaaca	ttctggtgct	agaccccacc	480
cacctcaactg	gcctacatgc	cctgcgtac	ctgtacatgg	atggcaactg	ctactacaag	540
aaccctgtcc	agggggcgct	ggaggtggtg	ccgggtgccc	ttctcgccct	ggcaacctc	600
acacatctct	cactcaagta	caacaatctc	acggaggtgc	cccgcagcct	gccccccagc	660
ctggagaccc	tgctgttgtc	ctacaaccac	attgtcaccc	tgacgcctga	ggacactggcc	720
aatctgactg	ccctgcgcgt	gtttgatgtg	ggggggaaact	gcgcgcgtg	tgaccatgcc	780
cgcaacccct	gcagggagtg	cccaaaggac	cacccaaggc	tgcactctga	cacccctcagc	840
cacctgagcc	gcctcgaagg	cctgggtttg	aaagacagtt	ctctctacaa	cctggacacc	900
aggtgttcc	gaggcctgga	caggctccaa	gtgctggacc	tgagtgagaa	tttcctctac	960
gactgcatca	ccaagaccac	ggccttccag	ggcctggccc	gactgcgcag	cctcaacctg	1020
tccttcaatt	accacaagaa	ggtgtccctt	gcccacctgc	acctggcacc	tttccttggg	1080
cacccctcggt	ccctgaagga	gctggacatg	catggcatct	tcttcgcgtc	gctcagttag	1140
accacgctcc	aacctctggt	ccaaactgcct	atgctccaga	ccctgcgcct	gcagatgaac	1200
ttcattaacc	aggcccagct	cagcatcttt	ggggccttcc	ctggcctgct	gtacgtggac	1260
ctatcgacca	accgcacatag	cgagactgca	aggccagtgg	ccattactag	ggaggtggat	1320
ggtagggaga	gggtctggct	gccttccagg	aacctcgctc	cacgtccact	ggacactctc	1380
cgctcagagg	acttcatgcc	aaactgcaag	gccttcagct	tcaccttgg	cctgtctcgg	1440
aacaacctgg	tgacaatcca	gtcggagatg	tttgctcgcc	tctcacgcct	cgagtgcctg	1500

cgcctgagcc acaa	cagcat ctc	cccaggcg	gtcaatggct	ctcagttgt	gccgctgacc	1560
agcctgcggg	tgctggac	ctt	gtcccacaac	aagctggacc	tgtatcacgg	1620
acggagctgc	cgcgcctgga	at	agcactggac	ctcagctaca	atagccagcc	1680
cagggtgtgg	gc	ccacaa	acct	cagttcgtg	cccagctgc	1740
ctggcg	caca	at	gacatcca	tagccgagt	tcccagc	1800
gccc	ttagcggcaa	at	gatctgagc	cggatgtggg	ctgagggaga	1860
cg	ttttcc	aa	aggcctaag	aagcttagtc	tggctggacc	1920
acc	cctgc	ac	cacgtgc	ggacaac	ccaaaagcc	1980
gacaataacc	tggc	ttt	caactggagc	agc	ctgaccc	2040
ctggacttgg	ctgg	aa	acca	gctgaaggcc	ctaagcaatg	2100
cagctgcgga	gg	ctt	ggac	cag	tgcc	2160
gccc	tggcca	ag	cagttaga	ag	actcaac	2220
cc	cctgg	c	ttggctcgat	gg	ctgaaagtcc	2280
ctgcactgtg	cctgtgg	g	ac	cttcgt	tgacgtgag	2340
cctgg	ctgc	ca	agtgtggc	at	cccg	2400
tttgcgcaag	acctgc	ct	gcctggat	gagacc	ctcg	2457

<210> 9
 <211> 1029
 <212> PRT
 <213> Bos taurus

<400> 9

Met	Gly	Pro	Tyr	Cys	Ala	Pro	His	Pro	Leu	Ser	Leu	Leu	Val	Gln	Ala
1					5				10				15		

Ala	Ala	Leu	Ala	Ala	Leu	Ala	Glu	Gly	Thr	Leu	Pro	Ala	Phe	Leu
							20		25				30	

Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Gln	Val	Asp	Cys	Asn	Trp	Leu	Phe
									35				40		45

Leu	Lys	Ser	Val	Pro	His	Phe	Ser	Ala	Gly	Ala	Pro	Arg	Ala	Asn	Val
								50					55		60

Thr	Ser	Leu	Ser	Leu	Ile	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp	Ser
									65				70		80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr

305	310	315	320
Asp Tyr Ile Thr Lys Thr Thr Ile Phe Asn Asp Leu Thr Gln Leu Arg			
325		330	335
Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His			
340		345	350
Leu His Leu Ala Ser Ser Phe Gly Ser Leu Val Ser Leu Glu Lys Leu			
355		360	365
Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Ile Thr Leu Gln			
370		375	380
Ser Leu Thr Arg Leu Pro Lys Leu Gln Ser Leu His Leu Gln Leu Asn			
385		390	395
400			
Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu			
405		410	415
Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Thr Pro			
420		425	430
Ala Ala Ala Leu Gly Glu Val Asp Ser Arg Val Glu Val Trp Arg Leu			
435		440	445
450			
Pro Arg Gly Leu Ala Pro Gly Pro Leu Asp Ala Val Ser Ser Lys Asp			
455		460	
Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn			
465		470	475
480			
Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu			
485		490	495
Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly			
500		505	510
Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser His			
515		520	525
Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln			
530		535	540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
660 665 670

Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Ile Arg Leu Gln Lys Leu
690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Ile Pro Gly Phe Phe Val
705 710 715 720

Arg Ala Thr Arg Leu Ile Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu Lys Ile
740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
755 760 765

Val Asp Phe Leu Leu Glu Arg Gln Glu Ala Val Pro Gly Leu Ser Arg
770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Thr Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
805 810 815

Phe Gly Leu Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met
820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys
835 840 845

Leu Ala His Leu Pro Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu
850 855 860

Leu Tyr Asp Ala Val Val Val Phe Asp Lys Val Gln Ser Ala Val Ala
865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly
885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly
900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys
915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg
930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp
945 950 955 960

Val Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr
965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro
980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Ile Ala
995 1000 1005

Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg
1010 1015 1020

Gly Pro Thr Thr Ala Glu
1025

<210> 10
<211> 818
<212> PRT
<213> Bos taurus

<400> 10

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala
1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Glu Gly Thr Leu Pro Ala Phe Leu
20 25 30

Pro Cys Glu Leu Gln Pro His Gly Gln Val Asp Cys Asn Trp Leu Phe
35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Gly Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser
65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Tyr Ile Thr Lys Thr Ile Phe Asn Asp Leu Thr Gln Leu Arg
325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu His Leu Ala Ser Ser Phe Gly Ser Leu Val Ser Leu Glu Lys Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Ile Thr Leu Gln
370 375 380

Ser Leu Thr Arg Leu Pro Lys Leu Gln Ser Leu His Leu Gln Leu Asn
385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu
405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Thr Pro

420 425 430

Ala Ala Ala Leu Gly Glu Val Asp Ser Arg Val Glu Val Trp Arg Leu
435 440 445Pro Arg Gly Leu Ala Pro Gly Pro Leu Asp Ala Val Ser Ser Lys Asp
450 455 460Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn
465 470 475 480Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu
485 490 495Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser His
515 520 525Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln
530 535 540Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr
625 630 635 640Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
 660 665 670

Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
 675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Ile Arg Leu Gln Lys Leu
 690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Ile Pro Gly Phe Phe Val
 705 710 715 720

Arg Ala Thr Arg Leu Ile Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
 725 730 735

Thr Val Asp Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu Lys Ile
 740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
 755 760 765

Val Asp Phe Leu Leu Glu Arg Gln Glu Ala Val Pro Gly Leu Ser Arg
 770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
 785 790 795 800

Thr Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
 805 810 815

Phe Gly

<210> 11
 <211> 3191
 <212> DNA
 <213> Bos taurus

<400> 11			
ggaaagtggg cgccaaagcat cttccctgc agtgcctcc caacctgccc gccagaccct			60
ctggagaagc cgcattccct gtcatggcc cctactgtgc cccgcacccc ctttctctcc			120
tggtgaggc ggcggcactg gcagcggccc tggccgaggg caccctgcct gccttctgc			180
cctgtgagct ccagccccat ggtcaggtgg actgcaactg gctgtccctg aagtctgtgc			240
cgcacttttc ggctggagcc ccccgccca atgtcaccag cctctcccta atctccaacc			300

gcatccacca	cttgcatgac	tctgacttcg	tccacctgtc	caacacctgg	gtcctcaacc	360
tcaagtggaa	ctgcccgcgg	gccggcctca	gccccatgca	cttcccctgc	cgtatgacca	420
tcgagccaa	caccccttcgt	gctgtgccc	ccctggagga	gctgaacctg	agctacaacg	480
gcatcacgac	cgtgcctgcc	ctgcccagtt	ccctcggtc	cctgtcgctg	agccacacca	540
gcatcctgg	gttagggccc	acccacttca	ccggcctgca	cgcctgcgc	tttctgtaca	600
tggacggcaa	ctgctactac	atgaacccct	gcccgcggc	cctggaggtg	gccccaggcg	660
ccctctcgg	cctgggcaac	ctcacgcacc	tgtcgctcaa	gtacaacaac	ctcacggagg	720
tgccccggc	cctgcccccc	agcctggaca	ccctgctgct	gtcctacaac	cacattgtca	780
ccctggcacc	cgaggacctg	gccaacctga	ctggcctgca	cgtgcttgac	gtgggtggga	840
actgcccgg	ctgcgaccat	gcccgcacc	cctgcaggga	gtgcccggaa	aacttccccca	900
agctgcaccc	tgacaccccttc	agtcacccctga	gccgcctgca	aggcctgggt	ttgaaggaca	960
gttctctcta	caaactagag	aaagattgg	tccgcggcct	gggcaggctc	caagtgcgt	1020
acctgagtga	gaacttcctc	tatgactaca	tcaccaagac	caccatcttc	aacgacccctga	1080
cccagctgcg	cagactcaac	ctgtccctca	attaccacaa	gaaggtgtcc	ttcgccccacc	1140
tgcacccatgc	gtccctccccc	gggagtctgg	tgtccctgg	gaagctggac	atgcacggca	1200
tcttcttccg	ctccctcacc	aacatcacgc	tccagtcgt	gaccggctg	cccaagctcc	1260
agagtctgca	tctgcagctg	aacttcatca	accaggccca	gctcagcatc	tttggggcct	1320
tcccggcct	gctcttcgtg	gacctgtcgg	acaaccgcatt	cagcggagcc	gcgacgcccag	1380
cggccgcct	gggggaggtg	gacagcagg	tggaaagtctg	gcgattgccc	aggggcctcg	1440
ctccaggccc	gctggacgccc	gtcagctcaa	aggacttcat	gccaagctgc	aacctcaact	1500
tcacccctgga	cctgtcacgg	aacaacctgg	tgacaatcca	gcaagagatg	tttacccgccc	1560
tctcccgcc	ccagtgcctg	cgccctgagcc	acaacagcat	ctcgcaggcg	gttaatggct	1620
cccagttcgt	gccgctgacc	agccctgcgag	tgctcgacct	gtcccacaac	aagctggacc	1680
tgtaccatgg	gcgcgtcatcc	acggagctgc	cgcagctgg	ggcactggac	ctcagctaca	1740
acagccagcc	cttcagcatg	cagggcgtgg	gccacaaccc	cagcttcgtg	gcccagctgc	1800
cctccctgcg	ctacctcago	cttgcgcaca	atggcatcca	cagccgcgtg	tcacagaagc	1860
tcagcagcgc	ctcggtgcgc	gcccctggact	tcagcggcaa	ctccctgagc	cagatgtggg	1920
ccgagggaga	cctctatctc	tgcttttca	aaggcttgag	gaacctggtc	cagctggacc	1980
tgtcccgagaa	ccatctgcac	accctctgtc	ctcgtaacct	ggacaacctg	cccaagagcc	2040

tgccggcagct	gctgtctccgg	gacaataacc	tggccttctt	caactggagc	agcctgaccg	2100
tcctgccccg	gctggaagcc	ctggatctgg	caggaaacca	gctgaaggcc	ctgagcaacg	2160
gcagcctgcc	gcctggcatc	cggctccaga	agctggacgt	gagcagcaac	agcatcggct	2220
tcgtgatccc	cggcttcttc	gtccgcgcga	ctcggctgat	agagcttaac	ctcagcgcca	2280
atgccctgaa	gacagtggat	ccctcctggt	tcgttcctt	agcagggacc	ctgaaaatcc	2340
tagacgtgag	cgcaccccg	ctccactgca	cctgcggggc	ggcctttgtg	gacttcctgc	2400
tggagagaca	ggaggccgtg	cccgggctgt	ccaggcgcgt	cacatgtggc	agtccgggcc	2460
agctccaggg	ccgcagcatc	ttcacacagg	acctgcgcct	ctgcctggat	gagaccctct	2520
ccttggactg	ctttggcctc	tcactgctaa	tggtggcgct	gggcctggca	gtgcccattgc	2580
tgcaccaccc	ctgtggctgg	gacctctggt	actgcttcca	cctgtgtctg	gcccatttgc	2640
cccgacggcg	gcggcagcgg	ggcgaggaca	ccctgctcta	tgtgccgtc	gtggcttgc	2700
acaagggtgca	gagtgcagtg	gctgattggg	tgtacaacga	gctccgcgtg	cagctggagg	2760
agcgccgggg	gcgcggggcg	ctccgcctct	gcctggagga	gcgagactgg	ctccctggta	2820
agacgctctt	cgagaacctg	tgggcctcgg	tctacagcag	ccgcaagacc	atgttcgtgc	2880
tggaccacac	ggaccgggtc	agcggcctcc	tgcgcgccag	cttcctgctg	gcccagcagc	2940
gcctgttgg	ggaccgcag	gacgtcgtag	tgctgggtat	cctgcgcctcc	gcccctatc	3000
ggtcccgcta	cgtgcggctg	cgcacccgc	tctgccgcca	gagcgtccctc	ctctggcccc	3060
accagccca	tggccagggt	agtttctggg	ccaacctggg	catagccctg	accagggaca	3120
accgtcaatt	ctataaccgg	aacttctgcc	ggggccccac	gacagccgaa	tagcacagag	3180
tgactgcccc	g					3191

<210> 12
 <211> 2454
 <212> DNA
 <213> Bos taurus

<400> 12						
atggggccct	actgtgcctt	gcacccctt	tcttcctgg	tgcaggcggc	ggcactggca	60
gcggccctgg	ccgagggcac	cctgcctgcc	ttcctgcctt	gtgagcttcca	gccccatggt	120
caggtggact	gcaactggct	gttcctgaag	tctgtgcgc	acttttcggc	tggagccccc	180
cgggccaatg	tcaccagcct	tccttaatc	tccaaaccgca	tccaccactt	gcatgactct	240
gacttcgtcc	acctgtccaa	cctgcgggtc	ctcaacctca	agtggaaactg	cccgccggcc	300
ggcctcagcc	ccatgcactt	cccctgccgt	atgaccatcg	agcccaacac	cttcctggct	360

gtgcccaccc	tggaggagct	gaacctgagc	tacaacggca	tcacgaccgt	gcctgccc	420
cccagttccc	tcgtgtccct	gtcgctgagc	cacaccagca	tcctggtgct	aggccccacc	480
cacttcacccg	gcctgcacgc	cctgcgc	ctt	ctgtacatgg	acggcaactg	540
aacccctgcc	cgcgccccct	ggaggtggcc	ccaggcgccc	tcctcggc	ctt	600
acgcacctgt	cgctcaagta	caacaaccc	acggaggtgc	cccgccgc	ctt	660
ctggacaccc	tgctgctgtc	ctacaaccac	attgtcaccc	tggcacc	ggac	720
aacctgactg	ccctgcgcgt	gcttgacgtg	ggtggaa	ctt	ccgcgt	780
cgcaacccct	gcagggagtg	ccaaagaac	ttccccaa	tg	acc	840
cacctgagcc	gcctcgaagg	cctgggttt	aaggacagtt	ctctctacaa	acta	900
gattggttcc	gccc	caggctccaa	gtgctgacc	t	gagtgagaa	960
gactacatca	ccaagaccac	cat	ttcaac	gac	ctgcag	1020
tccttcaatt	accacaagaa	gg	tgc	ttc	ccgtt	1080
agtctggtgt	ccctggagaa	gctggacatg	cac	ggc	atct	1140
atcacgctcc	agtcgctgac	ccgg	ctgccc	aag	ctgcat	1200
ttcatcaacc	aggcccagct	cag	cat	ttt	ggc	1260
ctgtcggaca	accgc	atcag	cg	gg	ccgtt	1320
agcagggtgg	aagtctggcg	at	tgccc	agg	ggc	1380
agctcaaagg	acttcatg	caac	ctcaactt	ca	c	1440
aacctggta	caatccagca	agagat	gttt	acc	cc	1500
ctgagccaca	acagcat	tc	gcaggcg	tt	atgg	1560
ctgcgagtgc	tcgac	ctg	ccacaaca	ag	tcgt	1620
gagctgccgc	agctggaggc	actggac	ctc	ttc	gtcc	1680
ggcgtggccc	acaac	ctc	agctgc	cc	ctgcgt	1740
gcgcacaatg	gcatccac	ag	cg	tc	atgc	1800
ctggacttca	gccc	actc	c	tgc	ggcc	1860
tttttcaaag	gcttggaggaa	cctgg	tc	ggac	tt	1920
ctcctgc	ctc	tc	caac	ctg	cc	1980
aataacctgg	ccttcttcaa	ctgg	gagc	agc	tc	2040
gatctggcag	gaaaccagct	gaagg	ccctg	agca	acggc	2100
ctccaga	aggac	gtg	ac	tc	ccgg	2160

cgcgcgactc ggctgataga gcttaacctc agcgccaatg ccctgaagac agtggatccc	2220
tcctggttcg gttccttagc agggaccctg aaaatcctag acgtgagcgc caacccgctc	2280
cactgcgcct gccccggcgc ctttgtggac ttcctgctgg agagacagga ggcgcgtgccc	2340
gggctgtcca ggccgtcac atgtggcagt ccgggcccagc tccagggcccg cagcatctc	2400
acacaggacc tgccctctg cctggatgag accctctcct tggactgctt tggc	2454

<210> 13
 <211> 1031
 <212> PRT
 <213> Equus caballus

<400> 13

Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln			
1	5	10	15

Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe		
20	25	30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu		
35	40	45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Asp Asn		
50	55	60

Val Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp			
65	70	75	80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp		
85	90	95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met		
100	105	110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu		
115	120	125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser		
130	135	140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro			
145	150	155	160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe
260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu
370 375 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly
405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu
420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu
435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe
610 615 620

Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln
645 650 655

Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu
740 745 750

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp
805 810 815

Asp Cys Phe Gly Leu Ser Leu Leu Val Val Ala Leu Gly Leu Ala Met
820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
835 840 845

Leu Gly Leu Ala Trp Leu Pro Arg Arg Gly Trp Gln Arg Gly Ala Asp
850 855 860

Ala Leu Ser Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala

865	870	875	880
Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg			
885	890	895	
Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu			
900	905	910	
Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser			
915	920	925	
Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Gln Val Ser Gly Leu			
930	935	940	
Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg			
945	950	955	960
Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Ala Arg Arg Ser			
965	970	975	
Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Phe			
980	985	990	
Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly			
995	1000	1005	
Met Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln Asn Phe			
1010	1015	1020	
Cys Arg Gly Pro Thr Met Ala Glu			
1025	1030		
<210> 14			
<211> 820			
<212> PRT			
<213> Equus caballus			
<400> 14			
Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln			
1	5	10	15
Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe			
20	25	30	
Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu			

35

40

45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Asp Asn
 50 55 60

Val Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp
 85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met
 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
 130 135 140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro
 145 150 155 160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly
 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro
 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
 195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr
 210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu
 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
 245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe
 260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu
370 375 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly
405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu
420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu
435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe
610 615 620

Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln
645 650 655

Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu
740 745 750

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
 755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu
 770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp
 805 810 815

Asp Cys Phe Gly
 820

<210> 15
 <211> 3391
 <212> DNA
 <213> Equus caballus

<400> 15
 ctctgttctc ttagctgttg ccgcgtgaag ggactgcgag cacaaagcat cttccctctgc 60
 agctgctgcc cagtgtgcc a cttggaccct ctggatcatc tcccactccc tgtcatgggc 120
 cttggccatg gtgcctgca gcccctgtct ctccctggc aggcggccat gctggccgtg 180
 gctctggccc aaggcaccct gcctcccttc ctgcctgtg agctccagcc ccacggcctg 240
 gtgaactgca actggctgtt cctgaagtcc gtgcctact tctcagcagc agcaccccg 300
 gacaatgtca ccagccttcc tttgtctcc aaccgcattc accacctcca cgactccgac 360
 tttgccttac tgcacttccc ctgcacatg accatcgagc ccaacacttt cttggctgt 420
 ctcagcccaac tgtccaaacct gcagaaaactc aacctcaaat ggaactgccc gccagccggc 480
 ctcagcccaac tgcacttccc ctgcacatg accatcgagc ccaacacttt cttggctgt 540
 agctccctcg tgtccctgat cttggccgc accaacatcc tgcagctaga cccaccaggc 600
 ctcacggggcc tgcacccctt ggcgttccata tacatggatg gcaactgcta ctacaagaac 660
 ccctgcgggc gggccctgga ggtggcccca ggcgttccat ttggccctggg caacccatc 720
 cacctgtcaca tcaagtacaa caacctcaca acggtgcccc gcagcctgcc ccctagcctg 780
 gagtacccatc tttgtccata caaccacatt gtcaccctgg cacctgagga cctggccat 840
 ctgactgccc tgcgtgtgtt cgatgtgggt ggaaactgccc ggcgttgc ccatgcacgc 900
 aaccctgcg tggagtgcac acataaaattc cccagctgc actccgacac cttcagccac 960

ctaagccgcc tagaaggcct cgtgttgaag gatagttctc tctaccagct gaaccccaga	1020
tggttccgtg gcctgggcaa cctcacagtg ctcgacctga gtgagaactt cctctacgac	1080
tgcacatcacca aaaccaaggc attccagggc ctggcccagc tgcgaaagact caacttgtcc	1140
ttcaattacc ataagaaggt gtccctcgcc cacctgacgc tggcaccctc cttcgggagc	1200
ctgctctccc tgcaggaact ggacatgcat ggcacatcttct tccgctcaact cagccagaag	1260
acgctccagc cactggcccg cctgcccattg ctccagcgtc tgtatctgca gatgaacttc	1320
atcaaccagg cccagctcg catcttcaag gacttccctg gtctgcgcta catagacctg	1380
tcagacaacc gcatcagtgg agctgtggag ccggtggcca ccacagggga ggtggatggt	1440
ggaaagaagg tctggctgac atccagggac ctcactccag gcccaactgga caccggcagc	1500
tctgaggact tcatgccaag ctgcaagaac ctcagcttca ccttggacact gtcacggaac	1560
aacctggtaa cagtccagcc agagatgttt gcccagctct cgccgcctcca gtgcctgcgc	1620
ctgagccaca acagcatctc gcaggcggtc aatggctcac agttcgtgcc actgaccagc	1680
ctgcaggtgc tggacctgtc ccataacaaa ctggacctgt accatggcgctc ctcgtttacg	1740
gagctgcccgc gactggaggc cctggacctc agctacaaca gccagccctt cagcatgcgg	1800
ggtgtgggcc acaacactcag ctttgtggcc cagctgcccac ccctgcgcta cctcagcctg	1860
gcacacaatg gcatccacag ccgtgtgtcc cagcagctct gcagcacccgc gctgtgggcc	1920
ctggacttca gccggcaattc cctgagccag atgtggctg agggagaccc ctatctccgc	1980
ttcttccaag gcctgagaag cctaattccgg ctagacctgt cccagaatcg tctgcataacc	2040
ctccctgccat gcaccctggg caacccccc aagagcttgc agctgtgcg tctccgtAAC	2100
aattacctgg ccttcttcaa ttggagcagc ctgaccctcc tgcccaacct ggaaaccctg	2160
gacctggctg gaaaccagct gaaggctctg agcaatggca gcctgccttc tggcaccctag	2220
ctccagaggc tggacgtcag caggaacagc atcatcttgc tggcccttgg cttctttgct	2280
ctggccacga ggctgcgaga gctcaacccctc agtgcacccgc ccctcaggac agaggagccc	2340
tcctggtttgc ttcccttagc aggctccctt gaagtccttag atgtgagcgc caaccctctg	2400
cactgcgcct gtggggcagc ctttgtggac ttccctgtgc aggttcaggc tgccgtgcct	2460
ggtctgcccac ccgcgcgtcaa gtgtggcagt ccggggccagc tccagggcccg cagcatcttc	2520
gcacaagacc tgccgcctctg cctggacaag tccctctctt gggactgttt tggctctca	2580
ttgctggttg tggccctggg cctggccatg cctatgttgc accacccctg cggctggac	2640
ctctggtaact gcttccacccctt gggcctggcc tggctgcccc ggcgggggtg gcagcggggc	2700

gcggatgccc tgagctatga tgccttgcgt gtctcgaca aggcacagag cgca	2760
gactgggtgt acaatgaact gcgggtgcgg ctagaggagc gccgtggcg cggcg	2820
cgcctgtgtc tggaggagcg tgactggcta cctggcaaga cgctgttcga aaac	2880
gcctcagtct acagcagccg caagatgctg tttgtgctgg cccacacgga ccagg	2940
ggcctcttgc gtgccagctt cctgctggcc cagcagcgtc tgctggagga c	3000
gttgtggcgc tggttaatcct gagccctgac gcccgcgtt cccgttacgt g	3060
cagcgcctct gcccgcagag tgcctcttc tggccccacc agcctagtg ccagcgc	3120
ttctgggccc agctaggcat ggccctgacc agggacaacc gccacttcta taacc	3180
ttctgcggg gcccgcacat ggctgagtag cacagagtga cagcctggca t	3240
ccagccctga ccttgcctct ctgcctatga tgcccagtct gcctcactct gtgac	3300
tgctctgcct ccgcacccct caccctggc atacagcagg cactcaataa atgc	3360
caggccaaac agccaaaaaaaaaaaaaaa a	3391

<210> 16
 <211> 2460
 <212> DNA
 <213> Equus caballus

<400> 16	
atgggcctt gccatggcgc cctgcagccc ctgtctctcc tggcgcaggc ggccat	60
gcccgtggcgc tggcccaagg caccctgcct ccattcctgc cctgtgagct ccag	120
ggcctggta actgcaactg gctgttcctg aagtccgtgc cccacttctc agcag	180
ccccggaca atgtcaccag ctttccttg ctctccaaacc gcatccacca c	240
tccgactttg cccaaactgtc caacctgcag aaactcaacc tcaaattggaa ctg	300
ccgggcctca gccccatgca cttccctgc cacatgacca tcgagccaa cactt	360
gtgtaccca ccctggagga gctgaacctg agctacaacg gcatcacgac t	420
ctgcccagct ccctcgtgtc cctgatcctg agccgcacca acatcctgca g	480
accagcctca cgggcctgca tgccctgcgc ttccatatac tggatggcaa ctg	540
aagaacccct gggggggggc cttggaggtg gccccaggcg ccctccctgg c	600
ctcaccacc tgcactcaa gtacaacaac ctcacaacgg tgccccgcag c	660
agcctggagt acctgctgtt gtcctacaac cacattgtca ccctggcacc tg	720
ccaaatctga ctgcctgca tgcgtcgat gtgggtggaa actgcgcgcg ctgt	780
gcacgcaacc cctgcgtgca gtggccacat aaattcccc agctgcactc cg	840

agccaccta a gccgcctaga aggccctcg t t g aaggata gttctctcta ccagctgaac	900
cccagatgg tccgtggcct gggcaac ctc acagtgc tgc acctgagtga gaacttcctc	960
tacgactgca tcaccaaaac caaggcat tc caggcctgg cccagctgcg aagactcaac	1020
ttgtccctca attaccataa gaagggtgtcc ttcgcccacc tgacgctggc accctcctc	1080
gggagcctgc tctccctgca ggaactggac atgcatggca tcttcttccg ctcactcagc	1140
cagaagacgc tccagccact ggcccgccctg cccatgctcc agcgtctgta tctgcagatg	1200
aacttcatca accaggccca gctcggcata ttcaggact tccctggct ggcgtacata	1260
gacctgtcag acaaccgc a c a c a c g c a t c a g t g g a g g t g t g g a g c c a c c a g g t g	1320
gatgggtgg a g a a g g t c t g g t g a g a a g g t c t g g t g a g g a c c t a c t c a g a c c	1380
cccagctctg aggacttcat gccaagctgc aagaacctca gcttcaccc ggacctgtca	1440
c g g a a c a a c c t g g t a a c a a c a c a g a g a t g t t t g c c c a g a c t g c a c t g	1500
ctgcgcctga gccacaacag catctcgac g c g g t c a a t g g t c a c a g t t c g t c a c t g	1560
accagctgc aggtgctgga cctgtcccat a a c a a c t g g a c t g t a c c a t g g a g g t g	1620
t t t a c g g a g c t g g c g a c t g g a g g c c c t g a c c t c a g g t a c a a c a g g c a	1680
atgcggggtg t g g g c c a c a a c t c a g g t t t g t g g c c a c c t g g t g c a c c t	1740
agcctggcac acaatggcat ccacagccgt gtgtcccagc agctctgc a c a c a c a g g c a c a g g c a	1800
t g g g c c t g g a c t t c a g c g g c a a t t c c c t g a g c a g a t g t g g c t g a g g g a g a c a c t	1860
c t c c g c t t c t c a a g g c c t g a g a a g c c t a a t c c g g c t a g a c t g t c t g	1920
cataccctcc t g c c a t g c a c c t g g c a a c c t c c c a a g a g c t g a c g t c t c	1980
c g t a a c a a t t a c t g g c c t t c t c a a t t g g a c g c t g a a c c t g g a a a c c t g g a a	2040
a c c c t g g a c c t g g a a c a c a g c a t c a a c c t g g a c c t g g a c c t g g a c c t	2100
a c c c a g c t c c a g g g t g g a a a c a c a g c a t g g a c c t g g a c c t g g a c c t	2160
t t t g c t c t g g a a a c a c a g g g t g g a c g a g g c t c a c t g g a c c t g g a c c t	2220
g a g c c t c c t g g a a a c a c a g g g t g g a c g a g g c t c a c t g g a c c t g g a c c t	2280
c c t c t g c a c t g g a a a c a c a g g g t g g a c g a g g c t c a c t g g a c c t g g a c c t	2340
g t g c c t g g t c t g g a a a c a c a g g g t g g a c g a g t g t g g a c g a g g c t c a c t	2400
a t c t c g c a c a a g a c c t g g a a a c a c a g g g t g g a c g a g t c c c t g g a c c t	2460

<210> 17
 <211> 1029
 <212> PRT
 <213> Ovis aries

<400> 17

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala
1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu
20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe
35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser
65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Tyr Ile Thr Lys Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg
325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg
370 375 380

Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn
385 390 395 400

Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu
405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp
435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp
450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn
465 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu
485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr
515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln
530 535 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
660 665 670

Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu
690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val
705 710 715 720

Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile
740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
755 760 765

Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg
770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
805 810 815

Phe Gly Phe Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met
820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys
835 840 845

Leu Ala His Leu Pro Arg Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu
850 855 860

Leu Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val Ala
865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly
885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly
900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys
915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg

930	935	940
Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp		
945	950	955
Val Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr		
965	970	975
Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro		
980	985	990
His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Met Ala		
995	1000	1005
Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg		
1010	1015	1020
Gly Pro Thr Thr Ala Glu		
1025		
<210> 18		
<211> 818		
<212> PRT		
<213> Ovis aries		
<400> 18		
Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala		
1	5	10
		15
Ala Ala Leu Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu		
20	25	30
Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe		
35	40	45
Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val		
50	55	60
Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser		
65	70	75
		80
Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn		
85	90	95
Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr		

100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Tyr Ile Thr Lys Thr Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg
325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
 340 345 350

Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu
 355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg
 370 375 380

Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn
 385 390 395 400

Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu
 405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
 420 425 430

Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp
 435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp
 450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn
 465 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu
 485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
 500 505 510

Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr
 515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln
 530 535 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
 545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
 565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
660 665 670

Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu
690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val
705 710 715 720

Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile
740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
755 760 765

Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg
770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
805 810 815

Phe Gly

<210>	19					
<211>	3199					
<212>	DNA					
<213>	Ovis aries					
<400>	19					
gtcggcacgg	gaagtgagcg	ccaagcatcc	ttccctgcag	ctgccgcaca	acttgcccgc	60
cagaccctct	ggagaagccg	cattccctgc	catggggccc	tactgtgccc	cgcacccccc	120
ttctctcctg	gtgcaggcgg	cggcgctggc	agcagccctg	gcccaaggca	ccctgcctgc	180
ttccctgccc	tgtgagctcc	agccccgggg	taaggtgaac	tgcaactggc	tgttccctgaa	240
gtctgtgccc	cgcttttcgg	ccggagccccc	ccgggccaat	gtcaccagcc	tctccttaat	300
ctccaaccgc	atccaccact	tgcacgactc	tgacttcgtc	cacctgtcca	acctgcgggt	360
cctcaacctc	aagtggaaact	gcccgcggc	cggcctcagc	cccatgcact	tcccctgcgg	420
catgaccatc	gagcccaaca	ccttcctggc	tgtgcccacc	ctggaggagc	tgaacctgag	480
ctacaatggc	atcacgaccg	tgcctgcct	gcccagttct	ctcgtatccc	tgtcgctgag	540
ccgcaccagc	atcctggtgc	taggccccac	ccacttcacc	ggcctgcacg	ccctgcgcctt	600
tctgtacatg	gacggcaact	gctactataa	gaacccctgc	cagcaggccg	tggaggtggc	660
cccgaggcgcc	ctccttggcc	tgggcaacct	cacgcacctg	tcgctcaagt	acaacaacct	720
cacggagggt	ccccgcggcc	tgcctccctag	cctggacacc	ctgctgctgt	cctacaacca	780
catcatcacc	ctggcaccccg	aggacctggc	caatctgact	gccctgcgtg	tgcttgatgt	840
gggcgggaac	tgccggccgt	gcgaccacgc	ccgcaacccc	tgcagggagt	gcccaaagaa	900
cttcccaag	ctgcacccctg	acaccttcag	ccacctgagc	cgccctcgaaag	gcctggtggt	960
gaaggacagt	tctctctaca	aactagagaa	agactggttc	cggggcttgg	gcaggctcca	1020
agtgctcgac	ctgagtgaga	acttcctcta	tgactacatc	accaagacca	ccatcttcag	1080
gaacctgacc	cagctgcgca	gactcaacct	gtccttcaat	taccacaaga	aggtgtcctt	1140
cgcccacctg	caactggcac	cctccttgg	gggcctggtg	tccctggaga	agctggacat	1200
gcacggcata	ttcttccgct	ccctcaccaa	caccacgctc	cgcccgctga	cccagctgcc	1260
caagctccag	agtctgagtc	tgcagctgaa	cttcatcaac	caggccgagc	tcagcatctt	1320
tggggccttc	ccgagcctgc	tcttcgtgga	cctgtcggac	aaccgcata	gcggagctgc	1380
gaggccggtg	gcggccctcg	gggaggtgga	cagcgggggtg	gaagtctggc	ggtggcccg	1440

gggcctcgct ccaggcccgc tggccgcgt cagcgcaaag gacttcatgc caagctgcaa	1500
cctcaacttc accttggacc tgtcacggaa caacctggtg acgatccagc aggagatgtt	1560
tacccgcctc tccccctcc agtgcctgctg cctgagccac aacagcatct cgcaggcggt	1620
taatggctcg cagttcgtgc cgctgaccccg cctgcgagtg ctcgacctgt cctacaacaa	1680
gctggacctg taccatgggc gctcggtcac ggagctgccc cagctggagg cactggacct	1740
cagctacaac agccagccct tcagcatgca gggcgtggc cacaacctca gcttcgtggc	1800
ccagctgccc tccctgcgct acctcagcct tgcgcacaac ggcattccaca gccgcgtgtc	1860
acagaagctc agcagcgcct cgctgcgcgc cctggacttc agcggcaact ccctgagcca	1920
gatgtgggcc gagggagacc tctatctctg cttcttcaaa ggcttgagga acctggtcca	1980
gctggacctg tccaagaacc acctgcacac cctcctgcct cgtcacctgg ataacctgcc	2040
caagagcctg cggcagctgc gtctccggga caataacctg gccttcttca actggagcag	2100
cctgactgtt ctgccccagc tggaagccct ggatctggcg ggaaaccagc tgaaggccct	2160
gagcaacggc agcctgcccac ctggcaccccg gctccagaag ctggacgtga gcagcaacag	2220
catcggtttt gtgacccttg gcttctttgt cttgccaac cggctgaaag agcttaacct	2280
cagcgccaaac gcccgtgaaga cagtggatcc cttctggttc ggctcgtaa cagagaccct	2340
gaatatccta gacgtgagcg ccaaccgct ccactgtgcc tgccccggg cctttgtgga	2400
cttcotgctg gagatgcagg cggccgtgcc tggctgtcc aggccgtca cgtgtggcag	2460
tccgggccag ctccagggcc gcagcatatt cgcacaggac ctgcgcctct gcctggatga	2520
gaccctctcc ttggactgct ttggcttctc gctgctaattt gtggcgctgg gcctggcggt	2580
gccccatgctg caccacctct gtggctggga cctgtggtaac tgcttccacc tgtgtctggc	2640
ccatttgcccc cgacggcgcc ggcagcgggg cgaggacacc ctgctctacg atgccttcgt	2700
ggtcttcgac aaggcgcaga gtgcagtggc cgactgggtg tacaacgagc tccgcgtgca	2760
gctggaggag cgccgcgggg gccggcgct ccgcctctgc ctggaggagc gagactggct	2820
ccctggcaag acgctttcg agaacctgtg ggcctcggtc tacagcagcc gtaagaccat	2880
gttcgtgctg gaccacacgg accgggtcag tggctcttg cgcgcagct tctgtgtggc	2940
ccagcagcgc ctgttggagg accgcaagga tgcgtggtg ctgggtatcc tgcccccgc	3000
cgcctaccgg tccccgtacg tgccggctgctg ccagcgccctc tgccgcccaga gcgttcttct	3060
ctggcccccac cagcccagtg gccaggtag cttctggcc aacctggca tggccctgac	3120
cagggacaac cgccacttct ataacccggaa cttctgcccgg ggccccacga cagccgaata	3180

gcacagagtg	actgcccag	3199				
<210>	20					
<211>	2454					
<212>	DNA					
<213>	Ovis aries					
<400>	20					
atggggccct	actgtgcccc	gcacccccc ttcttcctgg	tgcaggcggc	ggcgctggca	60	
gcagccctgg	cccagggcac	cctgcctgcc	ttccctgcct	gtgagctcca	gccccgggt	120
aaggtaact	gcaactggct	gttctgaag	tctgtccgc	gtttttccgc	cggagcccc	180
cgggccaatg	tcaccagcct	tccttaatc	tccaaccgca	tccaccactt	gcacgactct	240
gacttcgtcc	acctgtccaa	cctgcgggtc	ctcaacacta	agtggaaactg	cccgccggcc	300
ggcctcagcc	ccatgcactt	ccccctggc	atgaccatcg	agcccaacac	cttcctggct	360
gtgcccaccc	tggaggagct	gaacctgagc	tacaatggca	tcacgaccgt	gcctgcctg	420
cccagttctc	tctatccct	gtcgctgagc	cgcaccagca	tcctgggtct	aggccccacc	480
cacttcaccc	gctgcacgc	cctgcgttt	ctgtacatgg	acggcaactg	ctactataag	540
aacccctgcc	agcaggccgt	ggaggtggcc	ccaggcgccc	tccttggct	ggcaacctc	600
acgcacctgt	cgctcaagta	caacaacctc	acggaggtgc	cccgccgcct	gccccccagc	660
ctggacaccc	tgtgtgtc	ctacaaccac	atcatcaccc	tggcacccga	ggacctggcc	720
aatctgactg	ccctgcgtgt	gtttgatgtg	ggcgaaact	gcccggctg	cgaccacgccc	780
cgcaacccct	gcagggagtg	ccaaagaac	ttccccaaagc	tgcaccctga	cacccctcagc	840
cacctgagcc	gcctcgaaagg	cctgggttt	aaggacagtt	ctctctacaa	actagagaaa	900
gactggttcc	gcggcctggg	caggctccaa	gtgctcgacc	tgagtgagaa	cttcctctat	960
gactacatca	ccaagaccac	catttcagg	aacctgaccc	agctgcgcag	actcaacctg	1020
tccttcaatt	accacaagaa	ggtgtccttc	gcccacctgc	aactggcacc	ctcctttggg	1080
ggcctgggt	ccctggagaa	gctggacatg	cacggcatct	tcttccgctc	cctcaccaac	1140
accacgctcc	ggccgctgac	ccagctgccc	aagctccaga	gtctgagtt	gcagctgaac	1200
ttcatcaacc	aggccgagct	cagcatctt	ggggccttcc	cgagcctgct	cttcgtggac	1260
ctgtcgacca	accgcacatcag	cggagctgctg	aggccgggtgg	ccggccctcg	ggaggtggac	1320
agcgggggtgg	aagtctggcg	gtggccctgg	ggcctcgctc	caggcccgct	ggccgcccgtc	1380
agcgcaaagg	acttcatgcc	aagctgcaac	ctcaacttca	cttggaccc	gtcacggAAC	1440
aacctggtgaa	cgatccagca	ggagatgttt	accgcctct	ccgcctccaa	gtgcctgcgc	1500

ctgagccaca acagcatctc	gcaggcggtt aatggctcgc	agttcgtgcc	gctgaccgc	1560		
ctgcgagtgc tcgacctgtc	ctacaacaag ctggacctgt	accatggcg	ctcggtcacg	1620		
gagctgccgc agctggaggc	actggacctc agctacaaca	gccagccctt	cagcatgcag	1680		
ggcgtggcc acaacctcg	cttcgtggcc	cagctgccgt	ccctgcgcta	cctcagccctt	1740	
gcccacaacg gcatccacag	ccgcgtgtca	cagaagctca	gcagccctc	gctgcgcgccc	1800	
ctggacttca	gcggcaactc	cctgagccag	atgtggcccg	agggagacct	ctatctctgc	1860
ttcttcaaag	gcttgaggaa	cctggtccag	ctggacctgt	ccaagaacca	cctgcacacc	1920
ctcctgcctc	gtcacctgga	taacctgccc	aagagcctgc	ggcagctgcg	tctccggac	1980
aataacctgg	ccttcttcaa	ctggagcagc	ctgactgttc	tgccccagct	ggaagccctg	2040
gatctggcgg	gaaaccagct	gaaggccctg	agcaacggca	gcctgccacc	tggcacccgg	2100
ctccagaagc	tggacgtgag	cagcaacagc	atccggcttg	tgacccttgg	cttctttgtc	2160
cttgccaacc	ggctgaaaga	gcttaacctc	agcgccaacg	ccctgaagac	agtggatccc	2220
ttctggttcg	gtcgcttaac	agagaccctg	aatatcctag	acgtgagcgc	caacccgctc	2280
cactgtgcct	gcggggcggc	ctttgtggac	ttcctgctgg	agatgcaggg	ggccgtgcct	2340
gggctgtcca	ggcgcgtcac	gtgtggcagt	ccggggcagc	tccagggccg	cagcatctc	2400
gcacaggacc	tgcgcctctg	cctggatgag	accctctct	tggactgctt	tgcc	2454

<210> 21

<211> 1032

<212> PRT

<213> Canis familiaris

<400> 21

Met	Gly	Pro	Cys	Arg	Gly	Ala	Leu	His	Pro	Leu	Ser	Leu	Leu	Val	Gln
1						5						10			15

Ala	Ala	Ala	Leu	Ala	Leu	Ala	Leu	Ala	Gln	Gly	Thr	Leu	Pro	Ala	Phe
20							25						30		

Leu	Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Leu	Val	Asn	Cys	Asn	Trp	Leu
35						40						45			

Phe	Leu	Lys	Ser	Val	Pro	Arg	Phe	Ser	Ala	Ala	Ala	Pro	Arg	Gly	Asn
50					55						60				

Val	Thr	Ser	Leu	Ser	Leu	Tyr	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp
65						70				75			80		

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu
115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe
260 265 270

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe
290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu
370 375 380

Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu
385 390 395 400

Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu
420 425 430

Pro Ala Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val
435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly
450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp
465 470 475 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln
500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu
515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr
530 535 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro

545	550	555	560
Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu			
565	570	575	
Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg			
580	585	590	
Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser			
595	600	605	
Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg			
610	615	620	
Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn			
625	630	635	640
Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser			
645	650	655	
Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp			
660	665	670	
Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly			
675	680	685	
Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln			
690	695	700	
Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro			
705	710	715	720
Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala			
725	730	735	
Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly			
740	745	750	
Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys			
755	760	765	
Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro			
770	775	780	

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly
 785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu
 805 810 815

Ser Trp Val Cys Phe Ser Leu Ser Leu Leu Ala Val Ala Leu Ser Leu
 820 825 830

Ala Val Pro Met Leu His Gln Leu Cys Gly Trp Asp Leu Trp Tyr Cys
 835 840 845

Phe His Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Arg Gly
 850 855 860

Val Asp Ala Leu Ala Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
 865 870 875 880

Ser Ser Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu
 885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
 900 905 910

Trp Val Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
 915 920 925

Ser Ser Arg Lys Thr Leu Phe Val Leu Ala Arg Thr Asp Arg Val Ser
 930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
 945 950 955 960

Asp Arg Lys Asp Val Val Leu Val Ile Leu Cys Pro Asp Ala His
 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
 980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
 995 1000 1005

Leu Gly Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
 1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Thr Ala
1025 1030

<210> 22
<211> 822
<212> PRT
<213> Canis familiaris

<400> 22

Met Gly Pro Cys Arg Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Ala Leu Ala Leu Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu
115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe
260 265 270

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe
290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu
370 375 380

Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu
385 390 395 400

Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu
420 425 430

Pro Ala Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val
435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly
450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp
465 470 475 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln
500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu
515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr
530 535 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro
545 550 555 560

Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu
565 570 575

Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg
580 585 590

Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser
595 600 605

Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg
610 615 620

Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn
625 630 635 640

Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser
645 650 655

Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp

660

665

670

Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly
 675 680 685

Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln
 690 695 700

Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro
 705 710 715 720

Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala
 725 730 735

Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly
 740 745 750

Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys
 755 760 765

Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro
 770 775 780

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly
 785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu
 805 810 815

Ser Trp Val Cys Phe Ser
 820

<210> 23
 <211> 3334
 <212> DNA
 <213> Canis familiaris

<400> 23
 aggaaggggc tgtgagctcc aagcatcatt tcctgcagct gctgcccagc ctgccagcca 60
 gaccctctgg agaagccccc gctccctgtc atggccccc gccgtggcgc cctgcacccc 120
 ctgtctctcc tggtgccagcc tgccgcgcta gcctggccc tggcccaggg caccctgcct 180
 gccttcctgc cctgtgagct ccagcccat gcctggta actgcaactg gctgttcctc 240
 aagtccgtgc cccgttctc ggcagctgca ccccgcggtc acgtcaccag cctttccttg 300

tactccaacc	gcatccacca	cctccatgac	tatgactttg	tccacttcgt	ccacactgcgg	360
cgtctcaatc	tcaagtggaa	ctgccccccc	gcccgcctca	gccccatgca	ctttccctgt	420
cacatgacca	ttgagcccaa	cacccctctg	gctgtgccc	ccctagagga	cctgaatctg	480
agctataaca	gcatcacgac	tgtgcccccc	ctgcccagtt	cgcttgtgtc	cctgtccctg	540
agccgcacca	acatcctgg	gctggaccct	gcccacccctgg	caggccctta	tgcctgcgc	600
ttcctgttcc	tggatggcaa	ctgctactac	aagaacccct	gccagcaggc	cctgcagggt	660
gccccaggtg	ccctcctggg	cctgggcaac	ctcacacacc	tgtcaactcaa	gtacaacaac	720
ctcaccgtgg	tggccgggggg	cctgcccccc	agcctggagt	acctgctt	gtcctacaac	780
cacatcatca	ccctggcacc	tgaggacctg	gccaatctga	ctgcctgcg	tgtcctcgat	840
gtgggtggga	actgtcgccg	ctgtgaccat	gcccgttaacc	cctgcaggga	gtgccccaaag	900
ggcttccccc	agctgcaccc	caacacccctc	ggccacccctga	gccacccctga	aggccctgg	960
ttgagggaca	gctctctcta	cagcctggac	cccaggtgg	tccatggcct	gggcaaccc	1020
atggtgctgg	acctgagtga	gaacttcctg	tatgactgca	tcacaaaaac	caaagccctc	1080
tacggcctgg	cccggtcg	cagactcaac	ctgtccttca	attatcataa	gaaggtgtcc	1140
tttgcacc	tgcatactggc	atcctcccttc	gggagcctac	tgtccctgca	ggagctggac	1200
atacatggca	tcttcttccg	ctcgctcagc	aagaccacgc	tccagtcgt	ggccaccc	1260
cccatgctcc	agcgtctgca	tctgcagttg	aactttatca	gccaggccca	gctcagcatc	1320
ttcggcgct	tccctggact	gcgggtacgt	gacttgcag	acaacccat	cagtggagct	1380
gcagagcccg	cggctgccac	aggggaggt	gaggcagact	gtggggagag	agtctggcca	1440
cagtcccccgg	accttgcct	gggcccactg	ggcacccccc	gctcagaggc	cttcatgccc	1500
agctgcagga	ccctcaactt	cacccctggac	ctgtctcgga	acaacctagt	gactgttcag	1560
ccggagatgt	ttgtccggct	ggcgccctc	cagtgcctgg	gcctgagcca	caacagcatc	1620
tcgcaggcgg	tcaatggctc	gcagttcg	cctctgagca	acctgcgggt	gctggacctg	1680
tcccataaca	agctggaccc	gtaccacggg	cgctcggtca	cgaggactgcc	gcggctggag	1740
gccttgacc	tcaatggctc	cagccagccc	ttcagcatgc	ggggcggtgg	ccacaatctc	1800
agctttgtgg	cacagctgcc	agccctgcgc	tacccatgcc	tggcgaccaa	tggcatccac	1860
agccgcgtgt	cccagcagct	ccgcagcgcc	tgcgtccggg	ccctggactt	cagtggcaat	1920
accctgagcc	agatgtgggc	cgagggagac	ctctatctcc	gcttcttcca	aggccctgaga	1980
agcctgggttc	agctggaccc	gtcccagaat	cgccctgcata	ccctccgtcc	acgcaaccc	2040
gacaaccc	ccaaagagcc	gcggctccctg	cggtccgt	acaattaccc	ggcttcttc	2100

aactggagca	gcctggccct	cctaccgaag	ctggaagccc	tggacctggc	gggaaaccag	2160
ctgaaggccc	ttagcaatgg	cagcttgc	cc aacggcaccc	agctccagag	gctggac	2220
agcggcaaca	gcatcggtt	cgtggtcccc	agctttttg	ccctggc	gaggcttcg	2280
gagctcaacc	tcagcgccaa	cgcctcaag	acggtg	gagc	cctctgg	2340
gcgggtgccc	tgaaagt	cct	agacgtgacc	gccaaccc	tgcattg	2400
accttcgtgg	acttcttg	ctgg	ggaggtgc	gctgcgg	ccggc	2460
aagtgcggca	gcccggcca	gctccagg	gc	cagcat	tcgcac	2520
tgcctggacg	aagcgctc	ctgg	gtctgt	ttcagc	cgtgc	2580
agcctggctg	tgccatg	ct	gcaccag	tgtgg	ac	2640
ctgtgcctgg	cctgg	ctg	ccggcgggg	cg	ggatgc	2700
gacgccttcg	tgg	ttcga	caaggc	agctcg	gg	2760
ctgcgggtac	agctagag	g	gcccgt	cgccgg	tacgc	2820
cgtgactggg	tacccgg	aa	aaccctt	gagaac	ctgc	2880
cgcaagacgc	tgtt	gt	ccaaac	gc	ctc	2940
ttcctgctgg	cccaac	agcg	cctg	ctggag	gacc	3000
ctgtgccccg	acgccc	accg	ctccc	gtgc	ggc	3060
agtgtcc	tctgg	cc	ccagccc	actgc	gtgt	3120
acggccctga	ccagg	gacaa	ccgccc	acttct	gg	3180
acagcctgat	aggc	agacag	ccc	gacac	tgc	3240
ggatgcccga	cctg	ctgg	ct	acacc	cc	3300
taaagcgacc	gctcaataaa	tgct	ctgg	cc	agcc	3334

<210> 24
 <211> 2466
 <212> DNA
 <213> *Canis familiaris*

<400> 24	atggccct	gcgcgtggc	cc	tgcac	ccc	ctgtct	tgg	tgcagg	tgcc	cgct	60
	gc	c	c	tgc	c	c	tc	gc	cc	at	120
	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	180
	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	240
	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	300

gccagcctca	gccccatgca	cttccctgt	cacatgacca	ttgagccaa	caccctcctg	360
gctgtgcccc	ccctagagga	cctgaatctg	agctataaca	gcatcacgac	tgtgcccggc	420
ctgcccagtt	cgcttgcgtc	cctgtccctg	agccgcacca	acatcctggt	gtggaccct	480
gccaccctgg	caggcctta	tgccctgcgc	ttccctgtcc	tggatggcaa	ctgctactac	540
aagaacccct	gccagcaggc	cctgcagggt	gccccagggt	ccctcctggg	cctgggcaac	600
ctcacacacc	tgtcactcaa	gtacaacaac	ctcaccgtgg	tgccgcgggg	cctgcccccc	660
agcctggagt	acctgtcttt	gtcctacaac	cacatcatca	ccctggcacc	tgaggacctg	720
gccaatctga	ctgcccctgcg	tgtcctcgat	gtgggtggga	actgtcgccg	ctgtgaccat	780
gcccgttaacc	cctgcaggga	gtgccccaaag	ggcttccccc	agctgcaccc	caacacccctc	840
ggccacctga	gccacctcga	aggcctgggt	ttgagggaca	gctctctcta	cagcctggac	900
cccaggtgg	tccatggcct	gggcaacctc	atggtgctgg	acctgagtga	gaacttcctg	960
tatgactgca	tcacccaaaac	caaagccttc	tacggcctgg	cccggctgcg	cagactcaac	1020
ctgtccttca	attatcataa	gaaggtgtcc	tttgcacc	tgcatctggc	atcctccttc	1080
gggagcctac	tgtccctgca	ggagctggac	atacatggca	tcttcttccg	ctcgctcagc	1140
aagaccacgc	tccagtcgct	ggcccacctg	cccatgctcc	agcgtctgca	tctgcagtt	1200
aactttatca	gccaggcccc	gctcagcatac	ttcggcgct	tccctggact	gccccgtacgt	1260
gacttgcag	acaaccgcata	cagtggagct	gcagagcccg	cggtgcac	aggggaggta	1320
gaggcagact	gtggggagag	agtctggcca	cagtcccggt	accttgctct	gggcccactg	1380
ggcacccccc	gtcagagggc	tttcatggcc	agctgcagga	ccctcaactt	caccttggac	1440
ctgtctcgga	acaacctagt	gactgttcag	ccggagatgt	ttgtccggct	ggcgccgcctc	1500
cagtgcctgg	gcctgagcca	caacagcatac	tcgcaggcgg	tcaatggctc	gcagttcg	1560
cctctgagca	acctgcgggt	gctggacctg	tcccataaca	agctggacct	gtaccacggg	1620
cgctcggtca	cggagctgccc	gccccgtggag	gccttggacc	tcaatggctc	gcagttcg	1680
ttcagcatgc	ggggcgtggg	ccacaatctc	agctttgtgg	cacagctgcc	agccctgcgc	1740
tacctcagcc	tggcgcacaa	tggcatccac	agccgcgtgt	cccagcagct	ccgcagcgcc	1800
tcgctccggg	ccctggactt	cagtggcaat	accctgagcc	agatgtggc	cgagggagac	1860
ctctatctcc	gtttcttcca	aggcctgaga	agctgggttc	agctggacct	gtcccagaat	1920
cgcctgcata	ccctcctgc	acgcaacctg	gacaacctcc	ccaagagcct	gccccgtacgt	1980
cggctccgtg	acaattacct	ggctttcttc	aactggagca	gcctggccct	cctacccaaag	2040

ctggaagccc tggacctggc gggaaaccag ctgaaggccc tgagcaatgg cagcttgc 2100
 aacggcaccc agctccagag gctggacctc agcggcaaca gcatcggctt cgtggtccc 2160
 agctttttg ccctggccgt gaggcttcga gagctcaacc tcagcgc 2220
 acggtgagc ctcctgggtt tggttcctg ggggtgccc taaaagtctt agacgtgacc 2280
 gccaacccct tgcattgcgc ttgcggcgca accttcgtgg acttcttgc 2340
 gctgcggtgc cccgcctgccc tagccgtgtc aagtgcggca gcccggcc 2400
 cgcagcatct tcgcacagga cctgcgc 2460
 ttcagc 2466

<210> 25

<211> 1031

<212> PRT

<213> Felis catus

<400> 25

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15

Ala Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe
 20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu
 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn
 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp
 85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
 100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
 130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe
260 265 270

Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe
290 295 300

His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu
370 375 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met
 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu
420 425 430

Leu Ala Ala Ala Thr Gly Glu Val Asp Gly Gly Glu Arg Val Arg Leu
435 440 445

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu
450 455 460

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser
 465 470 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser
485 490 495

Arg Leu Gln Cys Leu Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
 545 550 555 560

Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe

610	615	620
Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	635
His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg		
645	650	655
Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser		
660	665	670
Leu Val Leu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln		
675	680	685
Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln		
690	695	700
Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe		
705	710	715
Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu		
740	745	750
Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		
770	775	780
Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser		
785	790	795
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp		
805	810	815
Asp Cys Phe Gly Leu Ser Leu Leu Thr Val Ala Leu Gly Leu Ala Val		
820	825	830
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His		
835	840	845

Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Arg Gly Ala Asp
 850 855 860

Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala
 865 870 875 880

Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg
 885 890 895

Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu
 900 905 910

Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser
 915 920 925

Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu
 930 935 940

Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg
 945 950 955 960

Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His Arg Ser
 965 970 975

Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu
 980 985 990

Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly
 995 1000 1005

Thr Ala Leu Thr Arg Asp Asn Gln His Phe Tyr Asn Gln Asn Phe
 1010 1015 1020

Cys Arg Gly Pro Thr Thr Ala Glu
 1025 1030

<210> 26
 <211> 820
 <212> PRT
 <213> Felis catus

<400> 26

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15

Ala Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe
260 265 270

Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe
290 295 300

His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu
370 375 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu
420 425 430

Leu Ala Ala Ala Thr Gly Glu Val Asp Gly Gly Glu Arg Val Arg Leu
435 440 445

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu
450 455 460

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser
485 490 495

Arg Leu Gln Cys Leu Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg
645 650 655

Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Val Leu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala

725

730

735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu
 740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
 770 775 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
805 810 815

Asp Cys Phe Gly
820

<210> 27
<211> 3235
<212> DNA
<213> *Felis catus*

<400> 27
agggtctgcg agctccaggc attcttctct gccatcgctg cccagtctgc catccagacc 60
ctctggagaa gcccccaactc cctgtcatgg gcccctgcca tggggccctg caccggctgt 120
ctctccctggt gcagggtcgcc gcgcgtggccg tggccctggc ccagggcacc ctgcctgcct 180
ttctgtccctg tgagctccag cgcacggcc tggtaattt cgactggctg ttctcaagt 240
ccgtgccccca cttctcggcg gcagcgcccc gtggtaacgt caccagcctt tccctgtact 300
ccaaccgcac ccaccaccc cactgactccg actttgtcca cctgtccagc ctggggcgtc 360
tcaaccccaa atggaaactgc ccacccgcca gcctcagccc catgcacttc ccctgtcaca 420
tgaccattga gccccacacc ttccctggccg tgccccccct ggaggagctg aacctgagct 480
acaacagcat cacgacagta cccggccctgc ccagttccct cgtgtccctg tccttgagcc 540
gtaccaacat cctggtgctg gaccctgcca acctcgcagg gctgcactcc ctgcgttttc 600
tgttccctgga tggcaactgc tactacaaga accccctgccc gcaggccctg caggtggccc 660
cgggcgccct cttggccctg ggcaacctta cgcacccgttc actcaagtac aacaacccatca 720
ctgcgggtgcc ccggggccctg ccccccagcc tggagtaccc tctattgtcc tacaaccaca 780

tcatcacccct	ggcacacctgag	gacctggcca	acctgaccgc	cctgcgtgtg	ctcgatgtgg	840
gtgggaactg	ccgtcgctgt	gaccacgccc	gcaacccctg	tatggagtgc	cccaagggct	900
tcccgcacct	gcacccctgac	accttcagcc	acctgaacca	cctcgaaggc	ctggtggtga	960
aggacagctc	tctctacaac	ctgaacccc	gatggttcca	tgccctgggc	aacctcatgg	1020
tgctggacct	gagtgagaac	ttcctatatg	actgcacac	caaaaccaca	gccttccagg	1080
gcctggccca	gctgcgcaga	ctcaacttgt	cttcaatta	ccacaagaag	gtgtcctttg	1140
cccacctgca	tctggcgccc	tccttcggga	gcctgctctc	cctgcagcag	ctggacatgc	1200
atggcatctt	cttccgctcg	ctcagcgaga	ccacgctccg	gtcgctggtc	cacctgccc	1260
tgctccagag	tctgcacctg	cagatgaact	tcatcaatca	ggcccagctc	agcatcttcg	1320
gggccttccc	tggcctgcga	tacgtggacc	tgtcagacaa	ccgcataagt	ggagccatgg	1380
agctggcgcc	tgccacgggg	gaggtggatg	gtggggagag	agtccggctg	ccatctgggg	1440
acctagctct	gggcccaccc	ggcaccccta	gctccgaggg	cttcatgcca	ggctgcaaga	1500
ccctcaactt	caccttggac	ctgtcacgga	acaacctagt	gacaatccag	ccagagatgt	1560
ttgcccggct	ctcgccctc	cagtgcctgc	tcctgagccg	caacagcatc	tcgcaggcag	1620
tcaacggctc	acaattttatg	ccgctgacca	gcctgcaggt	gtggacactg	tccataaca	1680
agctggacct	gtaccatggg	cgtctttca	cggagctgccc	gcggctggag	gccctggacc	1740
tcagctacaa	cagccagccc	ttcagcatgc	agggcgtggg	tcacaacctc	agctttgtgg	1800
cacagctgcc	ggccctgcgc	tatctcagcc	tggcgcacaa	cgacatccac	agccgtgtgt	1860
cccagcagct	ctgcagcgcc	tcgctgcggg	ccttggactt	cagcggcaat	gccttgagcc	1920
ggatgtggc	cgagggagac	ctgtatctcc	acttcttccg	aggcctgagg	agcctggtcc	1980
gtttggatct	gtcccagaat	cgcctgcata	ccctcttgc	acgcaccctg	gacaacctcc	2040
ccaagagcct	gcggctgctg	cgtctccgtg	acaatttatct	ggctttcttc	aactggagca	2100
gcctggctct	cctccccagg	ctggaagccc	tggacctggc	ggaaaccag	ctgaaggccc	2160
tgagcaacgg	cagcttgcct	aatggaaccc	agctccagag	gctggacctc	agcagcaaca	2220
gtatcagctt	cgtggcctcc	agcttttttg	ctctggccac	caggctgcga	gagctcaacc	2280
tcagtgccaa	cgcctcaag	acggtgagc	cctcctggtt	cggttctcta	gcgggcaccc	2340
tgaaagtccct	agatgtgact	ggcaaccccc	tgcactgcgc	ctgtggggcg	gcctcgtgg	2400
acttcttgct	ggaggtgcag	gctgcagtgc	ccggcctgcc	aggccacgtc	aagtgtggca	2460
gtccaggtca	gtccaggggc	cgcagcatct	ttgcgcagga	tctgcgcctc	tgcctggatg	2520
aggccctctc	ctgggactgt	tttggcctct	cgctgctgac	cgtggccctg	ggcctggcccg	2580

tgcccatgct gcaccaccc tgggtggg acctctggta ctgttccac ctgtgcctgg	2640
cctggctgcc cccgggggggg cggcgccggg gcgcggatgc cctgcctac gatgccttg	2700
tggtcttcga caaggcacag agcgccgtgg ccgactgggt gtacaacgag ctgcgggtac	2760
ggctagagga gcccgtgga cggcggcgc tccgcctgtg cctggaggaa cgtgactggc	2820
tacccggtaa aacgctcttt gagaacctgt gggcctcagt ttacagcagc cgcaagatgc	2880
tgtttgtgtc ggcccacaca gacagggtca gcggccttgc ggcgcgcagc tttctgtgg	2940
cccagcagcg cctgctggag gaccgcaagg acgttgggt gctggtgatc ctgcgcggcg	3000
acgcccacccg ctcccgtat gtgcggctgc gccagcgcct ctgcgcgcag aegtcctcc	3060
tctggcccca ccagcccagt ggccagcgca gcttctgggc ccagctgggc acggccctga	3120
ccagggacaa ccagcacttc tataaccaga acttctgccg gggcccccacg acggcagagt	3180
gaccgcccag caccccaagg ctcctacacc ttgcctgtct gcctggatg ccggg	3235

<210> 28
 <211> 2460
 <212> DNA
 <213> *Felis catus*

<400> 28	
atggggccct gccatggcgc cctgcacccc ctgtctctcc tgggtgcaggg tgccgcgcgt	60
gcccgtggccc tggcccaggg caccctgcct gcctttctgc cctgtgagct ccagcgcac	120
ggcctggta attgcgactg gctgttccctc aagtccgtgc cccacttctc ggccggcagcg	180
ccccgtggta acgtcaccag cctttccctg tactccaacc gcattccacca cttccacgac	240
tccgactttg tccacctgtc cagcctgcgg cgtctcaacc tcaaattggaa ctgcccaccc	300
gccagcctca gccccatgca ctteccctgt cacatgacca ttgagccca caccttcctg	360
gcccgtgccc ccctggagga gctgaacctg agctacaaca gcattcacgac agtacccgcc	420
ctgcccagtt ccctcgtgtc cctgtccttg agccgtacca acatcctggt gctggaccct	480
gccaacctcg cagggctgca ctcccctgcgc tttctgttcc tggatggcaa ctgtactac	540
aagaacccct gcccgcaggc cctgcaggtg gccccgggg ccctccttgg cctggcaac	600
cttacgcacc tgcactcaa gtacaacaac ctcactgcgg tgccccgcgg cctgcccccc	660
agcctggagt acctgctatt gtcctacaac cacatcatca ccctggcacc tgaggacctg	720
gccaacctga ccgcctgcg tgcgtcgat gtgggtggaa actgcccgtcg ctgtgaccac	780
gccccgcaacc cctgtatgga gtgcggcaag ggcttccgc acctgcaccc tgacaccc	840
agccacccctga accacccctgca aggcctggtg ttgaaggaca gtcctctcta caaccc	900

cccagatggt	tccatgccct	gggcaaccc	atggtgctgg	acctgagtga	gaacttccta	960
tatgactgca	tcacccaaaac	cacagccccc	cagggcctgg	cccagctgcg	cagactcaac	1020
ttgtctttca	attaccacaa	gaaggtgtcc	tttgcccacc	tgcacatctggc	gccctccccc	1080
gggagccctgc	tctccctgca	gcagctggac	atgcacatggca	tcttcttccg	ctcgctcagc	1140
gagaccacgc	tccggtcgct	ggtccacctg	cccatgctcc	agagtctgca	cctgcagatg	1200
aacttcatca	atcaggcccc	gctcagcatc	ttcggggcct	tccctggcct	gcgatacgtg	1260
gacctgtcag	acaaccgcac	aagtggagcc	atggagctgg	cggctgccac	gggggaggtg	1320
gatggtgggg	agagagtcgg	gctgccatct	ggggacctag	ctctggggcc	accgggcacc	1380
cctagctccg	agggcattcat	gccaggctgc	aagaccctca	acttcaccc	ggacctgtca	1440
cggaacaacc	tagtgcacaaat	ccagccagag	atgtttgccc	ggctctcgcg	cctccagtgc	1500
ctgctctga	ggcgcaacag	catctcgccag	gcagtcaacg	gctcacaatt	tatgcccgtg	1560
accagccctgc	aggtgctgga	cctgtcccat	aacaagctgg	acctgtacca	tggcgctct	1620
ttcacggagc	tgccgcggct	ggaggccctg	gacccatct	acaacagcca	gcccttcagc	1680
atgcagggcg	tgggtcacaa	cctcagcttt	gtggcacagc	tgccggccct	gctatctc	1740
agcctggcgc	acaacgcacat	ccacagccgt	gtgtcccagc	agctctgcag	cgcctcgctg	1800
cgggccttgg	acttcagcgg	aatgccttg	agccggatgt	ggcccgaggg	agacctgtat	1860
ctccacttct	tccgaggcct	gaggagctg	gtccgggttgg	atctgtccca	gaatcgccctg	1920
cataccctct	tgccacgcac	cctggacaac	ctccccaaaga	gcctgcggct	gctgcgtctc	1980
cgtgacaatt	atctggcttt	cttcaactgg	agcagccctgg	tcctcctccc	caggctggaa	2040
gccctggacc	tggcgaaa	ccagctgaag	gccctgagca	acggcagctt	gcctaattggaa	2100
acccagctcc	agaggctgga	cctcagcagc	aacagtatca	gcttcgtggc	ctccagcttt	2160
tttgctctgg	ccaccaggct	gcgagagctc	aacctcagtg	ccaacgcctt	caagacggtg	2220
gagccctccct	ggttcggttc	tctagcgggc	accctgaaag	tcctagatgt	gactggcaac	2280
cccctgcact	gcccctgtgg	ggccgccttc	gtggacttct	tgctggaggt	gcaggctgca	2340
gtgcccggcc	tgccaggcca	cgtcaagtgt	ggcagtcag	gtcagctcca	ggcccgccagc	2400
atctttgcgc	aggatctgcg	cctctgcctg	gatgaggcccc	tctcctggaa	ctgtttggc	2460

<210> 29
 <211> 1032
 <212> PRT
 <213> *Mus musculus*

<400> 29

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu

225	230	235	240
Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg			
245	250	255	
Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser			
260	265	270	
Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly			
275	280	285	
Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe			
290	295	300	
Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu			
305	310	315	320
Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu			
325	330	335	
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala			
340	345	350	
Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu			
355	360	365	
Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu			
370	375	380	
Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met			
385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala			
405	410	415	
Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr			
420	425	430	
Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu			
435	440	445	
Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser			
450	455	460	

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser
565 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
645 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr
660 665 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn
675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
740 745 750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
805 810 815

Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val
820 825 830

Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
835 840 845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser
850 855 860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
900 905 910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
980 985 990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln
995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
1025 1030

<210> 30
<211> 821
<212> PRT
<213> Mus musculus

<400> 30

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His His Leu His Asn
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala

340

345

350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu
 355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu
 370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met
 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala
 405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
 420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu
 435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser
 450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
 465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
 485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
 500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
 515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
 530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
 545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser
 565 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
645 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr
660 665 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn
675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
740 745 750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
805 810 815

Trp Asp Cys Phe Gly
820

<210> 31
<211> 3200
<212> DNA
<213> Mus musculus

<400> 31	
tgtcagaggg agcctcgaaa gaatcctcca tctccaaaca tggttctccg tcgaaggact	60
ctgcacccct tgcacccctt ggtacaggct gcagtgtgg ctgagactct ggcctgggt	120
accctgcctg ctttccatcc ctgtgagctg aagcctcatg gcctgggtga ctgcaattgg	180
ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgctccaa catcaccgc	240
ctctccttga tctccaaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc	300
aacctgcggc agctgaacct caagtggAAC tgcacccca ctggccttag cccctgcac	360
ttctcttgcc acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag	420
ctgaacctga gctataatgg tatcaccact gtgcggcgtac tgcccagctc cctgggtgaat	480
ctgagcctga gccacaccaa catcctgggtt cttagatgcta acagcctcgc cggcctatac	540
agcctgcgcg ttctcttcat ggacggaaac tgctactaca agaaccctg cacaggagcg	600
gtgaaggtga ccccaaggcgc ctttccatggc ctgagcaatc tcacccatct gtctctgaag	660
tataacaacc tcacaaaggt gccccggccaa ctgcggggccaa gcctggagta cttccctgg	720
tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttcga	780
gtacttgatg tgggtggaa ttggcgtgc tgccgaccatg ccccaatcc ctgtatagaa	840
tgtggccaaa agtccctcca cctgcacccct gagaccttcc atcacctgag ccatctggaa	900
ggcctgggtgc tgaaggacag ctctctccat acactgaact cttccctgggtt ccaaggcttg	960
gtcaacctct cggtgctgga cctaagcgag aactttctct atgaaagcat caaccacacc	1020
aatgccttca agaacctaac ccgcctgcgc aagctcaacc tgccttcaa ttaccgcaag	1080
aaggatccct ttgccccctt ccacctggca agttccttca agaacctgggt gtcactgcag	1140
gagctgaaca tgaacggcat cttctccgc tgcgtcaaca agtacacgct cagatggctg	1200
gccgatctgc ccaaactcca cactctgcattt cttcaatga acttcatcaa ccaggcacag	1260
ctcagcatct ttggcacctt ccgagccctt cgctttgtgg acttgcaga caatcgatc	1320
agtggccctt caacgctgatc agaagccacc cctgaagagg cagatgtgc agagcaggag	1380
gagctgttgt ctgaggatcc tcacccagct ccactgagca cccctgcttc taagaacttc	1440

atggacaggt gtaagaactt caagttcacc atggacctgt ctggaaacaa cctggtgact	1500
atcaagccag agatgtttgt caatctctca cgccctccagt gtcttagcct gagccacaac	1560
tccattgcac aggctgtcaa tggctcttag ttcctgccc tgactaatct gcaggtgctg	1620
gacctgtccc ataacaaact ggacttgtac cactggaaat cgttcagtga gctaccacag	1680
ttgcaggccc tggacctgag ctacaacagc cagccctta gcatgaaggg tataggccac	1740
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac	1800
attcataccc gtgtgtcctc acatctcaac agcaactcag tgaggttct tgacttcagc	1860
ggcaacggta tggggccgcat gtgggatgag gggggcctt atctccattt cttccaaggc	1920
ctgagtgccc tgctgaagct ggacctgtct caaaataacc tgcatatcct cggccccag	1980
aaccttgaca acctccccaa gaggctgaag ctgctgagcc tccgagacaa ctacctatct	2040
ttctttaact ggaccagtct gtccttcctg cccaaacctgg aagtccataga cctggcaggc	2100
aaccagctaa aggccctgac caatggcacc ctgcctaattt gcaccctcct ccagaaactg	2160
gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgtct ggcggcag	2220
ctgaaagagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg	2280
cccatgtga tgaacctgac agttcttagac gtgagaagca accctctgca ctgtgcctgt	2340
ggggcagcct tcgttagactt actgttggag gtgcagacca aggtgcctgg cctggctaat	2400
ggtgtgaagt gtggcagccc cggccagctg cagggccgta gcatcttcgc acaggacctg	2460
cggctgtgcc tggatgaggt cctctttgg gactgctttg gccttcact cttggctgt	2520
gccgtggca tgggtgggcc tatactgcac catctctgctg gctggacgt ctggtaactgt	2580
tttcatctgt gcctggcatg gctacctttg ctggccgca gcccacgcag cggccaaagct	2640
ctcccctatg atgccttcgt ggtttcgat aaggcacaga ggcgcgttgc ggactgggt	2700
tataacgagc tgcgggtgcg gctggaggag cggcgccggtc gcccggccct acgcttgt	2760
ctggaggacc gagattggct gcctggccag acgctttcg agaacctctg ggctccatc	2820
tatggagcc gcaagactct atttgtctg gcccacacgg accgcgtcag tggcctcctg	2880
cgcaccagct tcctgctggc tcagcagcgc ctgttggaaag accgcaagga cgtgggtgt	2940
ttgggtatcc tgcgtccgga tgccccccgc tcccgctatg tgcgactgcg ccagcgtctc	3000
tgccggccaga gtgtgtctt ctggcccccag cagcccaacg ggcagggggg cttctggcc	3060
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgcccgg	3120
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatctt catgcctggt	3180
tcccgagttg ctctgcctgc	3200

<210> 32
 <211> 2463
 <212> DNA
 <213> *Mus musculus*

<400> 32
 atggttctcc gtcgaaggac tctgcacccccc ttgtccctcc tggcacaggc. tgcagtgtg 60
 gctgagactc tggccctggg taccctgcct gccttcctac cctgtgagct gaagcctcat 120
 ggcctgggtgg actgcaattt gctgttccctg aagtctgtac cccgtttctc tgcggcagca 180
 tcctgctcca acatcaccccg cctctcccttgc atctccaacc gtatccacca cctgcacaac 240
 tccgacttcg tccacactgtc caacactgcgg cagctgaacc tcaagtggaa ctgtccaccc 300
 actggcctta gccccctgca cttctcttgc cacatgacca ttgagccag aaccttcctg 360
 gctatgcgta cactggagga gctgaacctg agctataatg gtatcaccac tgtgccccga 420
 ctgcccagct ccctgggtgaa tctgagccctg agccacacca acatcctggt tctagatgct 480
 aacagcctcg cccgcctata cagcctgcgc gttctttca tggacgggaa ctgtactac 540
 aagaacccct gcacaggagc ggtgaagggtg acccccaggcg ccctcctggg cctgagcaat 600
 ctcacccatc tgtctctgaa gtataacaac ctcacaaagg tgccccgcca actgcccccc 660
 agcctggagt acctcctggt gtcctataac ctcattgtca agctggggcc tgaagacctg 720
 gccaatctga cttcccttcg agtacttgat gtgggtgggaa attgccgtcg ctgcgaccat 780
 gcccccaatc cctgtataga atgtggccaa aagtccctcc acctgcaccc tgagaccttc 840
 catcacctga gccatctgga aggcctggtg ctgaaggaca gctctctcca tacactgaac 900
 tcttcctggt tccaagggtct ggtcaaccc tcgggtgtgg acctaagcga gaactttctc 960
 tatgaaagca tcaaccacac caatgcctt cagaacctaa cccgcctgcg caagctcaac 1020
 ctgtccttca attaccgcaa gaaggtatcc tttgcccccc tccacctggc aagttccttc 1080
 aagaacctgg tgtcaactgca ggagctgaac atgaacggca tcttcttccg ctcgctcaac 1140
 aagtacacgc tcagatggct ggccgatctg cccaaactcc acactctgca tcttcaaattg 1200
 aacttcatca accaggcaca gctcagcatc tttggcacct tccgagccct tcgccttgg 1260
 gacttgcag acaatcgcat cagtgggcct tcaacgctgt cagaagccac ccctgaagag 1320
 gcagatgatg cagagcagga ggagctgttg tctgcggatc ctcacccagc tccactgagc 1380
 acccctgctt ctaagaactt catggacagg tgtaagaact tcaagttcac catggacctg 1440
 tctcgaaaca acctggtgac tatcaagcca gagatgtttg tcaatctctc acgcctccag 1500
 tgtcttagcc tgagccacaa ctccattgca caggctgtca atggctctca gttcctgccc 1560

ctgactaatac	tgccagggtgct	ggacacctgtcc	cataacaaac	tggacttgtta	ccactggaaa	1620
tcgttcagtg	agctaccaca	gttgcaggcc	ctggacactga	gctacaacag	ccagcccttt	1680
agcatgaagg	gtataggcca	caatttcagt	tttggggccc	atctgtccat	gctacacagc	1740
cttagcctgg	cacacaatga	cattcatacc	cgtgtgtccct	cacatctcaa	cagcaactca	1800
gtgagggttcc	ttgacttcag	cggcaacgggt	atggggccgca	tgtgggatga	ggggggccctt	1860
tatctccatt	tcttccaagg	cctgagtgcc	ctgctgaagc	tggacactgtc	tcaaaataac	1920
ctgcataatcc	tccggggccca	gaaccttgac	aaccctccca	agagcctgaa	gctgctgagc	1980
ctccgagaca	actacctatac	tttcttaac	tggaccagtc	tgtccttcct	gcccaacctg	2040
gaagtcctag	acctggcagg	caaccagcta	aaggccctga	ccaatggcac	cctgcctaatt	2100
ggcacccctcc	tccagaaaact	ggatgtcagc	agcaacagta	tcgtctctgt	ggtcccagcc	2160
ttcttcgctc	tggcggtcga	gctgaaagag	gtcaacacta	gccacaacat	tctcaagacg	2220
gtggatcgct	cctgggttgg	gcccatgtg	atgaacactga	cagttctaga	cgtgagaagc	2280
aaccctctgc	actgtgcctg	tggggcagcc	ttcgttagact	tactgttgga	ggtgcagacc	2340
aaggtgcctg	gcctggctaa	tgggtgtgaag	tgtggcagcc	ccggccagct	gcagggccgt	2400
agcatctcg	cacaggacct	gcggctgtc	ctggatgagg	tcctctcttg	ggactgcttt	2460
ggc						2463

<210> 33
 <211> 1032
 <212> PRT
 <213> Homo sapiens

<400> 33

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
 50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu

305	310	315	320
Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu			
325	330	335	
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala			
340	345	350	
His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu			
355	360	365	
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu			
370	375	380	
Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met			
385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly			
405	410	415	
Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu			
420	425	430	
Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu			
435	440	445	
Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu			
450	455	460	
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser			
465	470	475	480
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser			
485	490	495	
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val			
500	505	510	
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu			
515	520	525	
Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu			
530	535	540	

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545 550 555 560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg
675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg
690 695 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
 805 810 815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
 820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
 835 840 845

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
 850 855 860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
 865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
 885 890 895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
 900 905 910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
 915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
 930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
 980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
 995 1000 1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
 1010 1015 1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu
1025 1030

<210> 34
<211> 820
<212> PRT
<213> Homo sapiens

<400> 34

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu

420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
435 440 445Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu
450 455 460Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
500 505 510Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
515 520 525Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
530 535 540Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545 550 555 560Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
 660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg
 675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg
 690 695 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
 705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
 725 730 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
 740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
 755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
 770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
 805 810 815

Asp Cys Phe Ala
 820

<210> 35
 <211> 3352
 <212> DNA
 <213> Homo sapiens

<400> 35
 aggctggat aaaaatctta cttcctctat tctctgagcc gctgctgccc ctgtggaaag 60
 ggacctcgag tctgaagcat cttccctgt agctgctgtc cagtcgtccc gccagaccct 120
 ctggagaagc ccctgcccc cagcatgggt ttctgcccga gcgcctgtca cccgctgtct 180
 ctcctgggtgc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc 240
 ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct 300

gtgccccact	tctccatggc	agcacccgt	ggcaatgtca	ccagccttc	cttgtctcc	360
aaccgcatcc	accacctcca	tgattctgac	tttgcacc	tgcccagcct	gcggcatctc	420
aacctcaagt	ggaactgccc	gccgggtggc	ctcagccca	tgcacttccc	ctgccacatg	480
accatcgagc	ccagcacctt	cttggctgtg	cccaccctgg	aagagctaaa	cctgagctac	540
aacaacatca	tgactgtgcc	tgcgctgccc	aaatccctca	tatccctgtc	cctcagccat	600
accaacatcc	tgatgctaga	ctctgcccagc	ctcgccggcc	tgcattgcct	gctgttccta	660
ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggcactgga	ggtgcccccg	720
ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	caacctcact	780
gtggtgcccc	gcaacctgcc	ttccagccctg	gagtatctgc	tgttgtccct	caaccgcac	840
gtcaaactgg	cgcctgagga	cctggccaat	ctgaccgccc	tgcgtgtgct	cgtatgtggc	900
ggaaattgcc	gccgctgcga	ccacgctccc	aaccctgca	tggagtgc	tcgtcacttc	960
ccccagctac	atcccgatac	cttcagccac	ctgagccgtc	ttgaaggcct	ggtgttgaag	1020
gacagttctc	tctcctggct	gaatgccagt	tggttccgtg	ggctggaaaa	cctccgagtg	1080
ctggacctga	gtgagaactt	cctctacaaa	tgcattacta	aaaccaaggc	cttccagggc	1140
ctaacacagc	tgcgcagact	taacctgtcc	ttcaattacc	aaaagaggg	gtcctttgcc	1200
cacctgtctc	tggcccttc	cttcggagc	ctggtcgccc	tgaaggagct	ggacatgcac	1260
ggcatcttct	tccgctcact	cgtatgcacc	acgctccggc	cactggcccc	cctgcccatt	1320
ctccagactc	tgcgtctgca	gatgaacttc	atcaaccagg	cccagctcgg	catcttcagg	1380
gccttccctg	gcctcgctca	cgtggacactg	tcggacaacc	gatcagcgg	agcttcggag	1440
ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	gcctggggac	1500
cttgctccgg	cccccagtgg	cactcccagc	tctgaagact	tcaggccaa	ctgcagcacc	1560
ctcaacttca	ccttggatct	gtcacggAAC	aacctggat	ccgtgcagcc	ggagatgttt	1620
gcccagctct	cgcacctgca	gtgcctgcgc	ctgagccaca	actgcatttc	gcaggcagtc	1680
aatggctccc	agttccgtcc	gctgaccggt	ctgcaggtgc	tagacctgtc	ccgcaataag	1740
ctggacctct	accacgagca	ctcattcact	gagctaccgc	gactggaggc	cctggacactc	1800
agctacaaca	gccagccctt	tggcatgcag	ggcgtggcc	acaacttcag	cttcgtggct	1860
cacctgcgca	ccctgcgcca	cctcagccctg	gcccacaaca	acatccacag	ccaagtgtcc	1920
cagcagctct	gcagtacgtc	gctgcggcc	ctggacttca	gctggcaatgc	actggccat	1980
atgtggcccg	agggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	tttgatctgg	2040

ctggacttgt	cccagaaccc	cctgcacacc	ctcctgcccc	aaaccctgcg	caacccccc	2100
aagagcctac	aggtgctgcg	tctccgtgac	aattacctgg	ccttctttaa	gtggtggagc	2160
ctccacttcc	tgcccaaact	ggaagtccctc	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcacccgg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttcg	tggcccccgg	cttctttcc	aaggccaagg	agctgcgaga	gctcaacctt	2340
agcgccaacg	ccctcaagac	agtggaccac	tcctggtttgc	ggcccccggc	gagtgcctg	2400
caaatactag	atgtaagcgc	caaccctctg	cactgcgcct	gtggggcggc	ctttatggac	2460
ttcctgctgg	aggtgcaggc	tgccgtgccc	ggtctgccc	gccgggtgaa	gtgtggcagt	2520
ccggggccage	tccagggcct	cagcatctt	gcacaggacc	tgccgcctcg	cctggatgag	2580
gccctctcct	gggactgttt	cgcctctcg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctggac	ctctggta	gcttccacct	gtgcctggcc	2700
tggctccct	ggcgggggcg	gcaaagtggg	cgagatgagg	atgcctgccc	ctacgatgcc	2760
ttcgtgtct	tcgacaaaac	gcagagcgca	gtggcagact	gggtgtacaa	cgagttcgg	2820
gggcagctgg	aggagtgccc	tggcgctgg	gcactccgccc	tgtgcctgga	ggaacgcgac	2880
tggctgcctg	gcaaaaccct	cttgagaac	ctgtggccct	cggctatgg	cagccgcaag	2940
acgctgtttg	tgctggccca	cacggaccgg	gtcagtggtc	tcttgcgcgc	cagcttcctg	3000
ctggcccagc	agcgccctgct	ggaggaccgc	aaggacgtcg	tggctgtgt	gatcctgagc	3060
cctgacggcc	gcccgtcccg	ctacgtgcgg	ctgcgcgcagc	gcctctgccc	ccagagtgtc	3120
ctcctctggc	cccaccagcc	cagtggtcag	cgcagttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cggaacttct	gccagggacc	cacggccgaa	3240
tagccgtgag	ccggaatcct	gcacggtgcc	acccacac	tcacctcacc	tctgcctgcc	3300
tggctgacc	ctccctgtct	cgcctccctc	accccacacc	tgacacagag	ca	3352

<210> 36
 <211> 2460
 <212> DNA
 <213> Homo sapiens

<400> 36						
atgggtttct	ggcgcagcgc	cctgcaccccg	ctgtctctcc	tggtgccaggc	catcatgctg	60
gccatgaccc	tggccctggg	taccttgcct	gccttcctac	cctgtgagct	ccagccccac	120
ggcctggta	actgcaactg	gctgttcctg	aagtctgtgc	cccacttctc	catggcagca	180
ccccgtggca	atgtcaccag	ccttccttg	tcctccaacc	gcatccacca	cctccatgat	240

tctgactttg	cccacctgcc	cagcctgcgg	catctcaacc	tcaagtggaa	ctgcccggcg	300
gttggcctca	gccccatgca	cttcccctgc	cacatgacca	tcgagcccag	caccttcttgc	360
gctgtgccc	ccctggaaaga	gctaaacactg	agctacaaca	acatcatgac	tgtgcctgcg	420
ctgccc	aaat	ccctcatatc	cctgtccctc	agccatacca	acatcctgat	480
gccagcctcg	ccggcctgca	tgccctgegc	ttcttattca	tggacggcaa	ctgttattac	540
aagaacccct	gcaggcaggc	actggaggtg	gccccgggtg	ccctccttgg	cctggcaac	600
ctcacc	accacc	tgtca	cttcaaaac	ctcaactgtgg	tgccccgcaa	660
agcctggagt	atctgctgtt	gtc	cttacaac	cgcatcgtca	aactggcgcc	720
gcaatctga	ccgc	ctgcg	tgtgctcgat	gtggcggaa	attgccgccc	780
gctcc	caacc	cctgc	atggaa	gtgcccgt	cacttcccc	840
agccac	ctgt	ccgt	aggc	cttgcgt	ttgaaggaca	900
gccag	ttgg	tccgt	gggac	cgagtgc	acctgagtg	960
tacaaat	tgca	tcact	aaaaac	caaggc	cttc	1020
ctgt	ccttca	attac	aaaaa	gagggt	gtcc	1080
gggag	ccttg	tcg	ccctgaa	ggagctggac	atgcacggca	1140
gagacc	acgc	tccgg	ccact	ggccgc	cctgc	1200
aactt	catca	accagg	ccca	gctcgg	catc	1260
gac	cttcg	acaacc	gc	cagg	actg	1320
gat	gggg	agaagg	tctg	gtc	agcgc	1380
cccag	ctctg	aagact	tcag	ccact	gtc	1440
cgga	acaacc	tgg	gaccgt	gcagg	atgtt	1500
ctgc	gcctga	gccaca	actg	atctcg	cc	1560
accgg	tctgc	agg	tgctaga	cctgtcc	aataag	1620
ttc	acgg	tac	ggagg	ccctg	gac	1680
atgc	agg	gg	ccacaa	ttcag	cttca	1740
agc	ctgg	aca	acaacat	gtgtcc	actgc	1800
cgg	ccctgg	caat	ccacag	ccgc	atgt	1860
ctg	ca	tc	ttcaagg	gagcg	tttgc	1920
cac	ccctcc	tgcccc	aaac	cctgc	gcaac	1980
cgt	gacaatt	ac	ctgg	cctt	tttaagtgg	2040

gtcctcgacc tggcagggaaa ccggctgaag gccctgacca atggcagcct gcctgctggc 2100
acccggctcc ggaggctgga tgtcagctgc aacagcatca gcttcgtggc cccggcttc 2160
tttccaagg ccaaggagct gcgagagctc aaccttagcg ccaacgcctt caagacagtg 2220
gaccactcct ggtttgggcc cctggcgagt gccctgaaa tactagatgt aagcgccaac 2280
cctctgcact ggcctgtgg ggcggccccc atggacttcc tgctggaggt gcaggctgcc 2340
gtgcccggtc tgcccagccg ggtgaagtgt ggcagtcggc gccagctcca gggcctcagc 2400
atctttgcac aggacctgcg cctctgcctg gatgaggccc tctcctggga ctgtttcgcc 2460

<210> 37
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 37
accttgcctg ctttcctacc ctgtga 26

<210> 38
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 38
gtccgtgtgg gccagcacaa a 21

<210> 39
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 39
tccatgacgt ttttcatgtt 20

<210> 40
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 40
tccataacgt ttttcatgtt

20

<210> 41
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 41
tccatcacgt ttttcatgtt

20

<210> 42
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 42
tccattacgt ttttcatgtt

20

<210> 43
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 43
tccatggcgt ttttcatgtt

20

<210> 44
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 44
tccatgccgt ttttcatgtt

20

<210> 45
<211> 20
<212> DNA
<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 45

tccatgtcgt ttttcatgtt

20

<210> 46

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 46

tccatgtatgt ttttcatgtt

20

<210> 47

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 47

tccatgaagt ttttcatgtt

20

<210> 48

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 48

tccatgaggt ttttcatgtt

20

<210> 49

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 49

tccatgacat ttttcatgtt

20

<210> 50

<211> 20

<212> DNA

<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 50
tccatgacct ttttgatgtt

20

<210> 51
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 51
tccatgactt ttttgatgtt

20

<210> 52
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 52
tccatgacgc ttttgatgtt

20

<210> 53
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 53
tccatgacga ttttgatgtt

20

<210> 54
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 54
tccatgacgg ttttgatgtt

20

<210> 55
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 55
tccatgacgt ctttgatgtt

20

<210> 56
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 56
tccatgacgt atttgatgtt

20

<210> 57
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 57
tccatgacgt gtttgatgtt

20

<210> 58
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 58
tcgtcgaaaa gtcgttttgtt cgtt

24

<210> 59
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 59
tgctgctttt gtgttttgtt gctt

24

<210> 60
<211> 20
<212> DNA

<213> Artificial sequence
<220>
<223> Synthetic oligonucleotide

<400> 60
tccatgacgt tcctgatgct

20

<210> 61
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 61
tccatgagct tcctgatgct

20

<210> 62
<211> 16
<212> PRT
<213> Artificial sequence

<220>
<223> Consensus oligopeptide

<220>
<221> MISC_FEATURE
<222> (4)...(5)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (7)...(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)...(15)
<223> Any amino acid

<400> 62

Gly Asn Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
1 5 10 15

<210> 63
<211> 16
<212> PRT
<213> Homo sapiens

<400> 63

Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys
1 5 10 15

<210> 64
<211> 16
<212> PRT
<213> *Mus musculus*

<400> 64

Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Ile Cys
1 5 10 15

<210> 65
<211> 31
<212> PRT
<213> *Artificial sequence*

<220>
<223> *Consensus oligopeptide*

<220>
<221> MISC_FEATURE
<222> (2)...(8)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (10)...(10)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (12)...(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)...(22)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (25)...(30)
<223> Any amino acid

<400> 65

Arg Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Xaa Xaa Xaa Xaa Xaa Xaa Tyr
20 25 30

<210> 66
<211> 31
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid

<400> 66

Gln Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Arg Leu Xaa Xaa Xaa Xaa Xaa Tyr
20 25 30

<210> 67
<211> 31
<212> PRT
<213> Mus musculus

<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (10)...(10)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (12)...(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)...(22)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (25)...(30)
<223> Any amino acid

<400> 67

Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Gln Leu Xaa Xaa Xaa Xaa Xaa Xaa Tyr
20 25 30

<210> 68
<211> 31
<212> PRT
<213> Homo sapiens

<400> 68

Gln Val Leu Asp Leu Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His
1 5 10 15

Ser Phe Thr Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr
20 25 30

<210> 69
<211> 31
<212> PRT
<213> Mus musculus

<400> 69

Gln Val Leu Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys

Ser Phe Ser Glu Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr
 20 25 30

```
<210> 70
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 70
tccaggactt ctctcagggtt
```